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Abstract 
Neurodegenerative conditions such as Multiple Sclerosis (MS) and spinal 
cord injury (SCI) affect hundreds of thousands of people each year 
worldwide, and numerous cell transplant-based therapeutic strategies are 
being investigated to aid in the repair and regeneration of the central 
nervous system. Of particular interest are mesenchymal stem cells (MSCs), 
due to their differentiation potential, their immunomodulatory effects, 
and their ability to stimulate various biological properties due to the 
substantial variety of growth factors, chemokines, and other signalling 
molecules secreted by these cells. MSCs taken from the bone marrow (BM-
MSCs) have demonstrated significant reparative potential in animal models 
of both MS and SCI. The question I address throughout this thesis however, 
is whether MSCs from another niche; the olfactory mucosa (OM-MSCs), are 
a preferable or at least alternative candidate for such therapies, compared 
to BM-MSCs, and if they are, why are they? 
 
Previous studies have shown that OM-MSCs can be purified and grown from 
human olfactory mucosa and when incubated with rat glial/neuronal co-
cultures are capable of increasing axonal myelination, an effect not 
elicited by BM-MSCs. This potentially has great therapeutic benefit for a 
range of neurodegenerative conditions, as a significant part of the 
regenerative process involves replacing the protective myelin membrane 
which ensheaths axons.  
 
A comparative study of the two types of MSCs shows a number of 
similarities, including the expression of the same panel of MSC markers, a 
64% homology in miRNA expression, an ability to differentiate towards 
bone and fat, and a propensity for bone formation when cultured on 
osteogenic nanotographies.  
 
This thesis also outlines a number of differences between each phenotype 
which suggest that OM-MSCs could even be a preferred alternative, 
especially in neuroregenerative therapies. OM-MSCs were shown to express 
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significantly more Nestin than BM-MSCs, and to proliferate at a significantly 
higher rate, two observations which may be related. This increased 
proliferation would have enormous benefit for their use, as BM-MSCs are 
mitotically quite slow, and any MSC-based therapies would require very 
large numbers of cells. Twenty six different miRNA were shown to be 
differentially expressed between BM-MSCs and OM-MSCs. Three of these; 
miR-140-5p, miR-146a-5p, and miR-335-5p were linked to three important 
biological functions; myelination, cell survival, and cell proliferation 
respectively. These three biological functions, importantly, are ones which 
were observed as being behavioural differences between OM-MSCs and BM-
MSCs. OM-MSCs were also shown to secrete significantly more of the pro-
myelinating chemokine, CXCL12, which was confirmed as being regulated 
by the microRNA, miR-140-5p. This offered a potential mechanism for the 
pro-myelinating effect of OM-MSCs, and also opens up new research 
potential for investigating therapeutic targets to regulate myelination.  
 
The data presented in this thesis shows many similarities between BM-MSCs 
and OM-MSCs, but it also highlights some profound differences which 
suggest that either they originate from a different lineage entirely, or that 
the cellular niche that they reside in does indeed affect the differentiation 
and behaviour of mesenchymal stem cells.      
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1. General Introduction 
1.1. Mesenchymal Stem Cells (MSCs) 
Mesenchymal stem cells are a uniquely dynamic and multi-faceted 
eukaryotic cell with huge potential importance in the field of regenerative 
medicine. Not only are they essential for the development of the human 
body, and the support and constant regulation of a number of niches 
throughout, they have been implicated in a number of regenerative 
therapies which will be discussed in due course.  
 
MSCs from different niches are thought to carry out separate important 
roles, and some have been shown to stimulate biological mechanisms that 
MSCs from other niches do not. The basis of this thesis stems from the 
discovery by Lindsay et al. (1) that MSCs from the olfactory system have 
the ability to promote axonal myelination whereas MSCs from the bone 
marrow do not. Throughout this thesis I will compare and contrast the 
identity and behaviour of both MSC phenotypes to try and understand some 
of the underlying mechanisms behind their behavioural differences.  
 
This project incorporates cell biology, materials biochemistry, and 
neuroscience, and, as will be fully explained within the context of this 
thesis, has potential therapeutic implications in fields of research such as 
Multiple Sclerosis (MS), Spinal Cord Injury (SCI), and orthopaedics.  
 
1.1.1. A Brief History of Stem Cells 
As a result of chemical warfare and the use of atomic weaponry during 
world war 2, post-war cancer rates soared, leading to a huge drive towards 
biomedical research, and in particular regenerative medicine (2-4). This 
lead to Jean Dausset identifying the human leukocyte antigen (HLA), 
allowing the first successful bone marrow transplant in 1958 (5), and the 
discovery in 1961 of the haematopoietic stem cell (HSC) by Till and 
McCulloch (6). In 1968, Tavassoli and Crosby discovered a connection 
between bone marrow and osteogenesis (7, 8), and further studies by 
Friedenstein in the late 1960’s and 1970’s associated these findings with a 
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another distinct but minor population of stem cells which resides in the 
bone marrow; a stromal cell which forms bone (9, 10). Further work by 
Friedenstein et al. identified these cells as having a fibroblastic 
morphology, an adherent capability to plastic surfaces allowing in vitro 
expansion, and a colony forming behaviour which lead to them being 
termed colony forming unit fibroblasts (CFU-Fs) (11). It was then shown 
that in vivo transplantation of these cells could result in the formation of 
cells from the other mesenchymal lineages; cartilage, fat, and connective 
tissue (7), resulting in the common term that is used today; mesenchymal 
stem cells (MSCs), which was coined by Caplan in 1991 (12).  
 
To date, the only officially used stem cell therapy across the world is the 
bone marrow transplant. A well established and fully viable therapy for 
blood related disorders such as leukaemias (13), lymphomas (14), and 
severe aplastic anaemia (15), as well as immunological disorders such as 
severe combined immunodeficiency (SCID) (16), and leukocyte adhesion 
deficiency (17), the bone marrow transplant has saved millions of lives 
since its genesis in 1958, with over 1,800 patients requiring a bone marrow 
transplant every year in the UK alone (494). There are a number of human 
clinical trials involving embryonic stem cells (ESCs) and induced pluripotent 
stem cells (iPSCs) as therapies for diseases such as Parkinson’s (PD) (495), 
Stargardt’s macular dystrophy (SMD) (496), and age-related macular 
degeneration (AMD) (497). However, due to the ethical issues surrounding 
ESCs and the autologous potential of MSCs, MSCs are considered by many to 
be much better alternatives as therapeutic targets, and are currently being 
studied and trialled across the globe for a wide range of disorders which 
will be discussed in more detail in section 1.3. 
 
1.1.2. Origins of MSCs 
All human life starts when sperms meets ovum, and within 4-5 days of 
conception dramatic changes have occurred, transforming the fertilised 
ova (zygote) into a structure called a blastocyst (Figure 1.1). The 
blastocyst is a simple vesicle consisting of a single layer outer shell of 
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totipotent stem cells called the trophectoderm, from which ~20 embryonic 
stem cells are derived and form in an inner compartment of the blastocyst 
called the inner cell mass, surrounded by a fluid filled cavity called the 
blastocoel. The embryonic stem cells grow and transform into a tissue 
called the epiblast from which each of the three germ layers are formed; 
the ectoderm, mesoderm, and endoderm. Once the three germ layers have 
begun to form, the whole structure is referred to as the gastrula. The 
outer layer of the gastrula will eventually form the male or female 
primordial germ cells, whilst the three germ layers continue to develop 
into all of the remaining cells which make up the human body (Figure 1.2).  
 
 
 
Figure 1.1: Schematic diagram of the first stages of embryogenesis, 
starting from the zygote through to the blastocyst, and finally the gastrula. 
The embryonic stem cells in the blastocyst’s inner cell mass of the 
blstocyst differentiate into the epiblast of the late blastocyst, and finally 
into the three germ lines which start to form at the gastrula; the 
ectoderm, mesoderm, and endoderm. Diagram modified from Chen et al. 
(2009) (498). 
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Figure 1.2: Schematic diagram outlining the cells involved in each stage of 
embryogenesis, starting from the blastocyst shown in figure 1.1. The 
trophectoderm (outer shell) forms the primordial germ cells 
(cytotrophoblasts, syncytiotrophoblasts, and intermediate trophoblasts), 
whereas the three germ layers; ectoderm, mesoderm, and endoderm 
provide all the other cell types throughout the body. Diagram modified 
from Gilbert’s Developmental Biology, 6th Edition (499). 
 
1.1.2.1. The Ectoderm 
The ectoderm, the outermost of the three germ layers, situated between 
the mesoderm and the trophectoderm (18), is influenced by numerous 
secreted factors such as nestin, noggin, and Sox2 to differentiate towards 
cells of the central and peripheral nervous systems, tooth enamel, 
keratinous structures such as nails and hair, the anus, sweat glands, and 
various epithelial structures such as the linings of the mouth and nasal 
cavities (19) (Figures 1.2 and 1.3). The word ectoderm comes from the 
Greek words for “outside” (ektos), and “skin” (derma), and the ectoderm 
itself consists of 2 parts; the surface or external ectoderm, and the 
neuroectoderm which consists of the neural crest and the neural tube (20). 
Figure 1.3, taken from Rojo et al. (21) shows the lineages of a number of 
surface ectodermal-derived cell populations. 
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Figure 1.3: Schematic diagram representing some of the surface 
ectodermal lineage cell types. Surface ectodermal stem cells 
(SurfaceEcSCs) branch off into either skin or oral lineages and differentiate 
towards numerous cells which form hair and nails, mammary glands, teeth, 
salivary and sweat gland, and mucous membranes such as the nasal and 
oral cavities, and the anus. Diagram taken from Rojo et al. (21). 
 
The neuroectoderm is also divided into two sub-sections; the neural crest 
and the neural tube which form between the non-neural (surface) 
ectoderm and the mesoderm when the epidermis converges on itself to 
form neural folds (22). The neural folds conjoin forming the neural tube, 
cells from the top of the neural tube where the fold joins transform from 
epithelial cells to mesenchymal cells, and the epidermis re-forms to create 
a neuro/mesenchymal niche called the neural crest (Figure 1.4) (499). 
Neural crest cells then migrate to form more mesenchymal peripheral 
tissues such as face cartilage, heart septum, and adrenal medulla, as well 
as the peripheral nervous system. Cells created in the neural tube go on to 
form all of the cells and components of the central nervous system. 
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Abbreviation Cell Name 
Alv Alveolar cell 
Am Ameloblast 
Com Companion layer 
Cor Cortex 
Csf Cuticle of the hair shaft 
Csh Cuticle of the hair sheath 
Duc Duct cell 
EcSCs Ectodermal stem cell 
EpSCs Epithelial stem cell 
Gr Granular duct cell 
He Henley’s inner root sheath layer 
Hu Huxley’s inner rot sheath layer 
Int Intercalated duct cell 
Med Medulla 
Myo Myoepithelial cell 
MuA Mucous acinus 
Oee Outer enamel epithelium 
ORS Outer root sheath 
SeA Serous acinus 
Si Stratum intermedium cell 
Sr Satellite reticulum 
Str Striated duct cell 
 
Table 1.1: Table of full cell names depicted by abbreviations in figure 1.3 
taken from Rojo et al. (21). 
 
Figure 1.5 shows a range of tissues associated with both the neural crest 
and neural tube.   
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Figure 1.4: Schematic diagram depicting the formation of the neural crest 
and neural tube. Taken from Bronner-Fraser et al. (2003) (500). 
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Figure 1.5: Spider diagram depicting the lineages and resultant tissue 
types of neural crest and neural tube-derived cells. 
 
1.1.2.2. The Endoderm 
The endoderm is the innermost of the three germ layers, situated between 
the mesoderm and the blastocoel, and is responsible for the genesis of the 
internal organs of the body (except the heart) such as the gut, liver, lungs 
etc. (23). Figure 1.6 outlines a schematic of endodermally-derived tissues 
(23). 
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Figure 1.6: Schematic diagram taken from Zorn and Mills (23) depicting 
the lineage of organogenesis occurring in the endodermal layer. 
 
1.1.2.3. The Mesoderm 
The central of the three germ layers, the mesoderm, is responsible for the 
genesis of the medial parts of the body; the bones, connective tissue, 
muscles, blood, and also the heart and gonads (24). This is the most 
important germ layer as far as this thesis is concerned, as it is the germ 
layer from which mesenchymal stem cells are derived. Figure 1.7 outlines 
the separate lineages which are derived from the mesodermal layer, and 
highlights the two distinct stem cell populations mentioned previously 
which are resident in bone marrow tissue; the haematopoietic stem cells 
and the mesenchymal stem cells. The mesenchymal stem cells produced by 
the mesoderm are completely distinct from the 
neuroepithelial/mesenchymal cells which are derived from the neural 
crest. As previously mentioned, those cells form only certain ectodermally-
derived mesenchymal tissue such as face cartilage, whereas mesenchymal 
stem cells are responsible for the production of all other mesenchymal 
tissue throughout the body; bone, fat, and cartilage, as well as smooth, 
skeletal, and cardiac muscle (25, 26).  
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Figure 1.7: Spider diagram depicting the lineages and resultant tissue 
types of mesodermally-derived cells. 
 
1.1.3. Niche 
Niche in biology is much the same as in normal aetiology. It refers to a 
particular environment within the body where a specific cell might reside. 
Cell function is optimised by the microenvironment provided by the niche; 
this is particularly the case for some stem cells. Each niche is different, 
containing different cells, and a different biochemical environment, 
different stiffness's, and different roughness's, all to optimise the function 
and survival of the cells within that niche. With MSCs however, they have 
been found to be resident in a number of separate and biologically distinct 
niches, whilst still maintaining their MSC phenotype (27). MSCs are 
classically linked to the bone marrow (28, 29), but they have since been 
isolated from a number of other niches such as adipose tissue (30), corneal 
stroma (31), Wharton’s jelly of the umbilical cord (32), tooth pulp (33), 
amniotic fluid (34), and the olfactory mucosa (1, 35, 36). Although these 
studies have all identified each niche-derived MSC as true MSCs, very little 
has been done to compare MSCs from these different niches to identify any 
differential function, behaviour, gene expression, factor secretion, or 
effect on separate biological systems. The two niches that are most 
important throughout this study are the bone marrow and the olfactory 
mucosa, which will be discussed in more length. 
 
1.1.4. MSC Morphology, Detection, and Function 
1.1.4.1. Morphology  
When first discovered in the 1960’s, MSCs were termed colony forming unit 
fibroblasts (11) due to their fibroblast-like morphology. This similar 
morphology however is as far as the similarities between the two cell types 
go. Fibroblasts don’t share the same differentiation capabilities, nor do 
they have the same cell surface markers (37, 38). Like fibroblasts though, 
MSCs have small cell bodies with large nuclei and multiple processes, and 
40 
 
can often be mistaken for fibroblasts when studying them under phase 
microscopy.  
 
1.1.4.2. Detection 
MSCs express a number of cell surface markers and intracellular proteins 
which define them as MSCs. Each MSC phenotype may not express each 
marker, but there are a number of “classic” MSC markers which are 
expressed by all MSCs and not fibroblasts. Some of these are CD90, CD105, 
CD166, and CD271. A list of widely used MSC markers can be found in Table 
1.2.             
 
 
 
Table 1.2: List of MSC-associated cell surface markers and intracellular 
proteins used to identify MSCs (501). 
 
MSCs have a number of identifiable traits, one being their ability to adhere 
to plastic surfaces (12). These adherent cells can then be analysed for any 
number of these MSC markers by immunocytochemistry, flow cytometry, or 
RT-qPCR. Once the presence of these markers has been established, the 
cells can be further identified by inducing them to differentiate towards 
bone and fat. If, under these conditions, their morphology, MSC marker 
expression, and ability to form bone and fat has been established, then the 
identity of the MSC can be conclusively validated. 
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1.1.4.3. Function 
MSCs play a number of important roles throughout the body, roles which 
may differ depending on the location of the particular MSC, but regardless 
of the MSC’s niche, their defining biological capabilities are the same. 
MSCs are like mini biochemical factories, secreting vast amounts of 
chemical modulators which regulate many different biological functions, as 
follows: 
 
1.1.4.3.1. Differentiation 
Their primary function is to differentiate towards cells from lineages 
pertaining to the mesenchyme; bone, fat, cartilage, connective tissue, and 
muscle (39, 40). This is true of all MSCs. Figure 1.8 outlines each cell 
lineage which originates from MSCs.   
 
 
 
Figure 1.8: Schematic diagram representing each cellular lineage which 
can originate from a parent MSC. Image taken from DiMarino et al. (40).  
 
This differentiation can be induced using factor rich media which 
determine the fate of MSC by triggering various signalling pathways (41, 
42), and also by triggering similar pathways using non-media solutions such 
as substrate topographies and matrix stiffness’s (43-46). A full list of 
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universally recognised induction media used throughout this study can be 
found in materials and methods Table 2.10, and the subject of substrate 
topographies will be further discussed in section 1.3.3.1. 
 
1.1.4.3.2. Immunosuppression 
Although the exact mechanisms of immunosuppression induced by MSCs 
aren’t fully understood, it is thought that a number of adhesion molecules 
and contact-mediated immunosuppressive soluble factors are involved. 
Cell-cell contact seems crucial in the production of the required soluble 
factors, either from the MSC’s themselves or from the target cells upon 
contact initiation by the MSC’s. For example, Augello et al (47) showed 
that T cell proliferation can be suppressed by the release of the inhibitory 
molecule PD1, and also nitric oxide (inhibits T cell activation) and 
indoleamine 2,3-dioxygenase (IDO) (reduces Tryptophan levels essential for 
lymphocyte proliferation) have been shown to be released by MSC’s only 
after contact with target cells initiates the release of IFNγ (48). Possibly as 
a self-regulatory mechanism, IFNγ releasing TH cells are themselves 
inhibited by MSC-derived IDO, which can also work in conjunction with 
other cytokines such as prostaglandins to inhibit the activity of natural 
killer (NK) cells (49). A number of other factors such as TNF, Il-1α or Il-1β 
(stimulate chemokine production by MSC’s), transforming growth factor-β1 
(TGFβ1), hepatocyte growth factor (HGF), Il-10, pGe2, haem oxygenase-1 
(HO1), and Il-6 are also prevalent in MSC-mediated immunosuppression 
(50). 
 
1.1.4.3.3.  Migration 
Administration of stem cells to the host for therapeutic purposes is clearly 
very important. In situ administration is of course the preferred means but 
is not always possible, either due to the dangerous or inaccessible location 
of the injury site, such as the CNS, or due to the systemic nature of the 
injury as is the case with multiple sclerosis. Fortunately MSC’s are able to 
locate and migrate to the area(s) of damage when administered 
intravenously (51), where they can then maintain repair and restore 
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function (52). This migration is possible due to MSC’s ability to traverse 
blood vessels via surface adhesion molecules, and to elicit a mechanism of 
“rolling” dependant on p-selectin and vascular cell-adhesion molecule 1 
(VCAM-1) (53). This migration is the result of the detection of chemokines 
from the site of injury, picked up by the MSC’s cell surface receptors (54), 
and the release of enzymes which allow endothelial degradation and 
movement across blood vessels (55).   
 
1.1.4.3.4. The “Bystander” Effect  
This refers to the MSC’s ability to passively or transiently help in a 
situation of trauma or injury, for example by suppressing immunity or 
activating endogenous reparative cell populations.  
 
This effect was first witnessed during a skin graft experiment on non-
human primates where an in situ injection of MSC’s prolonged the survival 
of the graft (56). This was the first of many such bystander effects 
observed, from the inhibition of pathogenic antibodies (55)  to the 
neuroprotective effect of their releasing anti-inflammatory, anti-
apoptotic, and trophic factors (57), the ability of MSC’s to 
transdifferentiate into neuronal cells (58) (Figure 1.9), and their propensity 
to guide differentiation of neural progenitors towards an oligodendrocytic 
fate (58).  
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Figure 1.9: The bystander effects and transdifferentiation potential of 
MSC’s in the CNS. MSC’s anti-inflammatory capacity can protect microglial 
cells, their anti-apoptotic effects can increase the proliferation of 
neuroprotective astrocytes, their trophic factors can influence the 
differentiation of neural precursor cells, as well as generating neurons and 
neural precursor cells by transdifferentiation. Image taken from Ruster et 
al. (51).  
 
In short, MSC’s are multipotent self-renewing cells, with not only the 
capacity to differentiate into different mesenchymal cell types, but 
potentially also some cells from other germ layers, as well as having an 
immunoprotective effect, an ability to migrate to the site of injury after 
systemic delivery, and also the ability to influence the genesis of and 
protection of other neuroprotective cells in the CNS.  
 
1.2. The Central Nervous System (CNS) 
The CNS is the core functional compartment of the human body, which 
takes all information from external and internal stimuli, and translates this 
into the movement, function, and regulation of each and every cell in the 
body. It is the computer of the body, and without any of its constituent 
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parts, the body would cease to function. It consists of the brain, the spinal 
column, the optic system, and the olfactory bulb of the olfactory system 
(59, 60), each comprising of a number of different cell types. The Brain 
and spinal cord can be divided into two distinct areas, the white matter 
and gray matter (59). The optic and olfactory systems are essentially 
extensions of the brain, and thus don’t comprise of white and gray matter, 
but they are still considered part of the CNS due to their proximity and 
connection to the brain (59, 60). The CNS consists predominantly of 
neurons and glial cells, which work in tandem with each other but have 
very unique functions. 
 
1.2.1. Cells of the CNS 
1.2.1.1.  The Neuron 
The neuron is a large cell consisting of 3 major parts; the Soma (cell body), 
the Axon, and the Dendrites (synaptic terminals) (Figure 1.10) (502). 
Neurons are the wiring of the human body. They transmit messages from 
distal sensory parts of the body to central localised areas requiring an 
action to that message, as well as maintaining bodily function by relaying 
all kinds of messages from within. Neurons carry action potentials 
generated in the cell’s membrane down the axon which is covered by a 
lipid rich protein membrane called myelin. This myelin sheath acts as 
insulation, and protects both the signal and the axon itself, much like flex 
that covers a normal electrical cable. When the action potential reaches 
the axon terminus, vesicles of signalling molecules called 
neurotransmitters are formed and secreted across junctions called 
synapses to be accepted by receptors on the synaptic terminals. These 
signals are then transported to neighbouring cells via the telodendria 
(Figure 1.11) (503).   
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Figure 1.10: Diagram depicting the different sections of the neuron. The 
cell body contains the nucleus and is responsible for signal production, the 
axon guides the action potential towards the axon terminus where the 
signal is transmitted via signalling molecules called neurotransmitters into 
the synaptic terminals (dendrites) from which the signals are transmitted 
to neighbouring cells. Image from Wikimedia Commons (502). 
 
 
 
Figure 1.11: Diagram depicting the signal transduction of a neuron via 
neurotransmitter secretion from axon to dendrite. Image modified from 
Wikimedia Commons (503). 
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1.2.1.2. Glia 
Glia (from the greek word for “glue”) refer to the cells of the nervous 
system, both PNS and CNS, who act as support cells by way of 
scaffold/tissue structure, supplying nutrients, production of protective 
membranes, and recycling dead cells (61-63). CNS glia consist of Microglia, 
Astrocytes, Oligodendrocytes, Ependymal cells, and Radial glia: 
 
1.2.1.3. Microglia 
Microglia are the macrophages of the CNS. The soldiers and scavengers, 
which phagocytose any xenoparticles and apoptotic debris. Unlike other 
glial cells which are derived from the ectoderm, adult microglia are 
derived from haematopoietic stem cells from the mesodermal lineage after 
injury or disease (64). They are stellate (star shaped) with numerous 
processes extending from their cell body (Figure 1.12) with which they are 
constantly touching and assessing the local environment in the search for 
sub-optimal conditions (61-63). They can be isolated from CNS cultures by 
their cell surface markers; CD11b, CD45, ED-1, and CD200. 
 
 
 
Figure 1.12: Diagram depicting a microglial cell, including its stellate 
shape, neuronal interaction, and some of its cell surface markers. Image 
taken from Ransohoff et al. (65).  
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1.2.1.4. Astrocytes 
Astrocytes are the most abundant cells in the CNS (66). It is still under 
debate exactly how abundant they are compared to neurons, but it is 
generally accepted that they make up the bulk of the stromal tissue in the 
CNS. As well as providing the architecture for the CNS, astrocytes play 
other crucial roles, particularly regarding formation of the glial scar post 
injury (67-70). Astrocytes exist in a continuum of states ranging between 
reactive and non-reactive (71). Post insult or injury to the CNS, astrocytes 
become reactive, changing their morphology to extend more processes, 
and upregulating production of numerous proteins such as Glial Fibrillary 
Acidic Protein (GFAP), Nestin, and Vimentin (72-74). These reactive 
astrocytes then form a glial scar, protecting the site of injury from further 
damage (65-75). Like microglia, astrocytes are also stellate (Figure 1.13), 
and can be isolated by any of their numerous cell surface markers and 
intracellular proteins such as GFAP, ALDH1L1, and S100-β (75).  
 
 
 
Figure 1.13: Fluorescent image of astrocytes showing positive reactivity to 
GFAP (Green). Image kindly donated by Daniel McElroy.  
 
1.2.1.5. Oligodendrocytes 
Derived from oligodendrocyte precursor cells (OPCs), Oligodendrocytes are 
the myelinating cells of the CNS (76). Their multiple processes allow them 
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to interact with multiple axons at once, ensheathing each axon with 
approximately 1 µm of myelin (76). It is thought that oligodendrocyte 
myelination is regulated by pro-myelinating factors secreted by astrocytes 
(70, 77, 78). Ioannidou et al. demonstrated with in vivo imaging techniques 
that the processes of each oligodendrocyte are constantly extending and 
retracting, wrapping strands of myelin round the axon in a corkscrew type 
manner, before spreading out along the axon to form a sheath (79, 80). 
Oligodendrocytes are the final CNS phenotype to be formed during 
embryogenesis, and can be identified during each stage of their 
development by a number of different cell surface markers outlined in 
Figure 1.14 (76). 
 
 
 
Figure 1.14: Schematic diagram depicting the different stages of 
oligodendrogenesis, and the cell surface markers which are expressed by 
the cells at each stage. Image was taken from Baumann et al. (76). 
 
1.2.1.6. Ependymal Cells 
Ependymal cells are epithelia-like cells which line the central part of the 
spinal column, and also the ventricular system of the CNS (81). They are 
covered in a layer of immotile cilia which circulates cerebral spinal fluid 
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(CSF) that the cells themselves help to produce as part of the choroid 
plexus (81, 82).  
 
1.2.1.7. Radial Glia 
Radial glia have two primary roles in the CNS. During development, radial 
glia can serve as primitive progenitors to neurons, astrocytes, 
oligodendrocytes, and ependymal cells (83). They’re also utilised by 
developing neurons as scaffolds, helping to maintain the architecture of 
the CNS (83-85).  
 
1.2.2. White Matter and Gray Matter 
1.2.2.1. White Matter 
Making up the majority of the inner brain, and the external parts of the 
spinal cord, the white matter is predominantly comprised of glia and 
myelinated axons (86). White matter is responsible for the signal 
transduction and message relay from the cognitive parts of the CNS to the 
rest of the body (86). It is essentially the network of electrical circuits 
which connect the mainframe (brain) to the rest of the system (body). It is 
white, mainly due to the lipid rich myelin which protects each axon (86), 
and as an individual gets older, more and more white matter is lost 
without being regenerated, leading to increasingly impaired cognitive 
function over time (87). In demyelinating conditions such as multiple 
sclerosis (MS), the axon’s protective myelin sheath is attacked by the 
body’s immune system, and large parts of white matter are degraded and 
die off (88, 89). Other conditions which effect the white matter include 
degenerative conditions such as Alzheimer’s, during which solid amyloid 
plaques form over time and disrupt the signalling capabilities of the axons, 
eventually leading to their degradation and loss of white matter (90, 91). 
White matter injuries separate to these neurodegenerative conditions, are 
more likely to be reversible, as the damaged axon is still attached to a 
healthy cell body and can still be repaired by endogenous glia populations 
(92, 93). Figure 1.15 shows the white matter and gray matter areas of the 
CNS. 
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1.2.2.2. Gray Matter 
If the white matter is to be thought of as the electrical circuits extending 
from the central processing unit (CPU), the gray matter is the CPU itself. It 
consists mainly of glia and neuronal cell bodies, and is the cognitive part of 
the CNS where all the signals and messages are processed and generated to 
be passed through the white matter and into the body (94). Gray matter is 
located predominantly at the external areas of the brain and in the central 
regions of the spinal cord, although in the brain, gray matter diffuses with 
white matter in areas such as the basal ganglia and brain stem nucleus 
(94). Chronic neurophysiological conditions like Alzheimer’s also affect 
gray matter due to the build-up of plaques denying any repair potential 
(95). In addition smoking has been heavily linked with increased gray 
matter degradation (96). 
 
 
   
 
 
 
 
 
 
A 
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Figure 1.15: Examples of white matter and gray matter in spinal cord (A) 
and the human brain (B). Images modified from Wikimedia Commons (A) 
(504) and the National Institute of Health (B) (505).   
 
1.2.3. CNS Injury 
As just touched upon, the CNS can be damaged by a number of 
autoimmune disorders, age-related conditions, and of course from physical 
trauma caused by accident or injury. Each can be debilitating, 
degenerative, and even fatal, and although there are a number of 
treatments available, to date there are no cures for any CNS related 
conditions, with current therapies focusing mainly on treating secondary 
symptoms and slowing any disease progression (97). There are many 
reasons as to why the CNS is so difficult to repair. It is a very complex and 
sensitive structure which is very susceptible to secondary damage and thus 
difficult to operate on. Diseases of the CNS are often multifactorial, 
involving multiple pathologies and affecting multiple cellular phenotypes. 
The CNS also has its own repair mechanisms which can impair any potential 
regeneration (98). 
 
 
 
B 
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1.2.3.1. Autoimmune disorders of the CNS 
An autoimmune disorder is one where the body’s immune system 
malfunctions and starts attacking certain parts of the body. There are a 
number of autoimmune disorders which affect the CNS such as Diffuse 
myelinoclastic sclerosis (99), Acute haemorrhagic leukoencephalitis (AHL) 
(100), Transverse myelitis (101), Neuromyelitis optica (102), Acute 
disseminated encephalomyelitis (ADE) (103, 104), and multiple sclerosis 
(MS) (105).  
 
1.2.3.1.1.    Acute Disseminated Encephalomyelitis (ADE) 
ADE is an acute demyelinating disease of the brain which is usually caused 
by a viral, bacterial, or parasitic infection, but spontaneous ADE can also 
occur (106-108). It affects a very small number of people (~8 in every 
100,000), and is most common in younger children, especially those who 
have just experienced an upper tract infection or vaccination (106-108). It 
results in axonal demyelination, leading to neuronal degeneration and 
lesions in the white matter of the brain, but as the disease is associated 
with an acute pathology, and is most common in young people, the damage 
is often reversible and thus only fatal in ~5% of cases (106-108). The 
aetiology of the disease is not fully understood but it is thought to involve 
a defective immune response to myelin basic protein (MBP) (108). 
Symptoms can include, fever, malaise, nausea, and sometimes coma 
and/or death (106-108). 
 
1.2.3.1.2. Multiple Sclerosis (MS)    
MS is a far more serious condition to ADE, although the demyelinating 
pathology is the same (108, 109). Unlike the acute nature of ADE, MS is a 
progressive chronic condition which is ultimately fatal. MS is most common 
among Caucasian women living in Europe, North America, New Zealand, 
and parts of South East Australia, is much less common amongst Hispanics, 
Africans, and Asians, and is very rare amongst indigenous people such as 
Maori, Aboriginals, and the Inuit (110). Figure 1.16 outlines the 
geographical incidence of MS. The gender link to MS is yet to be 
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established, but the geographical link has been linked to Vitamin D, or a 
lack of it (111-115). Canada and Scotland have the highest incidences of MS 
in the world, countries which have relatively low annual rates of sunshine 
compared to the rest of the world. People of New Zealand and Australia 
are extremely vigilant when it comes to protecting against skin cancer due 
to a large hole in the ozone layer over New Zealand and South East 
Australia. This has led to an increase in the use of sun block and also to the 
rise of Vitamin D related conditions such as rickets (116). Consumption of 
dietary vitamin D is also low in western society, with people opting for a 
more meat rich diet over vitamin D rich vegetables such as spinach and 
broccoli (117), and in some countries like Scotland, changes in fishing 
regimes have seen a switch from the consumption of large amounts of 
vitamin D rich oily fish to white fish such as cod which has comparatively 
low amounts of vitamin D. This link between MS and vitamin D has also 
been associated with polymorphisms in genes involved in the vitamin D 
pathway (118), so there is definitely an established association between 
the two. This is far from the solution however. There are many potential 
causes of MS, and treatment is a multi-factorial process depending on the 
progression of the disease (119-125), but this is one very active field of 
research in what is a far from well understood condition. 
 
 
 
Figure 1.16: Map of the world highlighting the most prevalent areas of MS 
worldwide. Taken from multiplesclerosis.net (506). 
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MS is characterised by a malfunction of lymphocyte populations in the 
brain and spinal cord, neurons, and oligodendrocytes which leads to axonal 
demyelination, gliosis, and neuronal cell death affecting both gray and 
white matter (119-125). Attacks are transient, and endogenous repair can 
occur to an extent, but due to the chronic nature of the disease, the 
affected sites are progressively degraded over time until irreparable 
lesions are formed, leading to a loss of cognitive function, and ultimately 
death (119-125). There are four stages of MS pathology outlined by Lublin 
et al. (126). They are: 
 
 Relapse remitting – the initial stage where symptoms are present, but 
can partially recede or even go completely 
 Secondary progressive – can take 15 years to get to this stage, where 
symptoms cease to remit and start to persist 
 Primary progressive – when symptoms start to progress to more 
serious cognitive complaints such as walking and speech impairment 
 Progressive relapsing – the final stage of the disease where cognitive 
function gets progressively worse to a fatal conclusion. Patients at this 
stage will be wheelchair bound. 
 
Initial symptoms of MS are malaise, nausea, headaches etc, quite general 
symptoms which often lead to the patients being undiagnosed for long 
periods. 
  
There are a number of cells, factors, and signalling molecules involved in 
the pathogenesis of MS, making it incredibly difficult to understand the 
exact mechanisms involved. Studies have highlighted certain factors and 
interactions involved; Steinman (124) demonstrated a mechanism involving 
VLA4 secretion by T cells which triggers osteopontin (OPN) production by  
neuronal cell bodies, ultimately leading to damaged oligodendrocytes. This 
alongside the production of antibodies to proteins such as Myelin 
Oligodendrocyte Glycoprotein (MOG), MBP, and Proteolipid Protein (PLP) 
which lead to the destruction of myelin, and also the secretion by 
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astrocytes of αB crystallin, which has been shown to cause remission of MS. 
Hemmer et al. (125) showed a link between CD8+ T cells stimulating 
apoptosis of neuronal and glial cells via FAS ligation, a binding by 
glutamate of neurotoxins which are secreted by glial cells, antibody 
mediated compliment activation leading to a complex which attacks the 
myelin membrane, and the release of inflammatory cytokines from 
macrophages, microglia, and astrocytes. The full story of how and why MS 
occurs though is still not fully understood. 
 
Much research is focused on reversing the effects of the disease such as 
looking at ways to stimulate re-myelination (127), and stimulating local 
glial populations to aid damage repair (128). Stimulation of myelin 
production is of great significance throughout this thesis. The potential of 
mesenchymal stem cells found in the olfactory mucosa to stimulate axonal 
myelination has been established by Lindsay et al. (1). The exact 
mechanisms involved have yet to be established however, and this project 
will set out to try and further understand these mechanisms and how they 
might be of any future therapeutic potential.  
 
1.2.3.2. Spinal Cord Injury (SCI) 
According to the World Health Organisation, up to half a million people 
each year are victims of a spinal cord injury, which can often result in a 
lifetime of complete paralysis (507). Statistics show that the vast majority 
of SCI’s are the result of road traffic accidents, falls, sporting injuries, or 
violence (Figure 1.17) (508). Likely due to an increased exposure to risk 
factors such as fast driving, violence  and reckless behaviour, SCI’s are 
most common amongst young males between 20 and 29 years old (506). 
SCI’s lead to irreversible paralysis when the spinal cord is severed, 
breaking any connection between the brain and motor neurons of the 
peripheral nervous system (129).  
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Figure 1.17: Pie chart representing the different causes of SCI and their 
relative percentages of prevalence. Taken from the Christopher and Dana 
Reeve Foundation (508) 
 
SCI can be immediately fatal depending on the severity of the imposed 
trauma, but those who survive can be classified as to the severity of the 
injury, the location of the injury, and the secondary effects of the injury 
(130). Survival can lead to secondary complications which can cause 
fatalities years after the initial occurrence of the SCI. This most commonly 
occurs within two years of the initial injury, but even though SCI survivors 
can regain full fitness, life expectancy is generally lower compared to able 
bodied individuals (507). 
 
To date there are no viable treatments regarding SCI repair other than 
physiotherapy. The spinal cord is a complex structure consisting of 
multiple different cell types, and damage to it results in a cascade of 
reparative mechanisms which ultimately result in the site of injury being 
unable to regenerate back to its normal functional state (69, 131-133). 
Possibly the most important local response to SCI is the formation of the 
glial scar. As the spinal cord is compromised, the danger of infiltration by 
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potentially harmful cells and immunomodulators is very high, so to prevent 
further damage, astrocytes flood the site of injury and form a protective 
barrier called a glial scar (Figure 1.18) (69, 131-133). Paradoxically 
however, this scar is impenetrable to neurons, preventing axonal 
regeneration, and inhibiting all signalling between neurons above and 
below the injury site (69, 131-133). This presents a major challenge to 
researchers, as any attempt to prevent the glial scar would undermine its 
protective nature and compromise the injury site further. Even if the glial 
scar could be prevented from forming, there is still a large empty lesion 
where all the damaged axons have retracted or degraded completely. 
Neurons are very large cells with long axons and multiple neurites 
extending from the terminal ends, it would be very difficult to bridge the 
lesion and encourage the neurons to extend far enough to make the 
required connections at the other side.  
 
 
 
Figure 1.18: Schematic diagram of the glial scar formed post-spinal cord 
injury. Microglia and macrophages infiltrate the site of injury to clean up 
debris, and astrocytes fill the extremities of the injury site to prevent 
further damage. Adapted from Rolls et al. (131).  
 
SCI repair is far from a unilateral approach, and all of these factors will 
have to be incorporated in order for a successful outcome. Studies are 
currently looking at factors to inhibit the glial scar (132) whilst modulating 
the environment to compensate for the loss of protection that the scar 
allows (69), and also looking into potential scaffolds to bridge the gap 
formed at the injury site (134) whilst encouraging neurite outgrowth to 
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extend neuroregeneration and re-establish connections across the lesion 
(135, 136). 
 
1.2.4. The Olfactory System 
Like the nervous system, the olfactory system (OS) has both a central and a 
peripheral component, although the whole system is an extension of the 
CNS (35, 137). The central component of the OS consists of the olfactory 
bulbs which extend from the base of the forebrain and rest on the 
cribriform plate, a piece of bone at the apical part of the nose which 
separates the brain and the nasal cavity (35, 137). The peripheral 
component of the OS consists of the olfactory mucosa (OM), which is 
located across the cribriform plate between it and the nasal cavity. 
Transcending the cribriform plate from the OM are olfactory receptor 
neurons (ORNs). These bipolar neurons have their cell bodies within the 
OM, and project axons down towards the basal edge of the OM, and 
upwards through the cribriform plate and into the olfactory bulb where 
they connect to mitral cells via glomeruli at the base of the bulbs (Figure 
1.19) (509).  
 
This whole system allows the CNS to capture and interpret smells, but is 
also a target of constant insult and damage due to the inhalation of 
chemically noxious and physically damaging airborne particles. 
Consequentially, the olfactory system, particularly the OM, is a locus of 
constant neuroregeneration, and thus of great interest to those concerned 
with conditions such as MS and spinal cord injury where neuroregeneration 
does not occur (138-140). To harness this endogenous reparative capability 
and replicate it ectopically would be extremely beneficial for a number of 
neurodegenerative conditions throughout the body. 
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Figure 1.19: Schematic diagram of the olfactory system, taken from 
Thuret et al. (509). 
 
1.2.4.1. The Olfactory Mucosa 
For decades it was thought that you were born with your lifetime’s supply 
of neurons and that the body was incapable of neurogenesis throughout 
adulthood. It has since been demonstrated however that there are certain 
areas throughout the CNS that are capable of neurogenesis throughout the 
life of humans. Sohur et al (141) identified 2 constituent neurogenic areas 
of the adult CNS in the olfactory bulb and the hippocampal dentate gyrus, 
and a number of other areas throughout the CNS which contain multipotent 
neural progenitor cells. More recently it was discovered that the OM 
contained not just neural progenitors but also multipotent adult stem cells 
which reside in the Lamina Propria of the OM (35, 36, 142-145).  
 
The olfactory mucosa (OM) is a multicellular structure located at the apex 
of the nasal cavity, and consists of two distinct regions; the olfactory 
epithelium (OE) and the lamina propria (LP) (Figure 1.20) (35). Amongst 
the many cells which make up the OM are two distinct stem-like cell types 
located in the OE; The horizontal basal cells (HBC’s) and globose basal 
cells (GBC’s), referred to as putative stem cells or adult neural progenitors 
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of the olfactory system, that are considered to give rise to new neurons in 
the OM as well as help regenerate all the other constituent cells of the OM 
(146, 147). As the name suggests, the GBC’s are more spherical in 
morphology than the HBC’s, and they are dorsally situated relative to the 
HBC’s (Figure 1.20).  
 
 
 
Figure 1.20: Schematic diagram depicting the cellular make up and 
physical structure of the olfactory mucosa (35). 
 
As one of the first contacts of noxious or toxic inhalations, GBC turnover is 
relatively high, and consequentially they proliferate at a higher rate than 
the HBC’s which are often in a state of quiescence (36). GBC’s are thought 
to give rise to olfactory receptor neurons (ORN’s) and sustentacular cells 
(support cells for ORN’s) (148), and HBC’s are thought to regenerate the 
GBC’s themselves (146). HBC’s have also been shown to differentiate in 
vitro towards both neuronal and non-neuronal lineages (146). Both cell 
types are capable of self-renewal, and their specific activation is 
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dependent on the extent of the damage to the OM, i.e. minor damage to 
the ORN’s would only necessitate the activation of the GBC’s to regenerate 
them, whereas more serious damage resulting in the degradation of 
multiple cell types including the GBC’s would require the activation of 
HBC’s (36, 146). This data has prompted the suggestion that it is the HBC 
that is the adult neural stem cell of the OM, although studies are still 
ongoing. 
 
Also residing in the LP are a small population (~1% of total cells) of 
mesenchymal stem cells, which are thought to assist in the regeneration 
and the functional repair of damaged neurons post-injury (35). Only 
discovered quite recently, little is known about their function in the OM. 
Studies have confirmed them to express MSC markers such as CD90, CD105, 
CD166, and Nestin, and have demonstrated their ability to form bone and 
fat, so their identity as an MSC is no longer under dispute. MSCs are multi-
functional cells so it’s unlikely that they are limited to just one role in the 
OM, but their exact functions have yet to be fully determined. They may 
regenerate or replace local mesenchymal tissue such as the cribriform 
plate and cartilage in the nose, or they may have an immunomodulatory 
role to control the local immune system post-injury. Of most interest in 
terms of neuroregeneration however is their potential to aid in the repair 
of damaged neurons or to even regenerate new neurons altogether. MSCs 
are known to secrete large amounts of numerous hormones, growth 
factors, and chemokines, which could potentially be aiding HBCs and GBCs 
to replenish the olfactory system, or stimulating local glial populations to 
increase myelin production on damaged or demyelinated axons.   
 
Lindsay et al. (1) have already demonstrated an ability for olfactory 
mucosa-derived MSCs (OM-MSCs) to stimulate axonal myelination in vitro. 
This pro-myelinating effect however was not observed with bone marrow-
derived MSCs (BM-MSCs) so it is likely that OM-MSCs are secreting at least 
one factor which has a pro-myelinating effect. 
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1.2.5. Cell Transplantation into the CNS 
Numerous regenerative therapies are being researched regarding the 
transplant of exogenous cells directly into the CNS (149-153). This covers 
such approaches as stimulating endogenous repair (154), replacing 
damaged tissue (155), grafting myelin producing cells (156), and 
transplanting stem cell populations to generate new cells such as damaged 
neurons (149). Such approaches are often coupled with biological scaffolds 
or devices to guide any cellular regeneration strategies (157, 158).   
 
1.2.5.1. Stimulating Myelination via Exogenous Cell Transplant 
CNS conditions such as MS and SCI result in the demyelination of axons and 
the deterioration of local populations of myelinating glial cells. If neurons 
aren’t irreversibly damaged, repair could be initiated by the restoration of 
the local glial population. Studies have shown that transplantation of 
oligodendrocyte precursor cells (OPCs) can enhance myelination and even 
functional recovery in animal models of MS and SCI (159, 160). Even 
ectopic cell transplants have seen enhanced repair in the CNS. Schwann 
cells, the myelinating cells of the PNS which won’t normally integrate in 
the CNS due to their inability to penetrate the astrocyte boundary, have 
been shown stimulate myelination when transplanted ectopically (156, 
161, 162). Olfactory ensheathing cells (OECs), a type of glia which are 
responsible for supporting the repair of olfactory receptor neurons in the 
olfactory system, have been shown to stimulate myelin production in vitro 
(163), and also to increase axonal repair when transplanted into a 
compromised CNS (164-168). 
 
1.2.5.2. Stem Cell Based Regeneration of Local Cell Populations  
There are a number of candidate cells for the transplant-mediated 
regeneration of CNS tissue. Embryonic stem cells (ESCs), capable of 
differentiating into any cell from any of the three germ layers, could be 
transplanted directly to the injury site, and via endogenous cues, 
differentiate to re-form damaged cells (169). The behaviour of 
undifferentiated ESCs however, is very unpredictable, and cells may not 
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integrate at all with the surrounding niche, or they could proliferate 
uncontrollably and lead to tumour formation (170). The most sustainable 
approach regarding ESC transplantation is to part differentiate the cells 
towards neuronal and glial lineages post-transplant, an approach which has 
seen success is various disease models (171, 172).  
 
Already part-programmed towards a neuronal fate, neuronal stem cells 
(NSCs) are also a candidate for transplant-mediated cell therapy (173).  
Not only are they capable of forming new neuronal and glial cells (174), 
they also elicit a neuroprotective “bystander effect”, releasing trophic 
factors and signalling molecules which guide endogenous regeneration 
(149, 175). 
 
1.3. MSCs in Health and Disease 
MSCs have for some time now, been considered as potentially ideal 
candidates for the treatment of a number of conditions such as stroke 
(176), Alzheimer’s (177), autoimmune diseases (178), amyotrophic lateral 
sclerosis (ALS) (179), and SCI (180). As well as these predominantly CNS 
and degenerative conditions, MSCs are also the subject of much research in 
the field of orthopaedics (181). The ability of MSCs to form bone in 
particular is of great importance when considering disorders of the 
musculoskeletal system and the body’s need for repair post-injury or post-
surgery. 
 
1.3.1. MSCs and MS   
MSCs have been considered as a candidate cell-based therapy to treat MS 
after studies in rodent Experimental Autoimmune Encephalomyelitis (EAE) 
models showed clinical and pathological improvements in animals treated 
intravenously with MSCs expanded in vitro (182). The suggested 
mechanisms of action of the MSCs on EAE were an induction of peripheral 
immune tolerance (183), the stimulation of endogenous neurotrophic 
factors (184), and the suppression of B cell activity (185). These findings 
led to numerous other studies which have demonstrated a therapeutic link 
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between MSCs and MS. It has been demonstrated that MSCs migrate to the 
EAE lesion site whether they are administered intravenously (186, 187), 
intrventricularly (188), or intraperitoneally (189), and although there is no 
definitive evidence of trans-differentiation occurring post-transplant (185-
187, 189), MSCs have been shown to develop a neuronal morphology once 
in the CNS (188). Other proposed repair mechanisms in the EAE model were 
by inducing endogenous oligodendrogenesis and neurogenesis as previously 
mentioned via the “bystander effect” of secreting regulatory soluble 
factors (50, 57, 58, 190). 
 
Current therapies involving patients at the relapse remitting phase of the 
MS are often insufficient to treat the disease, certainly insufficient to 
overcome it (191). Issues arise from patient intolerance (192) to a lack of 
control of the inflammatory effects of the disease (193), and there are 
often side effects (194-196). Even if the treatments were more robust, 
there are no current therapies which are able to reverse the 
neurodegenerative damage caused by the disease so a progression to the 
secondary progressive (SP) phase is inevitable (191). There are no currently 
available treatments for the primary progressive phase. For these reasons, 
MSC-based therapies are high on the agenda as potential treatments for 
MS. Further to their observed potential in EAE animal models, MSCs are 
also beneficial in terms of their autologous nature, their expansion 
capabilities, and their ease of administration into the patient. 
 
Progress is slow however, and by 2012 only 4 human trials were taking 
place worldwide (197-200), and three of those focused only on patient 
safety, with the other focused on differences in visual capacity. Pre-
clinical data is optimistic but purely anecdotal, with positive data 
regarding magnetic resonance imaging (MRI) and immunological studies. 
Low patient numbers and a general scope of study mean that these trials 
are very preliminary indeed. One post-2012 study however, has shown for 
the first time a neuroprotective effect elicited by MSC translplantation. 
Connick et al. demonstrated by analysis of visual endpoints that there 
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were physiological, structural, and functional improvements in patients 
treated with MSCs (201). There has been much excitement surrounding 
MSCs and MS, and their potential is undisputed. MS is a complex condition 
however, with multiple pathologies, and it is likely that MSC 
transplantation would be just one part of any successful therapy to treat 
MS. 
 
1.3.2. MSCs and SCI 
Although MS and SCI are pathologically distinct, they do share common 
symptomatic traits such as demyelination, apoptotic lesions, and local 
inflammation (180). Thus, for similar reasons as discussed with MSCs in MS, 
MSCs are also thought of as a potentially viable cell-based therapy for the 
treatment of SCI. 
 
Trans-differentiation of MSCs is still a topic of much debate. Studies have 
demonstrated that MSCs possess numerous neuronal and glial genes, and 
have demonstrated an ability to form cells of a neurogenic morphology 
which express neurogenic markers, but whether these cells can perform as 
fully functioning neurons with the same electrophysiological capabilities 
has yet to be determined (202-206). Their potential for neuronal trans-
differentiation in situ is still being investigated as a possible reparative 
mechanism. 
 
The spinal cord is such a challenging environment for self-repair due to 
weak neuronal plasticity; i.e. an inherent remodelling incapacity due to 
numerous endogenous mechanisms designed to protect the injury site 
(180). MSCs have the potential to overcome these mechanisms whilst 
maintaining the integrity of the injured spinal cord via its substantial 
secretome (207). MSCs secrete neuroprotective and neuroregenerative 
growth factors such as neural growth factor (NGF), vascular endothelial 
growth factor (VEGF), glia-derived neurotrophic factor (GDNF), and brain-
derived neurotrophic factor (BDNF) (56, 208-211), and also anti-
inflammatory cytokines such as TGF-β1 which can overcome the 
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endogenous pro-inflammatory molecules such as IL-1β, and TNF-α which 
are upregulated post-injury (212-214). MSCs have also been shown to 
produce exosomes; microvesicles rich in lipids, proteins, growth factor 
receptors, and messenger (mRNA) and micro RNA (miRNA), all of which can 
help to stimulate an endogenous regeneration of the damaged spinal cord 
(215-218). Further to this, MSCs have an immunomodulatory effect which 
can regulate local natural killer (NK) cell, B cell, and cytoxic T cell 
populations, as well as inhibiting apoptosis, creating an environment which 
is much more permissive to neuro and gliogenesis (218-224). Figure 1.21 
outlines the pathobiology of SCI and the potential MSC responses which 
counter these effects. 
 
There have been a number of studies on SCI animal models which have 
demonstrated increased motor function after perfusion with MSCs (225-
228). There are surprisingly few human clinical trials going ahead however, 
despite this success in animals. Early trials demonstrated the safety of the 
MSC transplants (229), highlighting the autologous nature of MSCs as one 
reason why they are such exciting prospects. Other more recent trials have 
shown therapeutic effects and increased neurological and motor function 
in patients of acute and sub-acute SCI (230, 231). For patients with chronic 
SCI, and indeed any patient looking to recover fully, strategies will likely 
have to be of a multi-lateral approach, incorporating MSC transplant and a 
dissolution of the glial scar to promote neurogenesis, and biomaterials 
technology to fill lesions and act as scaffolds for glia and neurite growth 
across the injury site (232). 
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Figure 1.21: Diagram modified from Forostyak et al. outlining the 
potential therapeutic effects of MSCs on the different pathologies of SCI 
(180). 
 
1.3.3. MSCs and Orthopaedics   
Due to their ability to form bone, cartilage, fat, marrow stroma, 
tendons/ligaments, and muscle, MSCs have long been thought of as a 
potential therapeutic agent in the field of orthopaedics. Their natural 
function is to continually regenerate such tissues throughout the body, and 
throughout life, so when there is a malfunction of, or an interference to 
these processes, such as disease, injury, or surgery, the introduction of 
exogenous MSCs or the stimulation of endogenous MSCs become vitally 
important strategies. For example, genetic conditions such as osteo 
imperfecta (OI) affect the body’s ability to properly form osteoblasts, 
leading to the formation of defective, brittle bones (181). These 
genetically defective MSCs could be replaced by MSC-derived osteoblasts 
which have been expanded in vitro and administered in situ, or exogenous 
MSCs could be simply transplanted into the patient to differentiate in vivo 
to form healthy osteoblasts (233-235).  
 
For other more reparative methods such as regenerating damaged tissue, a 
more multi-lateral approach needs to be considered. Areas where damage 
from disease, injury, or surgery has resulted in empty lesions, simply 
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administering exogenous populations of cells would not be viable. Great 
advances in cell engineering technologies has led to the use of 3D scaffolds 
which not only hold the cells in place, but allow them to proliferate, and 
even encourage them to differentiate towards a specific lineage (181). For 
example, MSCs incorporated inside porous 3D scaffolds made from natural 
orthopaedic materials such as collagen, fibronectin, laminin etc., can be 
surgically implanted into the compromised area. The scaffolds must be 
porous to allow the movement of the MSCs and their produced matrices, as 
well as the movement of bioactive molecules, and they must also be 
natural to the niche so that they are not rejected by a local immune 
response, and so that they can naturally “dissolve” once the MSCs suitably 
regenerated the area of injury. This technique has been successfully 
implicated in repairing bone (236-238), cartilage (239-245), and tendons 
(246, 247). 
 
1.3.3.1. Nanotopographies 
MSCs don’t just respond to biochemical cues in vivo. Different niches 
throughout the body are comprised of different structures of varying 
shapes, sizes, stiffness’s, and roughness’s. These parameters can alter a 
cell’s behaviour on contact, and guide it down a particular path depending 
on cues relayed to the cell via cell/topography interactions (248-252). 
Changes in surface nanotopographies are felt by a cell’s extracellular 
matrix (ECM), relaying signals into the cytoplasm to elicit changes in 
metabolic pathways which can alter the path towards which a cell can be 
guided (253-255). Engler et al. showed the importance of matrix stiffness 
in the fate of MSCs when he demonstrated changes in focal adhesion and 
differentiation patterns of MSCs cultured on substrates with different 
matrix elasticities (45), and Dalby et al. demonstrated the importance of 
nanotopography in the formation of bone, when he demonstrated the 
different osteogenic potentials of varying nanoscale patterns and pit 
heights to guide MSCs and osteoprogenitors towards an optimal osteogenic 
fate (256). These findings were ground-breaking in the field of 
orthopaedics, allowing surgeons, stem cell biologists, and engineers to 
70 
 
devise new implantable devices such as replacement hips which can 
stimulate endogenous populations of MSCs to form bone around the 
implanted device, and thus aid in a more successful and timely 
convalescence. Dalby et al. compared the osteogenic potential of cells 
cultured on 4 different nanotopographies; hexagonal, square, disordered 
square, and random, and showed that the disordered square pattern 
provided a significantly more osteogenic substrate compared to the other 
patterns, and to a non-patterned glass substrate (Figure 1.22) (256). 
Maclaine et al. also demonstrated the osteogenic potential of disordered 
square nanotopographies, and that different pit heights can also influence 
the cell’s behaviour in terms of increasing proliferation or inducing 
terminal differentiation (257). These two studies were the basis of chapter 
2 of my results, where I compared the behaviour of MSCs from the bone 
marrow and olfactory mucosa when cultured on nanotopography embossed 
polycaprolactone (PCL). 
 
 
 
Figure 1.22: Figure taken from Dalby et al. depicting the four different 
nanotopographies; hexagonal, square, disordered square, and random, and 
their ability to stimulate the immunoreactivity of bone markers 
osteopontin (OPN) and osteocalcin (OCN) (green). Cells are highlighted by 
the immunoreactivity of actin (red) (256). 
 
1.3.3.2. Polycaprolactone (PCL) 
PCL is a biodegradable plastic polymer which I used as a cell culture 
substrate to gather data for chapter 2 of my results. Due to its low melting 
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point of 60oC, it was malleable and easy to emboss onto it different 
nanoscale topographies. For my experiments throughout this results 
section, squares of PCL were melted onto pre-manufactured metal shims 
which were patterned in a disordered square manner of differing pit 
heights. Full details of this process can be found in Materials and Methods 
section 2.12. Being a biodegradable polymer, and being so malleable, 
allows the use of PCL of unlimited nanotopographies with in vivo biological 
systems, such as nanopatterned implants and 3D scaffolds. Due to prior 
studies demonstrating the osteogenic induction capabilities of disordered 
square nanoembossed PCL, I will be using similarly nanoembossed PCL 
substrates to compare the osteogenic potential of BM-MSCs and OM-MSCs 
when cultured on these substrates. 
 
1.4. The Myelinating Culture System 
Measuring axonal myelination is at the forefront of this project. With only 
in vitro methods at my disposal, the myelinating culture system was an 
ideal experimental tool to manipulate and measure axonal myelination. 
First described by Sorensen et al. in 2008, the myelinating culture system 
allows the growth and myelination of embryonic spinal cord on glass cover 
slips (78). The full protocol is outlined in materials and methods section 
2.17. As the support cells of the CNS, astrocytes are cultured from 
striatum-derived neurospheres onto 24-well plate glass cover slips. These 
act as a support matrix which feed and nurture the embryonic spinal cord 
mix which is layered on top. The embryonic spinal cord mix is a 
heterogenous suspension consisting of unmyelinated neurons, OPCs, 
astrocytes, and other glial cells. During the first 12 days of culture, the 
OPCs differentiate into mature myelinating oligodendrocytes, and for the 
remaining 14-16 days they myelinate the unmyelinated embryonic axons. 
After 28 days in culture, the amount of myelin in the cultures can be 
measured by immunocytochemistry, using fluorescent antibodies for myelin 
proteins such as PLP, MOG, MBP etc. The cultures have been shown to 
produce mature compact myelin with the correct location for nodal 
proteins (78, 258). 
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This is a very dynamic system, allowing the manipulation of myelin 
formation by the addition of soluble factors such as chemokines and 
hormones directly to the cultures. Factor-rich conditioned media taken 
from cells in culture can also be added, and even co-culture of these cover 
slips with other cover slips containing cells such as MSCs is possible and has 
been shown to have an influential effect on the way the axons are 
myelinated (1). This system is an excellent research tool in determining 
potential means of regulating myelination, and therefore has many 
implications in researching a number of demyelinating and degenerative 
conditions. Indeed a number of different studies have published data 
derived from the myelinating culture system (66, 70, 135, 136, 163, 197, 
258-261). As an in vitro system, it is not an indication of what will 
definitely happen in vivo, but it is a solid testing base from which more 
exploratory in vivo work can be taken. Data from the lab have shown 
astrocytes are crucial in supporting myelination, but equally can become 
activated and inhibit myelination (66). Our lab has shown the importance 
of chemokines in regulating myelination and this has relevance for MSCs 
which secrete a huge number of chemokines. 
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Figure 1.23: Schematic diagram outlining the different stages of the 
myelinating culture system. Antibodies used for immunocytochemistry 
analysis were SMI31 to label axons (blue), proteolipid protein (PLP) to label 
myelin (green), and O4 to label mature oligodendrocytes (red). Image 
compiled by Sue Barnett. 
 
1.5. miRNA 
MSCs have a vast secretome of numerous different cytokines which can be 
secreted at different concentrations under different conditions, depending 
on external cues (207). Secretion of particular cytokines at any particular 
time has to be regulated at a pre-translational level, and is done so by very 
short (~22 nucleotides) strands of RNA, called microRNA (miRNA). Their 
role is to bind to strands of mRNA to inhibit the translation of that mRNA, 
and thus inhibit the production of that particular cytokine (262, 263). 
miRNA have a promiscuous relationship with their respective cytokines 
which they regulate. Each individual miRNA is responsible for the 
regulation of numerous different cytokines, and each cytokine can be 
regulated by numerous different miRNA (262, 263). This allows for the 
specific regulation of one particular cytokine without there being a knock 
on inhibition of other cytokines which are regulated by that miRNA, but are 
required at that point also.  
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Figure 1.24: Diagram depicting three different pri-miRNA hairpin 
structures. Each pri-miRNA is from the Arabidopsis plant, and represent 
miR-393a (A), miR-416 (B), and miR-396b (C). The sequences inside the red 
boxes represent the mature miRNA strands. Image modified from Wang et 
al. (264). 
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Figure 1.25: Schematic diagram of the genesis, transport from the 
nucleus, and inhibitory action of miRNA on mRNA translation. Image taken 
from Jeffrey et al. (265). 
 
miRNA are produced in the nucleus either from introns or from their own 
genes. They are carried as needed into the cytoplasm by a protein called 
Exportin, in the form of a much larger hairpin structure called a pri-miRNA 
(Figure 1.24) (264). In the cytoplasm, the pri-miRNA are cleaved at the 
hairpin end by an enzyme called a Dicer, releasing a double stranded 
miRNA duplex. This duplex separates, and the single strand incorporates 
with a protein called an miRNA-induced silencing complex (RISC) and binds, 
not always in a fully complimentary way, to the target mRNA. The 
RISC/miRNA complex is then able to interfere with the translation of the 
mRNA by blocking it’s entry through the ribosome (265) (Figure 1.25). Due 
to their regulation of numerous proteins, they are very significant in a 
number of biomedical conditions such as cancer (266), heart disease (267-
269), obesity (270), and some neurological disorders such as schizophrenia 
(271, 272). For these same reasons, they are also a potential therapeutic 
target to treat such conditions, although any research into this is still in its 
infancy (273).  
 
miRNA are a very important  focus for this thesis. With Lindsay et al. 
having observed a very unique behavioural difference between BM-MSCs 
and OM-MSCs; an unknown pro-myelinating factor(s) secreted by OM-MSCs, 
it was essential for us to determine not only the secretory profiles of both 
cell types, but also the miRNA profiles of both, to see if there were any 
connections between the secretome and the miRNAome, and thus any 
potential therapeutic targets. If we could determine the secreted factor(s) 
which are/were responsible for this pro-myelinating effect, and then 
relate that/those to a particular miRNA, then we would be able to 
investigate whether or not regulation of that miRNA could be a potential 
therapeutic target for the manipulation of axonal myelination. For the 
determination of the miRNA profiles of BM-MSCs and OM-MSCs, we 
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collaborated with Sistemic, a developmental-stage biomedical company 
who specialise in miRNA technology, and miRNA fingerprinting techniques. 
More importantly they had the experience to compare two similar cell 
types and ask if they were related, and what, if anything, made them 
possess any differences in their biological behaviour like the poor 
myelinating potential of BM-MSCs. 
 
1.6. Cytokine Array 
Upon establishing a miRNA profile for each MSC, any pertinent miRNA 
which were differentially expressed between the two cell types, and the 
secreted factors associated with these miRNA, the next stage was to 
analyse the secretory profiles of both MSC types to investigate any 
differential secretion patterns which might relate to the differential miRNA 
expression. This was done using numerous cytokine arrays which allow the 
analysis of the media in which the MSCs have been cultured, and thus the 
secreted factors which have been released into the media. A number of 
commercially available arrays can be chosen, depending on which 
cytokines you wish to analyse your samples for, but each follow the same 
general mechanisms of action. Figure 1.26 outlines these mechanisms, and 
the full protocols can be found in Materials and Methods section 2.15.2. 
Briefly however, samples are combined with a number of beads which are 
each conjugated to an antibody to a specific cytokine. The antibody/bead 
conjugate binds to the cytokine, and is retained in the well whilst all 
unbound conjugate is washed away. Detectable secondary antibody then 
binds to the antibody/bead/cytokine complex, and the concentration of 
each cytokine is determined by a specific plate reader which measures the 
intensity of the fluorescence of each bound cytokine, and compares it to 
the fluorescence from the wells of a standard curve of pre-determined 
concentrations.  
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Figure 1.26: Schematic diagram representing the mechanisms of action 
occurring during a cytokine array. Image was taken from the 
LifeTechnologies website for Luminex® cytokine arrays (510). 
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The discovery by Lindsay et al. that OM-MSCs secrete a factor or factors 
which is/are responsible for stimulating axonal myelination and 
oligodendrocyte proliferation (1) is potentially ground breaking in the 
fields of MS and SCI research. MSCs have long been considered as potential 
therapeutic agents in a number of areas of biomedical research for their 
differentiation potential, immunomodulatory effects, and substantial 
secretome. OM-MSCs do not just offer up an alternative autologous source 
of MSCs, but may also be substantially more capable of contributing to the 
treatment of demyelinating conditions than those derived from bone 
marrow. Not only in MS and SCI research are OM-MSCs important. 
Breakthroughs in cell engineering and nanoscale cell/substrate interactions 
have revolutionised the field of orthopaedics. Research has focused 
predominantly on the behaviour of BM-MSCs on such substrates, but OM-
MSCs could present a far more easily accessible autologous source for post-
surgery or post-injury orthopaedic repair strategies. 
 
Due to their relatively recent discovery, little has been researched with 
regard to OM-MSCs and their therapeutic potential, let alone their pro-
myelinating potential. It is therefore my intention throughout this thesis to 
utilise well established analytical procedures such as RT-qPCR, 
immunocytochemistry, and cytokine arrays, as well as more neoteric 
technologies such as nanoscale cell engineering and miRNA fingerprinting, 
to compare and contrast the biochemical properties of BM-MSCs and OM-
MSCs, their differentiation capabilities using factor rich induction media 
and nanotopographically embossed substrates, and also their behaviour and 
biological effects on neurobiological systems. I will not only be outlining 
any such differences between the two MSC phenotypes, but also fully 
investigating the possible mechanisms by which these changes are 
occurring. 
The aim of my thesis is to identify the mechanism by which OM-MSc 
promote myelination and identify the optimal MSC for cell therapies. This 
will be carried out by: 
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1) Antigenic and morphologic characterisation using  
immunocytochemistry, RT-qPCR, and phase imaging techniques. 
2) Comparing the differentiation capabilities of both MSC phenotypes, 
using factor-rich induction media and nanoscale topograhies 
3) miRNA fingerprinting. 
4)  Bead-based multiplexing technology to identify and compare secreted 
factors 
 
These studies will compare and contrast the two MSC types and determine 
their potential for use in regenerative medicine strategies.  
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Materials and Methods: 
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2. Materials and Methods 
2.1. MSC and Astrocyte Culture Preparation 
Lindsey et al. (1) showed previously that MSC culture was more efficient 
when the cells were seeded onto collagen coated surfaces compared to 
those of non-coated plastic or glass. Throughout this study, all glass and 
plastic surfaces onto which MSCs were cultured, were coated with collagen 
(Sigma, C4243) diluted 1:300 with sterile PBS, by simply incubating the 
surface with the collagen solution at RT for 30-60 min before washing with 
sterile ddH2O and air drying. 
 
Similarly, Sǿrensen et al. (78) showed that survival of astrocytes cultured 
onto plastic or glass surfaces relied on these surfaces being coated with 
Poly-L-Lysine (PLL) (Sigma, P4707), at a final concentration of 13 µg/mL in 
sterile ddH2O. Plastic and glass surfaces are simply incubated at RT for 30-
60 min before washing with sterile ddH2O and air drying. 
 
2.2. Cell Culture 
Three major cell types were compared throughout this study; bone 
marrow-derived-MSCs (BM-MSCs), CD271 positively selected bone marrow-
derived-MSCs (BM271-MSCs), and CD271 positively selected olfactory 
mucosa-derived MSCs (OM-MSCs). Figure 2.1 details the methodology of 
these three cell types. 
 
2.2.1. Human Bone Marrow-Derived MSC (BM-MSC) Culture 
Human BM-MSCs were isolated from bone marrow aspirates obtained with 
ethics approval from 71 male and female patients (27 male, 44 female) 
undergoing routine hip replacement surgery from 2011 to 2013. Patients 
were predominantly elderly, but varied in age range from 32 to 86 years 
(average age 66.87 ± 12.55 (SD)), which was not significantly different 
from donor patients for OM-MSCs (all sample details are listed in Table 
2.1). All surgeries were supervised by Mr David Allen, consultant 
orthopaedic surgeon at the Southern General Hospital in Glasgow. Bone 
marrow aspirates were isolated from the femoral heads and placed 
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immediately in 20 mL DMEM (low glucose) (Life Technologies, 10567-014) 
with 5% v/v foetal bovine serum (FBS) (Sigma, F7524), 0.5% v/v heparin 
(LEO Laboratories, PL0043/0041R), and 0.1% w/v 
Ethylinediaminetetraacetic acid (EDTA) (Sigma, E6758), and stored at 4oC 
for no longer than 24 hr before either collection from theatre, or delivery 
to the Glasgow Biomedical Research Centre (GBRC). Isolation of BM-MSCs 
from the bone marrow aspirate sample was carried out by carefully 
layering all aspirate onto 20 mL of Histopaque®-1077 (Sigma, 10771) cell 
separation media in a 50 mL centrifuge tube, ensuring to not break the 
surface of the Histopaque®-1077 with the aspirate, and ensuring not to 
layer any solid or particulate matter. The sample was then centrifuged at 
604 x g (1500 rpm in a 24 cm radius centrifuge) for 35 min at RT, resulting 
in multi-layered content consisting (from top to bottom) of a waste 
media/adipose upper layer, an opaque interface layer termed the “buffy 
coat”, a layer of Histopaque®-1077 (sometimes consisting of coagulated 
matter, depending on the sample), and a bottom layer of mononucleated 
cells such as erythrocytes (Figure 2.2). The layer containing the BM-MSCs is 
the buffy coat, and was collected by first aspirating and discarding the top 
layer to within 1 cm of the buffy coat. This 1 cm of media, plus the buffy 
coat and 1cm of Histopaque®-1077 below the buffy coat (avoiding any 
coagulated matter) was then collected, retained, and washed thrice with 
sterile phosphate buffered saline (PBS) with 5% v/v FBS and 0.1% w/v 
EDTA, centrifuging at 386 x g (1200 rpm in a 24 cm radius centrifuge) for 3 
min between washes. The resultant pellet was then re-suspended in 7 ml 
DMEM (low glucose) plus 10% Hyclone™ FBS (Thermo Scientific™, 
SH3008803), and 0.05% L-Glutamine (Sigma, G7513) (henceforth referred 
to as DMEM:10% Hyclone), transferred to a collagen coated T75 cm3 culture 
flask and incubated at 37oC for 72 hr. After 72 hr, the media containing all 
non-adherant cells was removed, the flask washed with sterile PBS, and a 
fresh 7 mL of DMEM:10% Hyclone added.  
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Figure 2.1: Schematic diagram detailing the methodology of the three 
major cell types used in this investigation; OM-MSCs, BM-MSCs, and BM271-
MSCs. 
 
 
Figure 2.2: Diagram of the different layers resulting from the Histopaque® 
cell separation technique which isolates BM-MSCs from bone marrow 
aspirate samples. BM-MSCs are collected from the “buffy coat” layer, 
whilst all other layers are discarded to waste. 
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2.2.1.1. BM-MSC Purification to Isolate BM271-MSCs 
Once the flask reached confluency (21-28 days), BM-MSCs were purified 
using the EasySep® Human MSC CD271 positive selection kit (StemCell 
Technologies, 18659). Figure 2.3 highlights the major steps involved in this 
process. During this process, adherent cells were enzymatically dislodged 
using 5 mL Trypsin-EDTA 0.5% (Sigma, S8636), which was neutralised after 
5 min at 37oC using a further 5 mL of DMEM:10% Hyclone. The whole 
suspension was centrifuged at 386 x g for 3 min, and the pellet re-
suspended in 500 µL DMEM:10% Hyclone + 12.5 µL of Fc receptor blocker 
and 25 µL of CD271 positive selection cocktail, and transferred to a FACS 
tube. This suspension was then incubated at RT for 15 min before the 
addition of 25 µL of magnetic bead particles and further incubation at RT 
for 15 min. 2.5 mL of DMEM:10% Hyclone was then added to the 
suspension, and the tube inserted into the EasySep® magnet for 5 min. 
Without removing the tube from the magnet, the liquid contents of the 
tube were removed to waste by inversion. The tube was then removed 
from the magnet, and a further 2.5 mL of DMEM:10%  Hyclone was added 
before placing the tube back into the magnet for 5 min. This magnetic 
isolation of cells was repeated a further 2 times. After the final 
supernatant was discarded, the tube was centrifuged at 386 x g for 3 min, 
and the pellet of purified BM-MSCs (BM271-MSCs) re-suspended in 60 µL 
DMEM:10% Hyclone. This suspension was plated into T25 cm3 culture flasks 
in 3 x 20 µL strips, and incubated at 37oC for 15 min for the cells to adhere 
to the flask. The flask was then flooded with 3 mL of DMEM:10% Hyclone 
and incubated at 37oC until use. These purified BM-MSCs were henceforth 
termed BM271-MSCs, and are to be treated distinctly to non-purified BM-
MSCs. Cells were bulked up over time by enzymatically dislodging using 
trypsin-EDTA 0.5% (trypsinising), re-suspending them in fresh DMEM:10% 
Hyclone, and placing them back into a larger number of flasks. Any unused 
cells were trypsinised, re-suspended in 90% FBS + 10% dimethyl sulphoxide 
(DMSO), and stored in liquid nitrogen. 
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Figure 2.3: Schematic diagram of the EasySep® CD271 positive selection 
process carried out on BM-MSCs and on unpurified adherent OM cells. The 
resultant cells are termed BM271-MSCs and OM-MSCs. 
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Table 2.1: List of all bone marrow aspirate samples supplied between May 
2011 and August 2013. All samples were donated with consent from 
patients of Mr David Allen, consultant orthopaedic surgeon at the Southern 
General Hospital, Glasgow, undergoing routine hip replacement surgery. 
All samples were taken from the iliac crests of male and female patients 
between the ages of 32 and 86.  
 
2.2.2. Human Olfactory Mucosa-Derived MSC (OM-MSC) Culture 
Human OM biopsies were obtained with ethics approval from 37 male and 
female patients (21 male, 16 female) undergoing routine nasal 
septoplasty/polypectomy surgery from 2011 to 2014. Patients were 
predominantly elderly, but varied in age range from 32 to 86 years 
(average age 55.32 ± 13.89 (SD)), which was not significantly different 
from donor patients for BM-MSCs (all sample details are listed in Table 
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2.2). Surgeries were supervised by Mr Saghir Sheihk and Mrs Louise Clark, 
consultant ENT surgeons at the Southern General Hospital and at the 
Victoria Hospital, both in Glasgow.   Biopsies were taken from areas most 
commonly known to contain OM, the upper middle turbinates and uncinate 
process of the ethmoid bone. Biopsies were collected and placed 
immediately on ice in Hanks balanced salt solution (HBSS) (Life 
Technologies, 24020-117) containing 1% penicillin/streptomycin (Gibco, 
15070), and 0.5% fungizone (Gibco, 15290-018) for no more than 24 hr 
before collection.  After removing all solid and particulate matter from the 
tissue, it was homogenised with a scalpel blade, and digested in a 5 mL 
bijou using 1mL Leibovitz’s L-15 media (Life Technologies, 11415064) + 100 
µL of 1.33 % collagenase (Sigma-Aldrich, C0130) for 20 min at 37oC 
followed by incubation with DNAse to reduce cell clumping (0.04 mg/ml 
bovine pancreas DNAse (Sigma, DN25), 3.0 mg/ml bovine serum albumin-
fraction A (Sigma, A9647) in L15 media). Cells were mechanically 
dissociated by pipetting, then triturating through a 23G needle, 
centrifuged at 386 x g for 5 min and the pellet re-suspended in DMEM:10% 
Hyclone and plated on collagen coated (10 mg/ml, Sigma-Aldrich, UK) 25 
cm2 tissue culture flasks.  After 7 days, a heterogeneous monolayer of 
spindle shaped cells developed, and from this monolayer, human MSCs 
were purified using the EasySep® Human MSC CD271 positive selection kit 
previously described. After purification, cells were termed olfactory 
mucosa (OM)-MSCs. OM-MSCs were bulked up and stored long term using 
the same conditions as with BM-MSCs. 
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Table 2.2: List of all olfactory mucosa samples supplied between May 2011 
and January 2014. All samples were donated with consent from patients of 
either Mr Saghir Sheihk or Mrs Louise Clark, consultant ENT surgeons at the 
Southern General Hospital and at the Victoria Hospital, both in Glasgow, 
undergoing routine septoplasty/polypectomy surgery. All samples were 
taken from the upper middle turbinates and uncinate processes of the 
ethmoid bones of male and female patients between the ages of 32 and 86. 
 
2.2.3. Human Dermal Fibroblast Culture 
Human dermal fibroblasts were bought in, and were delivered frozen on 
dry ice (Life Technologies, C-013-5C). Cells were defrosted quickly in a 
water bath at 37oC, and immediately reconstituted in fibroblast culture 
media, Medium 106 (Life Technologies, M-106-500) which was fortified 
with Low Serum Growth Supplement (LSGS) (Life Technologies, S-003-10). 
Cells were centrifuged at 386 x g for 3 min to remove all transport media, 
the supernatant discarded, and the cells reconstituted in 7 mL of Medium 
106 + LSGS, transferred to a collagen coated T75 cm3 culture flask, and 
incubated at 37oC until confluent. Fibroblasts were bulked up and stored 
long term using the same conditions as with BM-MSCs and OM-MSCs. 
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2.2.4. “Flow through” Culture 
Cell suspensions discarded during the EasySep® CD271 purification process, 
termed “flow through” cells, were collected in a 50 mL centrifuge tube, 
and centrifuged at 386 x g to remove any excess media and waste 
chemicals from the purification process. Cells were re-suspended in 7 mL 
of DMEM:10% Hyclone, transferred to a collagen coated T75 cm3 culture 
flask, and incubated at 37oC until confluent. Flow through cells were 
bulked up and stored long term using the same conditions as with BM-MSCs, 
OM-MSCs, and fibroblasts. 
 
2.2.5. Rat Bone Marrow-Derived MSC (rBM-MSC) Culture 
Pregnant Adult Sprague-Dawley (SD) rats, euthanised for embryo removal, 
were harvested of their bone marrow by removing the whole back legs, 
stripping the bones of any tissue, and separating the femur from the rest 
of the leg. Both apical and dorsal ends of the femur were carefully 
removed, and DMEM passed through the central cavity of the bone by 1 mL 
syringe and 21 G needle, forcing the bone marrow from the bone by liquid 
pressure. Bone marrow was chopped thoroughly using a sterile scalpel 
blade, and transferred to a 5 mL bijou flask containing 2 mL DMEM:10% 
Hyclone. A cell suspension is created by triturating the marrow through a 1 
mL pipette and a 21 G needle, before being transferred to a 15 mL 
centrifuge tube and centrifuged at 386 x G for 3 min. Cells are 
resuspended in 7 mL of DMEM:10% Hyclone and incubated in collagen 
coated T75 cm3 culture flasks at 37oC for ~72 hr. All non-adherent cells 
were then removed by completely removing all media, washing with sterile 
PBS, and replacing with 7 mL DMEM:10% Hyclone. All adherent cells were 
henceforth termed rBM-MSCs, incubated at 37oC until confluent, and were 
bulked up and stored long term using the same conditions as with BM-MSCs, 
OM-MSCs, fibroblasts, and flow through cells. 
 
2.2.6. Rat Olfactory Mucosa-Derived MSC (OM-MSC) Culture 
Pregnant Adult SD rats, euthanised for embryo removal, were harvested of 
their olfactory mucosa by removing the whole head of the rat, stripping it 
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of all skin and tissue, and cutting it vertically down the centre of the skull 
from the tip of the nasal bone to the base of the occipital condyle (Figure 
2.4). Situated at the posterior of the premaxilla bone, between the nasal 
passage and the olfactory bulbs (Figure 2.5), the olfactory mucosa is a 
green/brown tissue, quite obvious to the naked eye. The whole tissue was 
removed, separated from any solid particulate matter, placed in 1 mL of 
Liebovitz’s L-15 media with 100 µL trypsin and 100 µL of 1.33 % 
collagenase, and cultured exactly as with human olfactory mucosa. As the 
rat olfactory mucosa contains large amounts of olfactory ensheathing cells 
(OECs) which are positive for the MSC selection marker CD271, the 
adherent rat OM tissue has to undergo an initial antigenic selection for the 
marker CD90, which is expressed on MSCs but not OECs. The remaining 
cells were cultured again until confluent before a 2nd antigenic selection 
for CD271. These final cells are termed rOM-MSCs, and were bulked up and 
stored long term using the same conditions as with BM-MSCs, OM-MSCs, 
fibroblasts, flow through cells, and rBM-MSCs. 
 
 
 
Figure 2.4: Diagram of the different bones of the rat skull  
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Figure 2.5: Diagram of a planar section of a rat skull showing the area 
from which the olfactory mucosa (OM) is removed (circled). The OM is 
surrounded by the arc of perpendicular plate (A), the cribriform plate (B), 
and the ceiling of oral cavity (C). 
 
2.3. MSC Proliferation Study 
BM-MSCs, BM271-MSCs, and OM-MSCs were seeded at 5 x103 cells/well in a 
200 µL meniscus onto collagen coated 6-well plates. The 200 µL meniscus 
was deemed optimal, allowing for the cell-cell contact required for cell 
survival, and also for minimal cell clumping at the latter stages of the 
experiment. The menisci were incubated at 37oC for 15 min to allow cell 
adhesion, and each well flooded with 1 mL of DMEM:10% Hyclone. Cultures 
were simply trypsinised at 5, 10, 15, 20, and 25 days, and their cell 
numbers counted using a haemocytometer. Due to the vast diversity in 
proliferation between OM-derived MSCs and BM-derived MSCs, OM-MSCs 
became confluent in the 6-well plates after 7 days in culture, so were 
trypsinised and cultured in T75 cm3 culture flasks henceforth. 
Trypsin/media suspensions were centrifuged at 386 x g, and re-suspended 
in 1 ml of DMEM:10% Hyclone. 10 µL of cell suspension was removed and 
added to the haemocytometer for visualisation under a phase microscope. 
The number of cells counted in one 4x4 grid x103 equates to the number of 
cells per 100 µL of cell suspension. All counts were multiplied a further 10 
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fold to give the total number of cells harvested in the 1 mL cell 
suspension.  
 
2.4. Cell Profiling 
2.4.1. By RT-qPCR 
OM-MSCs, BM-MSCs, BM271-MSCs, unpurified OM tissue, OM flow through, 
BM flow through, and human dermal fibroblasts were compared by their 
expression profiles of a number of different genes by measuring the levels 
of messenger RNA (mRNA) related to these genes within each cell type. 
The full list of primers used in this section can be found in Tables 2.3 and 
2.4, and the full list of samples used in sections 2.10.1 and 2.10.2 can be 
found in Tables 2.5 and 2.6. mRNA was extracted from each cell type using 
a Purelink® RNA mini kit (Life Technologies, 12183025) using their given 
protocol. Each cell type was cultured in DMEM:10% Hyclone on collagen 
coated cover slips, in triplicate at 5x104 cells/cover slip in 24-well plates, 
for ~24 h at 37oC. After incubation, all media was removed and cover slips 
washed in sterile PBS. 350 µL of lysis buffer was then added to the first of 
the 3 triplicate cover slips, and all cells were detached and lysed by 
agitation with a 1mL pipette tip. The full lysate was then transferred to 
the second of the triplicate cover slips where lysis was carried out using 
the same agitation method, which was repeated for the third of the 
triplicate cover slips. The final lysate was triturated by passing through a 
21G needle 5-10 times, and transferred to a 1.5 mL centrifuge tube on ice. 
All three of the triplicate wells were washed with one volume (350 µL) of 
70% ethanol (EtOH), which was added to the lysate in the centrifuge tube 
(final volume 700 µL). The lysate was either stored at -80oC for use at a 
later date, or transferred straight to a spin column and centrifuged at 
11337 x g (13,000 rpm in a 6cm radius centrifuge (Eppendorf mini spin)) for 
15 sec. Columns were then washed by centrifuging at 11337 x g for 15 sec 
with 1 x 700 µL of wash buffer 1 followed by 2 x 500 µL of wash buffer 2, 
with all waste discarded between each spin. Columns were then dried by 
centrifugation at 11337 x g for 2 min. The waste collection tubes were 
replaced with 1.5 mL centrifuge tubes, and 50 µL of ddH2O added to each 
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column, which were incubated at RT for ~60 sec before elution of mRNA by 
centrifugation at 11337 x g for 60 sec. mRNA samples were kept on ice 
whilst mRNA content was analysed using a Nanodrop 1000 
spectrophotometer (Thermo Scientific) and Nanodrop 1000 3.7.1 software. 
1 µL of sample was added to the nanodrop, and mRNA content recorded as 
a value of ng of RNA/µL of sample. mRNA purity was also measured by 
calculating the ratio of absorbance between 260 nm 280 nm wavelengths (a 
value of ~1.8 – 2.2 is accepted as pure for RNA). Samples were all 
equalised to 50 ng/µL total mRNA with ddH2O before reverse transcription 
to cDNA. All mRNA samples were transcribed to cDNA using a Quantitect® 
Reverse Trancription Kit (Qiagen, 205311) using their supplied protocol. 12 
µL of each sample was incubated with 2 µL of gDNA wipeout buffer (7x) in 
a thin walled PCR tube at 45oC for 2 min. 6 µL of reverse transcription 
master mix (1 µL reverse transcriptase, 4 µL RT buffer (5x), 1 µL RT primer 
mix) was added to each sample, which was then incubated at 42oC for 15 
min followed by incubation at 95oC for 3 min. The resultant cDNA was 
stored at -20oC until analysis by RT-qPCR. All samples were analysed on the 
ABI7500 real-time PCR system, using the Livak (ΔΔCT) method with GAPDH 
as the reference control gene, each sample analysed in triplicate. Each 
sample was analysed as a 20 µL SybrGreen/cDNA mix in 96-well plates, 
with each sample well containing 10 μL of SybrGreen reagent containing 
low ROX (Primer Design, Precision-LR-SY), 0.4 μL of each target primer 
(forward and reverse), 2 μL of cDNA (from samples equalised at 50 ng/µL 
total mRNA), and 7.2 μL of ddH2O. 2
ΔΔCT
 values were calculated in Microsoft 
Excel® using the equations ΔΔCT = (CT (target, BM-MSC) − CT (ref, BM-MSC)) 
− (CT (target, BM271-MSC) − CT (ref, BM271-MSC)) and ΔΔCT = (CT (target, 
BM271-MSC) − CT (ref, BM271-MSC)) − (CT (target, OM-MSC) − CT (ref, OM-
MSC)).  
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Table 2.3: List of all primers and their sequences used to identify MSC 
markers in BM-MSCs, BM271-MSCs, and OM-MSCs by RT-qPCR. 
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Table 2.4: List of all primers and their sequences used to identify 
differentiation markers in BM-MSCs, BM271-MSCs, and OM-MSCs by RT-
qPCR. 
 
 
 
Table 2.5: List of all samples and donors used for MSC classification 
experiments in sections 3.3 and 3.4 
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Table 2.6: List of all samples and donors used for MSC classification 
experiments in section 3.5 
Quantities of mRNA are reported as arbitrary -ΔΔCT  values, using the first 
sample analysed as a reference point against which all other samples are 
compared.  
 
2.4.2. By Immunocytochemistry 
OM-MSCs, BM-MSCs, BM271-MSCs, unpurified OM tissue, OM flow through, 
BM flow through, and human dermal fibroblasts were compared by their 
expression profiles of a number of different protein markers. The full list 
of primary (1o) antibody markers used can be found in Table 2.7. Each cell 
type was trypsinised and seeded at 1 x 103 in a 20 µL meniscus onto the 
centre of dry collagen coated glass cover slips, placed inside a 24-well 
plate (as cell-cell interactions are vital for MSC survival, the 20 µL 
meniscus allows for a close enough proximity to nurture survival, whilst 
also allowing for an optimal spacing to see good quality individual 
staining). Cells were seeded in triplicate for each antibody marker to be 
analysed for (2 normal stainings and 1 isotype control (secondary antibody 
only)), although due to a number of antibodies used having different 
isotypes, “double staining” was carried out where 2 antibodies were 
incubated onto the same sample. The menisci were incubated at 37oC for 
15 min to allow the cells to adhere to the cover slip, before the wells were 
flooded with 500 µL of DMEM:10% Hyclone, and the plates incubated at 
97 
 
37oC for 24 hr. Each cover slip was then removed from the plate, washed in 
PBS, and placed cell side up on a mounted staining tray. Cells were then 
fixed at RT for 10 min using 50 µL of 4% paraformaldehyde (PFA) (Sigma, 
P6148) for extracellular staining, and at -20oC using 50 µL of 100% 
methanol (VWR, 20847.307) for intracellular staining. The coverslips were 
washed in PBS and dH2O, and the cell’s receptors “blocked” for any non-
specific binding by adding 50 µL of 10% horse serum (HS) at RT for 30 min. 
Coverslips were washed again in PBS and ddH2O before the addition of each 
1o antibody in 50 µL of 10% HS. All dilutions can be found in Table 4. Cells 
were incubated with antibody either at RT for at least 60  
 
 
 
Table 2.7: List of all primary antibodies used for MSC classification 
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min, or overnight at 4oC (isotype controls were incubated with 10% HS 
only), and were then washed once more in PBS and ddH2O before 
incubation with the relevant secondary (2o) antibodies at RT for 60 min 
(prolonged incubation may lead to false staining and high background 
(auto) fluorescence). Finally, each coverslip was washed in PBS and ddH2O 
and “mounted” cell side down onto 5 µL of Vectashield® mounting media 
containing the nuclear stain 4’,6-diamidino-2-phenylindole, 
dihydrochloride (DAPI) (Vectorlabs, H-1200) which had been pipetted onto 
a glass microscope slide. DAPI immediately enters the nuclei and combines 
with A-T regions of DNA, resulting in the strong fluorescence of all live 
nuclei under UV light, allowing accurate cell counts to be made. Coverslips 
were then sealed with clear nail varnish and stored at 4oC to be imaged by 
Fluorescence microscopy. All imaging was carried out using an Olympus 
BX51 fluorescence microscope with a Lumen 200 Fluorescence Illumination 
System with Proscan 2 motorised stage system (Prior Scientific), and 
images taken using ImagePro 6.3 software. Images were analysed by taking 
the mean number of cells which positively express the protein of interest 
as a percentage of the total number of cells per image (field of view).  
 
2.5. Differentiation of MSCs 
A list of all samples and donors used in this section can be found in Tables 
2.8 and 2.9. 
 
2.5.1. Bone 
Each MSC type was seeded in triplicate (1 untreated control, 2 treated) at 
5 x 103 cells per well of collagen coated 6-well plates, as a 200 µL meniscus 
for 15 min. Untreated control wells were flooded with 1 mL of DMEM:10% 
Hyclone, and treated wells were flooded with 1 mL of osteogenic induction 
media (sodium L-ascorbate (Sigma, A4034), β-glycerophosphate disodium 
salt hydrate (Sigma, G9891), and dexamethasone (Sigma, D4902) in 
DMEM:10% Hyclone). All induction media and their constituent compounds 
can be found in Table 2.10. Cells were incubated at 37oC for 28 days, 
replacing 50% of the media every 72 hr. After 28 days, all media was 
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removed from each well and the wells washed with PBS before fixing the 
cells in 500 µL of 4% PFA for 10 min. Wells were washed 5 x with ddH2O 
prior to the addition of 1 mL of 40 mM Alizarin Red S Dye (Sigma, A5533). 
Plates were incubated at RT on a mechanical shaker at low speed for 60 
min, after which any unincorporated dye was removed, and each well 
washed thoroughly with ddH2O. All water was removed, air dried, and 
staining visualised by phase microscopy. All images were analysed using 
ImageJ version 1.47 software by calculating the number of pixels from the 
stained areas of the whole images. 
 
 
 
Table 2.8: List of samples and donors used for experiments represented in 
Results sections 3.6.1, 3.6.3, and 3.7   
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Table 2.9: List of samples and donors used for experiments represented in 
Results sections 3.6.2 and 3.6.4 
 
2.5.2. Fat 
Each cell type was seeded and cultured as per the above bone method, 
except that the treated cells were cultured in adipogenic induction media 
(dexamethasone (Sigma, D4902), Indomethacin (Sigma, I7378), 3-isobutyl-
1-methylxanthine (IBMX) (Sigma, I7018), and insulin (Sigma, I3536) in 
DMEM:10% Hyclone). Due to adipogenesis occurring more quickly than 
osteogenesis, cells were cultured for only 21 days, but were fixed as 
previously described in the bone protocol. Oil Red O dye (Sigma, O0625) 
was prepared by diluting the 5 mg/mL stock solution, 3 parts Oil Red O 
with 2 parts ddH2O, and filtering through Whatman #1 filter paper. 1 mL of 
the Oil Red O working solution was added to each well and incubated at RT 
on a mechanical shaker at low speed for 60 min. Cells were washed, 
imaged, and analysed as previously described in the bone protocol. 
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Table 2.10: Table of fat, bone, neuron, smooth muscle, and glia induction 
media and their constituent compounds, concentrations, and 
manufacturer’s details. All media was made by diluting their constituent 
compounds in 50 mL of DMEM:10% Hyclone.  
 
2.5.3. Neuron, Smooth Muscle, and Glia 
Each cell type was trypsinised and seeded in a 20 µL meniscus at 1 x 103 
cells/cover slip onto collagen coated glass cover slips in 24-well plates. 
Cells were seeded in triplicate (1 untreated control, 2 treated (one of 
which to be used as an isotype control (2o antibody only))), and incubated 
at 37oC for 15 min before wells were flooded with 500 µL DMEM:10% 
Hyclone for all untreated controls, and 500 µL of either neurogenic 
induction media (Retinoic acid (Sigma, R2625), and FGF (Sigma, F0291) in 
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DMEM:10% Hyclone), myogenic induction media (Dexamethasone (Sigma, 
D4902), and Hydrocortisone (Sigma, H0888) in DMEM:10% Hyclone), or glial 
induction media (FGF (Sigma, F0291), rhGGF2 (Reprokine, RKQ022979), 
Forskolin (Sigma, F6886), and PDGF-AA (R&D Systems, 221-AA) in 
DMEM:10% Hyclone). Cells were incubated at 37oC for 21 days, with 50% of 
the media being replaced every 72 hr. At day 21, coverslips were removed 
from their wells, washed in PBS, and fixed in methanol (MeOH) at -20oC for 
10 min before any non-specific binding sites were blocked with 10% HS. 
Neurogenically induced cells and their associate untreated controls were 
then incubated either at RT for 60 min or at 4oC overnight with 1o 
antibodies Tuj-1 and MAP2 (all antibodies and dilutions can be found in 
Table 4), except for isotype controls which were incubated with PBS only. 
The same protocol was followed for myogenically and glial induced cells 
and their associate untreated controls, only using MyoD and SMA, and GFAP 
1o antibodies respectively. All cover slips were incubated with their 
associate 2o antibodies at RT for 60 min before being mounted onto glass 
microscope slides, and analysed by immunofluorescence as previously 
described in section 4.2. 
 
2.5.4. Analysis of Media Induced Differentiation by RT-qPCR 
Media induced differentiation was carried out as previous described in 
section 2.11.3, except that each condition (treatments and untreated 
controls) was set up in triplicate to allow for a sufficient amount of mRNA 
collection. At day 21, mRNA was collected, reverse transcribed to cDNA, 
and analysed by RT-qPCR as previously described in section 2.10.1. 
 
2.6. Nanotopographically Embossed PCL 
2.6.1. Manufacture  
Nickel shims from which the nanotopographically embossed PCL used in 
this chapter was formed, were pre-fabricated off-site using the following 
methods taken from Maclaine et al. (257) 
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2.6.2. Nanopatterning and Die Fabrication 
PCL samples were fabricated using a three-step process utilizing a block 
co-polymer technique, nickel die fabrication, and thumb embossing. The 
embossing process produced samples “Smooth” (non-embossed, non-
patterned), “Surface A” (embossed with a disordered near square (DNSQ) 
nanotopography with 25 nm high islands) and “Surface B” (embossed with a 
DNSQ nanotopography with 20 nm high islands) which are used throughout. 
 
2.6.3. Block Co-Polymer Phase Separation 
Poly(styrene-block-poly-2-vinylpyridine) (PS-b-P2VP) inverse micelles were 
prepared in o-xylene with a solution concentration of 0.5% weight percent. 
The two different molecular weight forms of PS-b-P2VP used to form the 
two different topographies ‘‘A’’ and ‘‘B’’ were 190 500b-190,000 g/mol 
and 91 500-b-105,000 g/mol, respectively. A thin film of PS-b-P2VP 
micelles was spin coated onto clean silicon wafers at 5,000 r.p.m. in a 
relative humidity of 20–35%. This completed the topography formation. 
 
2.6.4. Nickel Shim Fabrication 
Ni-V was sputter coated onto the masters, which were subsequently 
electroplated to a nickel shim thickness of 300 mm. 
 
2.6.5. PCL Embossing 
PCL beads (Sigma, 704105) were placed in a circular pile ~15-20 cm in 
diameter, in the centre of glass sheet which is ~30 cm2 and ~1 cm thick. 
This was then placed in an oven at 80oC for 1.5 hr, along with another glass 
sheet of the same dimensions. Once the PCL beads have all melted, the 2nd 
glass sheet was placed on top of the melted PCL, and the two sheets held 
together with bulldog clips. This was returned to the oven at 80oC for a 
further 30 min until the liquid PCL had reached the edges of the glass 
sheets. This was left to cool down at RT (forcible cooling can damage and 
crack the PCL) until the PCL has returned to an opaque white colour. The 
PCL sheet was removed from between the glass sheets and cut into squares 
of ~ 15 mm. Each nickel shim used to form surfaces A and B were placed 
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topography upwards onto a hot plate pre-heated at 75oC, and a single 15 
mm PCL square placed on top. Once the PCL has fully melted, a glass 
microscope slide was placed on top, the whole structure removed from the 
hot plate, and pressure applied to the PCL using the thumb, forcing the 
melted PCL onto the nanotopography of the nickel shim and creating a 
“mirror image” pattern in the PCL substrate. This was left again to cool at 
RT until fully opaque, before being trimmed to ~6-10 mm and placed 
nanotopography up in a well of a 24 well plate. Smooth surface controls 
were manufactured in the same way, only replacing the nickel shims for a 
glass microscope slide. All PCL substrates were sterilised under UV in a 
sealed tissue culture hood for 45 min. Figure 2.6 outlines the process of 
PCL nanoembossing in schematic form. 
 
 
 
Figure 2.6: Schematic diagram of the process of nanoembossing PCL 
substrates onto which MSCs can be cultured and differentiated towards an 
osteogenic fate. Pellets of PCL were melted to form sheets which were cut 
into squares, melted, and pressed onto metal shims of varying 
nanotopographies. PCL squares then set hard, and cells can be seeded on 
top, and cultured under normal conditions. 
  
2.7. Cell Culture and Differentiation Analysis 
Cells were cultured onto PCL substrates exactly as they were when 
cultured onto glass cover slips. In all experiments, cells were cultured for 
21 days before analysis. Differentiation was analysed by studying changes 
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in protein expression using the same immunocytochemistry protocol as 
previously described, and by studying changes in mRNA expression using 
the same RT-qPCR protocol as previously described. All samples used 
throughout this section can be found in Tables 2.11 and 2.12 
 
 
 
Table 2.11: List of samples donors used for experiments represented in 
section 4.2 
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Table 2.12: List of samples donors used for experiments represented in 
section 4.3 
* = Samples used for OPN and OCN immunocytochemistry  
** = Samples used for Tuj-1, SMA, and GFAP immunocytochemistry 
 
2.8. miRNA Analysis by Sistemic 
4 x OM-MSC (all male, average age = 57.50 +/- 11) samples and 4 x BM271-
MSC (3 Female, 1 male, average age = 56.25 +/- 22) samples were 
harvested each from a confluent T75 cm3 culture flask by trypsinisation (a 
list of all samples used can be found in Tables 15 and 16). 5 mL of 
DMEM:10% Hyclone was added to each flask to neutralise the trypsin after 3 
min, and samples were centrifuged at 386 x g for 3 min. All media/trypsin 
was removed and cells were reconstituted in 1 mL of DMEM:10% Hyclone 
before being transferred to 1.5 mL centrifuge tubes. Samples were 
centrifuged again at 11337 x g for 3 min before removing all media and 
snap freezing the cells in dry ice/H2O. All samples were stored in dry ice 
and transported to Sistemic for miRNA analysis on that day. The following 
miRNA analysis protocol is taken from the final analytical report supplied 
to us by Sistemic: 
 
2.8.1. Samples 
Samples were from 8 individual donors; 4 from olfactory mucosa biopsies 
(OM-MSCs) and 4 from bone marrow aspirates (BM-MSCs) (Table 2.13 and 
2.14). The 8 samples were received at Sistemic as total flash-frozen cell 
pellets on dry-ice, representing 2 types of sample designated as OM-MSC 
and BM-MSC. Upon receipt, samples were stored at -800C until processed 
through Sistemic’s RNA isolation and QC checks and subsequently analysed 
on miRNA microarrays. 
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Table 2.13: Details of all OM-MSC samples used throughout the Sistemic 
miRNA array. Note that at the time of the array, OM-MSCs were referred to 
as LP-MSCs (lamina propria-derived MSCs), and annotation was changed to 
OM-MSCs subsequent to the completion of the array. 
 
 
 
Table 2.14: Details of all BM-MSC samples used throughout the Sistemic 
miRNA array. 
 
2.8.2. Sample Processing and Quality Control 
All total RNA samples were checked for concentration, yield and quality of 
RNA. RNA concentration was measured following Sistemic’s SOP (SSOP03). 
Absorbance ratios (Abs) at 260/280nm and 230/260nm were determined as 
indicators of sample yield and purity. For all samples, further RNA QC was 
performed using the Agilent 2100 Bioanalyser and the RNA 6000 Nano Kit 
following Sistemic’s SOP (SSOP04.3) to determine the RNA Integrity 
Number (RIN). All samples passed Sistemic’s RNA QC. A summary of the 
array QC metrics are in Appendix 1 and 2. 
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2.8.3. Microarray Profiling 
Samples were analysed on the Agilent miRNA platform (using Agilent’s 
SurePrint G3 Human v16 microRNA 8x60K microarray slides; miRBase 
version 16.0) following Sistemic SOP (SSOP07.3). One hundred nanograms 
of total RNA, from a working solution at 50ng/µl in nuclease-free water, 
was used as input for each microarray experiment. Each slide contains 8 
individual arrays, each array represents 1,349 microRNAs (1,205 Human; 
144 viral). The four key steps of the microarray process were: 
 
1. Labelling of RNA with single-colour, Cy3-based reagent. 
2. Hybridisation of the labelled RNA samples to the microarray. 
3. Wash steps. 
4. Slide scanning, data capture and feature extraction (matching array 
spots to miRNA IDs) and quality control checks on the resultant image and 
data files. 
 
2.8.4. Data Pre-Processing and QC 
The microarray data was normalised using Sistemic’s in-house pre-
processing and data quality control (QC) methods. Array quality control 
was performed using outlier testing based on the following metrics:  
 average signal per array  
 average background per array  
 % present (% of miRNAs where expression is detected on each array) 
 principal components 1-3 from PCA (Jackson JE, 1991) (511) of the 
full normalised sample set.  
 
In addition, a sample-to-sample correlation analysis was performed on the 
normalised data set using Pearson’s correlation metric. Outliers were 
identified using Grubbs’ outlier test (Grubbs, 1969) (512) with significance 
called at p < 0.05.   
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2.8.5. Data Analysis 
2.8.5.1. Overview of Detection Calls 
Detection calls (present or absent) for individual miRNAs were compared 
across the samples. The detection calls were calculated using the Agilent 
Feature Extraction (AFE) software version 10.7.3.1. A detailed description 
of how these calls are made is available in the Feature Extraction 
Reference Guide on the Agilent website 
(http://www.genomics.agilent.com). 
 
2.8.5.2. Variability Estimation 
The overall variability of the 8 data sets was assessed in relation to other 
data sets of similar characteristics. The estimation of variability was 
performed by calculating the pooled standard deviation of all miRNAs for 
the current data set as well as Sistemic’s in-house data sets. 
 
2.8.5.3. Summary Overview Visualisation of miRNA Expression Data 
A summary representation of the expression data was produced using 
Principal Component Analysis (PCA; Jackson JE, 1991) (511). PCA extracts 
the main effects from high-dimensional data such as microarray datasets, 
which for each sample have expression measurements from hundreds of 
miRNA. These main effects (principal components) can be displayed in a 
simplified graphical representation which retains the main properties of 
the data. The key point is that samples which have similar miRNA profiles 
cluster in the same space on the PCA plot.  
 
2.8.5.4. Hypothesis Testing – Identification of Equivalently-Expressed 
miRNAs and Differentially-Expressed and Between the Different Sample 
Groups 
Hypothesis testing was first utilised to identify a set of equivalently-
expressed miRNAs.  MiRNAs with equivalent expression levels (stably-
expressed markers) were identified using the Two One-Sided Tests (TOST) 
approach; see e.g. (Barker et al., 2002) (274). This approach is 
recommended for bioequivalence studies by the FDA (FDA guidance 
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document, 2001). The miRNAs with max (pFDR) < 0.05 from the lower and 
upper limits, respectively, were considered equivalently expressed. The 
expression level range (Δ) allowed for the equivalence corresponds to a 
fold-change of ≤1.5 in log2-space. 
 
To identify differentially-expressed miRNAs, the differences in miRNA 
expression between each sample group were evaluated by performing 
unpaired t-tests. The p-values generated from the t-tests were adjusted 
for multiple test inflation using the Benjamini-Hochberg method 
(Benjamini and Hochberg, 1995) (513) and are referred to as pFDR (FDR – 
False Discovery Rate). The miRNAs with significant differences were 
detected by hypothesis testing at pFDR < 0.05 and an absolute fold-change 
(FC) ≥ 1.5. 
 
2.8.5.5. Identification of Biological Processes and Pathways Enriched 
in the DE kmiR™ Lists  
GeneGO MetaCoreTM version 6.11 was used to map miRNAs to their 
validated mRNA targets and then to biological processes and pathways by 
generating networks for downstream interactions, including summary 
tables where the mRNA targets for each DE miRNA are listed along with the 
predicted or observed nature of the miRNA/mRNA interaction.  
 
2.8.5.6. Validation of miRNA 
BM-MSC and OM-MSC samples analysed by Sistemic were returned on dry 
ice, their mRNA concentrations determined using the Nanodrop 1000 
spectrophotometer (Thermo Scientific) and Nanodrop 1000 3.7.1 software, 
and reverse transcription carried out using the miScript II Reverse 
Transcription Kit (Qiagen, 218161), following the supplied protocol: 50 
ng/µL of mRNA was added to the reverse transcription master mix (5x 
miScript HiSpec Buffer (4 µL), 10x miScript Nucleics Mix (2 µL), Nuclease-
Free ddH2O (variable), and miScript Reverse Transcriptase Mix (2 µL)) and 
incubated at 37oC for 60 min, followed by incubation at 95oC for 5 min. 
cDNA samples were stored at -20oC until use. 100 ng of mRNA, from a 
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working stock of 50 ng/µL, was analysed in each well with SybrGreen 
Mastermix (Primer Design, Precision-LR-SY), nuclease-free ddH2O, 
PerfeCta® universal primer (Quanta Biosciences, 95109-500), and either 
miR-140-5p primer (IDT, CAGUGGUUUUACCCUAUGGUAG), miR-146a-5p 
primer (IDT, UGAGAACUGAAUUCCAUGGGUU), or miR-335-5p primer (IDT, 
UCAAGAGCAAUAACGAAAAAUGU). Standard curves were created in seven 
increments from 0.625 ng, doubling up through to 40 ng of miRNA, from 
which the amounts of miRNA per sample were extrapolated. RT-qPCR was 
carried out using the standard curve method, to determine relative levels 
of miR-140-5p, miR-146a-5p, and miR-335-5p in each of the samples using 
the ABI7500 real-time PCR system, and data exported to excel where r2 
values were calculated to indicate the viability of the standard curve, each 
being above the required 0.96 threshold. 
 
2.9. Luminex Array Analysis of Secreted Cytokines 
2.9.1. Collection of Conditioned Media 
4 x human Luminex arrays were carried out to analyse the presence of 
particular cytokines which had been secreted into the media in which each 
cell type was cultured, which we called “conditioned media” (CM). Each 
cell type; BM-MSC, BM271-MSC, OM-MSC, BM271-MSC Flowthrough (BM-FT), 
OM-MSC Flowthrough (OM-FT), and human dermal fibroblasts, was cultured 
as per standard protocol in T75 cm2 flasks until confluent. All media was 
removed, washed thrice with sterile PBS, and replaced with 12 mL of 
differentiation media without insulin (DM-) (DMEM High Glucose 
(Invitrogen, 10566-016), Hydrocortisone (Sigma, H0888), N1 mix (Sigma, 
N6530), Biotin (Sigma, B4501)) for 72 h. To allow for a difference in cell 
proliferation, cell counts were taken after CM was collected at 72 h, and 
CM samples were diluted with DM- at a ratio determined by equalising each 
cell type’s number to that of the lowest cell number in each case (BM-MSC) 
(data not shown). CM samples were then diluted 1:3 in DM-, and filtered to 
remove any cellular debris, then aliquoted and stored at -20 oC until use. 
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1 x rat Luminex array was also carried out using conditioned media 
collected from rat BM-MSCs, rat OM-MSCs, rat Olfactory Ensheathing Cells 
(OECs), and rat Schwann Cells by the same method as just described. 
 
2.9.2. Analysis of Conditioned Media 
2.9.2.1. Human  
All media conditioned by human cells was analysed using 3 separate arrays: 
 
 MILLIPLEX MAP Human Cytokine/Chemokine Magnetic Bead Panel II – 
Premixed 23 Plex – Immunology Multiplex Assay (Millipore, HCP2MAG-
62K-PX23). Analyses the CM for 6Ckine, BCA-1, CTACK, ENA-78, Eotaxin-2, 
Eotaxin-3, I-309, IL-16, IL-20, IL-21, IL-23, IL-28A, IL-33, LIF, MCP-2, MCP-
4, MIP-1d, SCF, SDF-1A+β, TARC, TPO, TRAIL, and TSLP. 
 
 MILLIPLEX MAP Human Cytokine/Chemokine Magnetic Bead Panel II – 
Premixed 41 Plex – Immunology Multiplex Assay (Millipore, HCYTMAG-
60K-PX41). Analyses the CM for EGF, Eotaxin, FGF-2, Flt-3 ligand, 
Fractalkine, G-CSF, GM-CSF, GRO, IFN-α2, IFN-γ, IL-10, IL-12 (p40), IL-12 
(p70), IL-13, IL-15, IL-17, IL-1ra, IL-1α, IL-1β, IL-2, IL-3, IL-4, IL-5, IL-6, IL-
7, IL-8, IL-9, IP-10, MCP-1, MCP-3, MDC (CCL22), MIP-1α, MIP-1β, PDGF-AA, 
PDGF-AB/BB, RANTES, TGFα, TNF-α, TNF-β, VEGF, and sCD40L. 
 
 Cytokine Human 30-Plex Panel (Invitrogen, LHC6003). Analyses the 
CM for IL-1RA, IL-12 (p40⁄p70) IL-13, FGF-Basic, G-CSF, IL-7, IFN-α, IP-
10, IL-17, IL-8, EGF, HGF, VEGF, MIG, RANTES, Eotaxin, MIP-1β, GM-
CSF, TNF-α, IL-1β, IL-2, IL-4, IL-5, IL-6, IL-10, MIP-1α, IL-2R, IL-15, MCP-
1, and IFN-γ. 
 
2.9.2.2. Rat 
All media conditioned by rat cells was analysed using the MILLIPLEX MAP Rat 
Cytokine/Chemokine Magnetic Bead Panel 27-plex Assay (Millipore, 
RECYMAG65K27PMX), which analyses the CM for EGF, Eotaxin, Fractalkine, 
G-CSF, GM-CSF, GRO/KC, IFN-γ, IL-10, IL-12 (p70), IL-13, IL-17A, IL-18, IL-
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1α, IL-1β, IL-2, IL-4, IL-5, IL-6, IP-10, LIX, Leptin, MCP-1, MIP-1α, MIP-2, 
RANTES, TNF-α, and VEGF. 
 
2.9.3. MILLIPLEX assays 
2.9.3.1. Preparing Reagents 
All reagents were left on the bench for 1 hr to allow them to return to RT 
before starting the assay. The bottle of pre-mixed beads was sonicated for 
30 sec then vortexed for 60 sec. Quality control (QC) samples 1 and 2 were 
each reconstituted with 250 µL of ddH2O, mixed by inversion several times, 
and left to sit for 10 min. Wash buffer (60 mL) was diluted in 540 mL of 
ddH2O and mixed by inversion. Cytokine/Chemokine standard was 
reconstituted in 250 µL ddH2O, mixed by inversion, vortexed for 10 sec, 
and allowed to sit for 10 min. Seven working standards (standard curve) 
were produced from this standard by serial dilution. These serial dilutions 
can be found in Table 2.15.  
 
 
 
Table 2.15: Preparation of working standards 1-7 used in each MILLIPLEX 
MAP Cytokine/Chemokine Magnetic Bead Panel Assay. 
 
2.9.3.2. Plate Preparation 
The placement of each sample (including standards and controls) in the 96-
well plate supplied was determined before any analysis occurred. All 
samples are analysed in triplicate, vertically from the top of the plate 
downwards. 200 µL of assay buffer was added to each well of the plate, 
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which was then sealed and mixed on a plate shaker for 10 min at RT. Assay 
buffer was decanted and all residual buffer removed by vigorous inversion 
and blotting on absorbent towels. 25 µL of each standard or control was 
added to the appropriate wells (assay buffer used for 0 ng/mL standard), 
along with 25 µL of assay buffer and 25 µL of control media (DM-). 25 µL of 
sample was added then added to each appropriate well, along with 25 µL 
of assay buffer and 25 µL of control media (DM-). 25 µL of pre-mixed beads 
was added to each well, the plate sealed and wrapped in foil, and 
incubated with agitation at RT on a plate shaker for 2 hr. The plate is 
placed into a hand held magnetic plate holder for 60 sec before gently 
removing the well contents by inversion and gentle blotting. The wells 
were washed with 200 µL of wash buffer by removing the plate from the 
magnet, adding the wash buffer, shaking for 30 sec, reattaching the plate 
to the magnet for 60 sec, and removing the entire wash buffer as 
previously described. This washed step was repeated twice more. 25 µL of 
detection antibodies were added to each well, the plate sealed and 
covered in foil, and incubated with agitation at RT on a plate shaker. 25 µL 
of streptavidin-phycoerythrin was added to each well, the plate sealed and 
covered in foil, and incubated with agitation at RT on a plate shaker. The 
plate was then washed with wash buffer as previously described. 125 µL of 
sheath fluid was added to each, and the beads re-suspended by agitation 
on a plate shaker for 5 min.  
 
2.9.3.3. Plate analysis 
The plate was finally analysed on a Bioplex 100 plate reader (BioRad) using 
Bioplex Manager software. 
 
2.9.4. Invitrogen 30 plex assay 
2.9.4.1. Preparing Reagents 
All reagents were left on the bench for 1 hr to allow them to return to RT 
before starting the assay. Wash solution was prepared by diluting the 
entire contents of the supplied concentrate with 285 mL of ddH2O. The 
standard solution was prepared by reconstituting the lyophilised standard 
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in 1 mL of ddH2O, allowing to stand for 10 min, mixing by gentle inversion, 
and leaving to sit at RT for a further 5 min. The standard curve was 
prepared by serial dilutions of this standard in assay buffer. These serial 
dilutions can be found in Table 2.16. The 30-plex antibody beads were 
supplied ready to use for the assay without further dilution, but were 
sonicated for 30 sec, and vortexed for 30 sec immediately prior to use. 
Biotinylated antibody and Streptavidin-RPE working concentrations were 
prepared by diluting 1 mL of the supplied 10 x concentrate in 10 mL of 
assay buffer.  
 
 
 
Table 2.16: Preparation of working standards 1-7 used in the Invitrogen 
Cytokine 30-Plex Panel Assay. 
 
2.9.4.2. Plate Preparation 
Each well of the supplied filter bottom plate is washed with wash buffer by 
filling each well, placing the plate in a vacuum manifold, and gently 
aspirating the liquid through (5 mm Hg max). Excess fluid was removed by 
lightly tapping or pressing the filter paper onto a clean paper towel, and 
wash repeated 2x more. 25 µL of antibody beads were added to each well, 
followed by 200 µL of wash solution, allowing the beads to soak for 30 sec. 
Fluid was aspirated using the vacuum manifold, and the wash step 
repeated. 50 µL of incubation buffer was added to each well. 100 µL of 
appropriate working standard solution was added to their appropriate 
wells, and 50 µL of sample + 50 µL of assay buffer was added to their 
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appropriately designated wells. Plate was sealed, covered in foil, and 
incubated with agitation on a plate shaker at RT for 2 hr. All liquid was 
aspirated by vacuum manifold, and wells washed twice with 200 µL of wash 
buffer, before the addition of 100 µL of biotinylated detector antibody to 
each well, and incubation with agitation at RT for 1 hr. All liquid was again 
aspirated by vacuum manifold, and washed twice with 200 µL of wash 
buffer, before the addition of 100 µL of Streptavidin-RPE to each well, and 
incubation with agitation at RT for 30 min. Each well was washed a further 
3 times with wash buffer, 100 µL of working solution added to each well, 
and the plate incubated by agitation at RT for 3 min.  
   
2.9.4.3. Plate analysis 
The plate was finally analysed on a Bioplex 100 plate reader (BioRad) using 
Bioplex Manager software. 
 
2.10. Transfection of BM-MSCs and OM-MSCs with miRNA 
inhibitors/mimics 
3 x BM-MSC samples (2 x Female, 1 x Male, average age 53 +- 19), and 3 x 
OM-MSC samples (1 x Female, 2 x Male, average age 56 +- 4) were 
transfected with miR-140-5p inhibitor (Ambion, MH10205) and mimic 
(Ambion, MC10205), miR-146a-5p inhibitor (Ambion, MH10722) and mimic 
(Ambion, MC10722), miR-335-5p inhibitor (Ambion, MH10063) and mimic 
(Ambion, MC10063), miRNA negative (scrambled) control (Ambion, 
RNU58A), and no miRNA (H2O), using the Attractene Fast-Forward 
Transfection Protocol. A full list of samples used can be found in Table 
2.17. Lyophelised miRNA treatments (5 nmol-1) were reconstituted in 100 
µL of ddH2O to make a 50 µM solution. Transfection reagent was prepared 
by incubating 1 µL/well of treatment miRNA (or ddH2O for no miRNA 
controls) with 80 µL/well of StemPro® MSC serum-free media (Invitrogen, 
A10332-01), and 3 µL/well of Attractene Transfection Reagent at RT for 15 
min. 105 cells were seeded in 1 mL of DMEM:10% Hyclone into each well of 
a 6-well plate, and 84 µL of the Attactene transfection complex 
immediately added and mixed by gently pipetting up and down. Due to the 
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method of analysis for cells transfected with miR-335-5p inhibitor/mimic, 
cells had to be seeded onto collagen coated cover slips, so the 1 mL 
transefctant/cell suspension was seeded as 2 x 500 µL suspensions onto 
collagen coated glass cover slips in 24-well plates.  
 
 
 
Table 2.17: List of samples donors used for experiments represented in 
section 5.3.1. 
 
2.10.1. miR140-5p 
Experiment was set up in duplicate; one for collection of conditioned 
media, and one for collection of mRNA for RT-qPCR analysis. 
 
2.10.1.1. Conditioned Media Collection 
Each condition was seeded in triplicate. Cells were incubated for 24 hr at 
37oC before removing all media, washing thrice with sterile PBS, and 
incubating further in 1 mL of DM- at 37oC for 48 hr. Each media was 
collected, the triplicates of each condition pooled together and diluted 1:3 
with DM-, filtered through Minisart® hydrophobic syringe filters (Sartorius 
Stedim, 16534), and stored at -20oC until use. 
 
2.10.1.2. mRNA/miRNA Collection 
Each condition was seeded in duplicate; one for CXCL12 analysis (mRNA), 
and one for miR-140-5p analysis (miRNA). Cells were incubated for 24 hr at 
37oC before removing all media, washing with PBS, and adding fresh media 
for a further 24 hour incubation. Cells were washed again in sterile PBS 
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before collecting either mRNA using a Purelink® RNA mini kit as described 
in section 2.10.1, or miRNA using a miRNEASY mini kit (Qiagen, 217004) 
following the supplied protocol: 700 µL of QIAzol Lysis Reagent was added 
to each well, and the cells disrupted with a 1 mL pipette tip. This 
suspension was transferred to a 1.5 mL centrifuge tube, and incubated at 
RT for 5 min before 140 µL of chloroform was added, and the tubes shaken 
vigorously for 15 sec. Samples were centrifuged at 12,000 x g at 4oC for 15 
min, and the upper aqueous layer transferred to a fresh 1.5 mL centrifuge 
tube. 525 µL of ethanol (EtOH) was added to each tube, and mixed 
thoroughly by pipetting, before transferring 700 µL into an RNeasy® Mini 
Column. Columns were centrifuged at 11,337 x g for 30 sec, the waste 
discarded, and the remainder of the sample added to the column and 
centrifuged as before. Waste was discarded again, and each column 
washed with 700 µL of wash buffer 1 by centrifugation as before, which 
was then repeated with 2 x 500 µL of wash buffer 2. Columns were 
centrifuged at 11,337 x g for 2 min to fully dry the membrane, before 
miRNA was eluted with 50 µL of nuclease-free ddH2O into a nuclease-free 
1.5 mL centrifuge tube. Samples were stored on ice whilst total miRNA 
content was analysed using the nanodrop method as previously described, 
and samples reverse transcribed using the miSCRIPT II RT kit as previously 
described. Samples were then stored at -20oC until analysed. 
 
2.10.1.3. RT-qPCR 
miRNA samples were analysed for miR-140-5p content using the primers 
and RT-qPCR standard curve method previously described in section 
2.14.5.6. mRNA samples were analysed using primers for CXCL12 (IDT, 
TGGGCTCCTACTGTAAGGGTT (forward), TTGACCCGAAGCTAAAGTGG 
(reverse)). Both primers were delivered in lyophilised form, and were 
resuspended in ddH2O (331 µL (forward) and 281 µL (reverse)) to produce 
100 µM solutions. All samples were analysed using the RT-qPCR standard 
curve method as preciously described. 
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2.10.2. miR-146a-5p 
Cells were transfected and lysed for western blot analysis to determine any 
increase/decrease in levels of expression of the Fas receptor protein CD95. 
Experiments were set up in duplicate so that transfection can be validated 
by RT-qPCR. 
 
2.10.2.1. Protein Collection  
2.10.2.1.1. “Normal” Expression Profile of CD95 on BM271-MSCs and 
OM-MSCs 
Four separate donor samples of both BM271-MSCs and OM-MSCs were 
cultured under normal conditions for 24 hours before being trypsinised and 
lysed for protein harvesting. All cells used for this experiment can be found 
in Table 2.18. Cells were washed in sterile PBS and lysed by the addition of 
500 µL of CellLytic™ MT cell lysis buffer (Sigma, C3228) and agitation with 
a 1 mL pipette tip. Lysates were triturated through a 21G needle, and 
transferred to a 1.5 mL centrifuge tube before protein concentrations were 
determined using the nanodrop 1000. Samples were diluted to a working 
concentration of 1 µg/µL, 16 µL of which was added to 6 µL of 4x LDS 
sample buffer (Invitrogen, NP0007) and 2 µL of sample reducing agent 
(Invitrogen, NO0004), and the whole protein suspension was incubated at 
80oC for 10 min. Samples were transferred directly to ice or stored at -20oC 
until needed. Stock samples were stored at -80oC long term. 
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Table 2.18: List of samples donors used for experiments represented in 
section 5.4 
 
2.10.2.1.2. Expression of CD95 Post-Transfection with Inhibitor and 
Mimic of miR-146a-5p 
Cells were incubated at 37oC for 24 hour post-transfection before all media 
was removed from each well, wells washed with PBS, and Fresh media was 
added for a further 24 hour incubation at 37oC. Cells were lysed and 
protein harvested by the same method as previously described in section 
2.16.2.1.1. 
 
2.10.2.2. Western Blot 
The western blot dock was prepared by adding 800 mL of MES SDS running 
buffer (Novex, NP0002, 40 mL of 20x diluted to 800 µL with ddH2O) to the 
dock, and placing in a NuPage 4-12% Bis-Tris 15-well gel (Novex, 
NP0323BOX). 5 µL of SeeBlue Plus 2 Prestained Standard (Invitrogen, 
LC5925) was added to the first well of the gel, and 20 µL of each sample 
was added to each subsequent well. Electrodes were attached, and the gel 
exposed to 200 V of electricity for 1 hr. The gel was then removed from its 
case, and blotted onto a membrane using an iBlot® Gel Transfer System 
(Invitrogen). Membranes were cut from the iBlot and any non-specific 
protein binding sites were blocked with a 5% milk solution, made up in PBS 
+ 0.01% Tween from Marvel® milk powder at RT for 30 min. The milk was 
poured to waste, primary (1o) antibody to CD95 (Abcam, ab82419) was 
diluted 1:1000 in 5% milk:PBS Tween solution and added to the blot, which 
was incubated at RT for 1 hr. 1o antibody was poured to waste, the blot 
washed for 3 x 20 min at RT, or overnight at 4oC, before addition of 
secondary (2o) antibody ECL anti-rabbit IgG, Horseradish peroxidase linked 
whole antibody from donkey (GE Healthcare, NA934V), 1:1000 in 5% 
milk:PBS Tween for 60 min at RT. Blot was washed for 3 x 20 min at RT, or 
overnight at 4oC, and developed by addition of 1 mL of Pierce ECL Western 
Blotting Substrate (Solutions A and B mixed 1:1) (Thermo Scientific, 32106) 
straight onto the membrane for 5 min at RT. ECL solution was then poured 
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off the membrane, and the blot developed onto x-ray film under dark room 
conditions. The membrane was “stripped” of its CD95 antibody by 
immersion in Western Blot Stripping Buffer (Thermo Scientific, 21059), re-
blocked in 5% milk:PBS Tween, and incubated in 1o antibody as before, but 
with anti-GAPDH antibody as a loading control. ECL peroxidase labelled 
anti-mouse antibody (GE Healthcare, NA931VS) was added as a 2o antibody, 
and the blot developed onto film as before.  
 
2.10.2.3. RT-qPCR 
miRNA was collected as previously described with miR-140-5p, samples 
were analysed for miR-146a-5p content using the primers and RT-qPCR 
standard curve method previously described in section 2.14.5.6. 
 
2.10.3. miR-335-5p 
Cells were analysed for any increase/decrease in proliferation prior to 
transfection with either an inhibitor or mimic of miR-335-5p. The 
experiment was set up for time-points at 48, 72, and 96 hr post 
transfection, and in duplicate so that transfection can be validated by RT-
qPCR.  
 
2.10.3.1. Cell Counting 
At each of the three time-points, all media was removed, cells washed 
with PBS, and fixed for 5 min in 4% PFA. Cells were mounted onto glass 
cover slips using Vectashield® mounting media with DAPI, and imaged 
using the same fluorescence microscope and software as previously 
described. 30 images per condition per time-point were taken, and cell 
counts taken by counting the DAPI stained fluorescent nuclei using 
CellProfiler cell image analysis software. 
 
2.10.3.2. RT-qPCR 
miRNA was collected as previously described with miR-140-5p, samples 
were analysed for miR-335-5p content using the primers and RT-qPCR 
standard curve method previously described in section 2.14.5.6. 
122 
 
2.11. Myelination Model using Rat Spinal Cord Cultures 
2.11.1. Astrocyte Culture 
Whole brains were removed from postnatal day 1 (P1) Sprague-Dawley (SD) 
rat pups immediately after euthanisation, and the striatum (caudate, 
putamen, and thalamus) removed and placed on ice in Leibovitz’s L-15 
media. Striata were homogenised by pipetting up and down with a 1 mL 
pipette, and triturated through a 21 G needle, before transferring to a 15 
mL centrifuge tube, and centrifuging at 386 x g for 3 min. Media was 
decanted to waste, and the cells reconstituted in 2 mL of neurosphere 
media (ddH2O, 10x DMEM/F12 (Invitrogen, 52100-021), 10x hormone mix 
(10x DMEM/F-12, 30% w/v glucose (Sigma, G7021), 7.5% NaHCO3 (Sigma, 
S5761), 1M HEPES (Sigma, H4034), ddH2O, transferrin (Sigma, T2252), 
Insulin (Sigma, I9278), Putrecine (Sigma, P7505), Selenium (Sigma, S9133), 
Progesterone (Sigma, P6149)), 30% w/v glucose, 1M HEPES, L-Glutamine 
(Gibco, 25030-081), Pen/Strep (Gibco, 15070-022), and 4% BSA (Sigma, A-
3059) in HBSS (Sigma, H4891)). This cell suspension was added to 18 mL of 
neurosphere media + 4 µL of endothelial growth factor (EGF) (Peprotech, 
315-09) in a T75 cm3 culture flask. A further 5 mL of neurosphere media 
and 4 µL of EGF was added every 72 hr until numerous neurospheres 
formed suspended in the media. Once the neurospheres reached a 
sufficient number and size, the whole suspension was transferred to a 50 
mL centrifuge tube, and spun down at 386 x g for 3 min. The formed pellet 
was re-suspended in 5 mL of DMEM (low glucose) (Invitrogen, 21885-025) 
plus 10% FBS (Sigma, F7524), and 0.05% L-Glutamine (Sigma, G7513), 
henceforth known as DMEM:10% FBS. Neurospheres were triturated gently 
through a 21 G needle, diluted further to 48 mL with DMEM:10% FBS, and 
500 µL transferred to each well of 4 x 24-well plates containing PLL coated 
glass cover slips (Section 1). Cells were incubated at 37oC, replacing 50% of 
the media every 72 hr until a confluent monolayer of astrocytes had 
formed. 
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2.11.2. Spinal Cord Dissection 
Embryos at 15 days gestation (E15) were removed from a female SD rat 
immediately after euthanisation. Whole spinal cord was removed from the 
embryos, all attached tissue and meninges removed, and placed on ice in a 
5 mL bijou flask containing 1 mL of Leibovitz’s L-15 media. For optimal 
enzymatic digestion, no more than 4 spinal cords were added to each 
bijou. Cords were homogenised by gently passing up and down a glass 
Pasteur pipette, and enzymatically digested by adding 100 µL of 2.5 
mg/mL trypsin (T8253)) and 100 µL of 1.33% collagenase, and incubating at 
37oC for 15 min. 1 mL of SD was added to neutralise the trypsin and 
collagenase, and reduce clumping, and the whole suspension transferred to 
a 15 mL centrifuge tube and spun down for 3 min at 386 x g. Waste media 
was decanted, and cells re-suspended in 2 mL of Plating Media (DMEM (Low 
Glucose), Hank’s Balanced Salt Solution (HBSS) (Invitrogen, 24020-091), 
Horse Serum (HS) (Sigma, H1270), L-Glutamine). 10 µL of suspension was 
added to a haemocytometer and a cell count determined per 100 µL of 
suspension, which was further diluted to give a total of 150,000 cells/100 
µL.  
 
2.11.3. Mixed Myelinating Culture Set-up 
Astrocyte cover slips were removed from their 24-well plates, and placed 3 
at a time in small petri dishes. 100 µL of spinal cord cell suspension was 
added as a meniscus on top of the astrocyte monolayer, and incubated at 
37oC for at least 2 hr. Each small petri dish is then “flooded” with 1 mL of 
plating media:DM+ (DMEM (High Glucose) (Invitrogen, 41966-029), Insulin, 
Hydrocortisone, N1, and biotin) at a ratio of 6:4, before incubation at 37oC 
for 28 days. 500 µL of the media is replaced with 600 µL of DM+ every 48-
72 hr until day 12. Henceforth, feeding with DM+ was replaced with 
treatments as desired or with DM- for control conditions.  
 
2.11.4. Mixed Myelinating Culture Analysis 
On day 28, cultures were stained using the immunocytochemistry protocol 
previously described, using AA3 antibody (hybridoma-derived) as an 
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indicator of the myelin protein phospholipoprotein (PLP), and SMI31 as an 
axonal marker. Fluorescent images were taken using the previously 
described method, and percentages of myelinated axons per condition 
were calculated using CellProfiler Cell Image Analysis software. 
Myelination of axons under experimental conditions was presented as fold 
increases of myelinated axons relative to untreated controls. 
 
2.11.5. Treatment of Mixed Spinal Cord Cultures with CXCL12, anti-
CXCL12, and CXCR4 blocker (AMD3100) 
From day 12 of incubation, mixed rat spinal cord cultures were treated 
with a neutralising antibody to CXCL12 (anti-CXCL12 (R&D Systems, 
MAB310)), a blocker of the CXCL12 receptor CXCR4 (AMD3100 (Sima, 
A5602)), 100 ng of CXCL12 (Peprotech, 400-32B), OM-MSC-CM, 100 ng 
CXCL12 + AMD3100, OM-MSC-CM + AMD3100, and 100 ng CXCL12 + anti-
CXCL12, using DM- treated cultures as an untreated control. AMD3100 
(molecular weight 794.5 g) was diluted to 39.7 mg/mL in ddH2O to give a 
50 mM stock solution. This stock solution was added to each designated 
culture at 1:1000, 1-2 hr before feeding to allow for optimal receptor 
blocking, giving a final concentration in the dish of 50 µM. 5 µL of CXCL12 
(1 µg/µL) was diluted in 2.5 mL of DM- to give a working solution of 200 
ng/mL. When feeding, 400 µL of media was replaced with 500 µL of 
CXCL12 working solution to give a total of 100 ng per dish. 5 µL of anti-
CXCL12 stock solution (50 µg/mL) was diluted in 500 µL of DM- to give a 
500 ng/mL diluted stock solution. 5 µL of this was then added to either 5 
mL of OM-MSC-CM or 5 mL of DM- 1-2 hr before feeding (final concentration 
5 ng/mL), and incubated at 37oC. When feeding, 400 µL of media was 
replaced with 500 µL of anti-CXCL12/DM- or anti-CXCL12/OM-MSC-CM 
working solutions. Cultures were fed every 48-72 hr until day 28 when they 
were stained using the immunocytochemistry protocol as previously 
described in section 2.10.2. 
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2.11.6. Treatment of Mixed Spinal Cord Cultures with Conditioned 
Media from MSCs Transfected with Inhibitor and Mimic of miR-140-5p 
From day 12, cultures were fed by removing 400 µL of media and replacing 
with 500 µL of conditioned media collected in section 2.16.1.1. Feeding 
occurred every 48-72 hr until day 28 when they were stained using the 
immunocytochemistry protocol as previously described in section 2.10.2. 
 
2.12. Statistical Analysis 
All statistical analysis was carried out using GraphPad Prism version 6.0. 
For comparing values taken from the analysis of each cell type over a 
single parameter, such as comparing the secretion of a single chemokine 
by each particular cell type, a 1-way ANOVA was carried out. When 
comparing values taken from the analysis of each cell type over multiple 
parameters, such as comparing the gene expression in each cell type on 
different topographies at different time points, a 2-way ANOVA was carried 
out. As each of the means of each column of data, which represent the 
biological replicates of a particular sample, were compared against each 
other, Tukey’s multiple comparison test was employed for each 1-way and 
2-way ANOVA. These analyses were consistant throughout the thesis, and 
no other statistical analysis was used, other than the Benjamini-Hochberg 
method of finding the false discovery rate which was utilised by Sistemic in 
Table 5.1.   
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Results: 
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3. Characterisation of MSCs 
Previous data from our lab has shown that MSCs extracted from the lamina 
propria of the olfactory mucosa have very different effects on axonal 
myelination in vitro compared to those derived from bone marrow (1). In 
order to try to identify by which mechanisms this might occur, we first 
have to carry out a comparative characterisation of both MSC types. In this 
chapter I will compare the biology of both olfactory mucosa-derived MSCs 
(OM-MSCs) and bone marrow-derived MSCs (BM-MSCs) taken from human 
donors, by means of morphology and proliferation, by classic MSC 
identifiers such as genetic and protein markers, and by their ability to 
produce bone and fat. To further emphasise any distinct biological 
properties,  human OM-MSCs and BM-MSCs will also be compared to BM271-
MSCs (bone marrow-derived MSCs which have undergone the same CD271 
positive selection process as OM-MSCs), as well as fibroblasts, non-purified 
adherent OM cells, and flow through (discarded) cells from both OM-MSC 
and BM-MSC purifications.  
 
3.1. Morphological Comparison of MSCs by Phase Microscopy 
The initial basic observation to characterise the three MSC types was 
simply to compare their morphology under normal culture conditions. 
Three separate samples of MSCs from 3 separate donors and 2 distinct 
niches (2 x bone marrow and 1 x olfactory mucosa) were imaged under 
phase microscopy at x20 magnification. Unpurified bone marrow-derived 
MSC samples were generated (selected from bone marrow aspirate by 
adhesion only) (BM-MSC) and purified by antigenic selection using a 
commercially available MSC stem cell purification kit using the  CD271 
antibody as a means for positive selection  (BM271-MSC). OM-MSCs were 
also purified by antigenic selection using the same CD271 positive selection 
kit. Each cell type was cultured for the same number of passages before 
imaging, and by simply observing the images of each cell type by eye it 
was clear that each was indistinguishable from the next (Figure 3.1). Each 
cell type showed a very similar morphology which is characteristic of MSCs; 
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small cell bodies with few processes which grew together to form palisades 
in a typical “fingerprint”, fibroblast-like morphology. 
 
 
 
Figure 3.1: Phase images of BM-MSC (A, donor = Maggie, female, age 51, 
passage 3), BM271-MSC (B, donor = Hazel, female, age 57, passage 3), and 
OM-MSC (C, donor = M6.12.61, male, age 50, passage 3). Images were 
taken live at 20x magnification with the scale bar representing 50 μm. 
 
3.2. Comparison of the Rates of Proliferation Between OM-MSCs and 
BM-MSCs 
Coming from two completely distinct cellular niches, BM-MSCs and OM-
MSCs are constantly influenced by environmental cues in situ. Although 
taking these cells from their niche and analysing them in vitro removes any 
niche dependant external cues, certain epigenetic changes may have 
occurred within the cells during their time within each niche. To begin to 
investigate any such effects, we first looked at the proliferation rates of 
each cell type by counting the number of cells in each culture at 5 day 
intervals over a 25 day period. Anecdotally, OM-MSCs displayed a much 
faster proliferative capacity than both BM and BM271-MSCs and were also 
able to survive longer numbers of passage, although their biological 
properties as MSCs were never analysed above passage 4 throughout this 
project. Table 3.1A lists each sample (n=3 experiments) and the actual cell 
counts at each 5 day period over the 25 day time course. Due to the 
impracticality of plotting such vastly differing figures in a line graph, log 
values were taken of each count (Table 3.1B) and plotted onto a line graph 
using GraphPad Prism 6 software (Figure 3.2). Statistical significance was 
determined via 1 way ANOVA using Tukey’s multiple comparison test, 
where *=p<0.05, **=p<0.01, ***=p<0.005, and ****=p<0.001, which showed 
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that OM-MSCs possess a vastly, and statistically significant (p<0.001) higher 
rate of proliferation compared to BM-MSCs and BM271-MSCs across every 
time point, with OM-MSCs showing an almost exponential growth pattern 
compared to the more linear pattern of growth displayed by BM-derived 
MSCs. Proliferation rates were significantly higher (p<0.005) in BM27-MSCs 
at day 5 decreasing to p<0.05 at day 10 compared to BM-MSCs, but by day 
15 there was no significant difference between the two. 
 
 
 
 
 
 
A 
B 
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Table 3.1: Cell counts (A), and the log values of these cell counts (B) 
comparing the proliferation of BM-MSCs, BM271-MSCs, and OM-MSCs over 25 
days. Counts were taken every 5 days, and the log values were determined 
of these counts due to the exponential increase in proliferation of OM-MSCs 
compared to BM- and BM271-MSCs. There was no significant difference 
between the average ages of each set of sample donors. 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.2: Line graph plotting the different rates of proliferation of BM-
MSCs, BM271-MSCs, and OM-MSCs. Due to their advance proliferative 
capacity, OM-MSCs were passaged upon confluency from day 7 onwards to 
maintain cell survival. Statistical analysis was carried out by 1 way ANOVA 
using Tukey’s multiple comparison test, where *=p<0.05, **=p<0.01, 
***=p<0.005, and ****=p<0.001. n=3. 
 
3.3. Comparative RT-qPCR of fibroblasts, BM– and OM- derived MSC, and 
their Resident Tissues  
The niche in which a cell resides can influence cell behaviour via numerous 
environmental cues including the ECM and various gradients of growth 
factors (275-279). However, there will also be molecular changes that can 
be studied to compare any differences between each cell type, e.g. at a 
transcriptional level, to identify if any such differences may be cell type 
specific. This experiment is also to confirm the phenotype of OM-MSCs 
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which, as a relatively novel MSC type, have previously been suggested to 
be fibroblasts. Moreover, these experiments will also validate the CD271 
positive selection process used to purify both BM- and OM-MSCs throughout 
this project. This was carried out by analysing cells normally discarded 
during the CD271 positive selection process (known as the flow through 
cells), as well as unpurified BM-MSCs and unpurified adherent OM cells 
(pre-enzymatic dissection) (see Materials and Methods Table 2.2 for full 
sample details). RT-qPCR was carried out, using the Livak (ΔΔCT) method, 
on cDNA from each cell type (BM-MSCs, BM271-MSCs, BM271-Flow through 
cells, unpurified adherent OM cells, OM-MSCs, OM-Flow through cells, and 
fibroblasts). This was done to identify a profile of mRNAs related to each 
cell, using a panel of MSC-related genetic markers (CD90, CD54, CD105, 
CD73, Nestin, CD166, and CD271 (p75NTR)) (Figure 3.3). A full list of primers 
used can be found in Materials and Methods Table 3.3. 
 
3.3.1. Comparison of the Transcription Profiles of OM-MSCs and 
Fibroblasts 
Statistical significance was determined via 1 way ANOVA using Tukey’s 
multiple comparison test, where *=p<0.05, **=p<0.01, ***=p<0.005, and 
****=p<0.001, which showed first, that comparison of OM-MSCs and 
fibroblasts demonstrated little or no expression of CD54 (B), CD105 (C), 
Nestin (E), CD166 (F), and CD271 (G) in fibroblasts which were in contrast  
highly expressed in OM-MSCs (Figure 3.3). Due to a large sample variation 
in the expression of CD54 and CD105, the difference between fibroblasts 
and OM-MSCs wasn’t statistically significant. However, the almost lack of 
CD54 and CD105 transcript in fibroblasts, coupled with significant 
differences in expression of Nestin, CD166, and CD271 (p<0.01) conclude 
that OM-MSCs are indeed distinct when compared to fibroblasts at a 
transcriptional level, when using this panel of MSC markers. 
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Figure 3.3: RT-qPCR analysis of MSC-associated transcripts CD90 (A), CD54 
(B), CD105 (C), CD73 (D), Nestin, (E), CD166 (F), and CD271 (p75NTR) (G) in 
n=3, BM-MSCs, BM271-MSCs, BM271-Flowthrough cells, unpurified OM 
tissue, OM-MSCs, OM-Flowthrough cells, and fibroblasts. Statistical analysis 
was carried out by 1 way ANOVA using Tukey’s multiple comparison test, 
where *=p<0.05, **=p<0.01, ***=p<0.005, and ****=p<0.001. RT-qPCR was 
carried out using the Livak (ΔΔC
T
) method with GAPDH as the reference 
control gene. 
 
3.3.2. Investigating the CD271 Positive Selection Method of MSC 
Isolation by RT-qPCR 
Using the commercially available MSC purification kit it was observed for 
each cell type that the expression of CD271 (G) was expressed in BM-MSCs 
and OM-MSCs pre- and post-purification. However, post-purification BM271-
MSCs and OM-MSCs express significantly higher levels of CD271 (BM-MSC vs 
BM271-MSC = p<0.05, and OM vs OM-MSC = p<0.01) than their parent tissue 
(Figure 3.3G), suggesting a much purer population of CD271 positive cells. 
Flow through cells collected from both BM271-MSC and OM-MSC 
purifications did not express CD271, suggesting that all CD271 positive cells 
were retained throughout the isolation procedure. In addition, as 
previously mentioned, fibroblasts also lacked expression of CD271. A 
similar expression profile for CD105 was detected in each cell type, 
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another typical MSC marker. CD166 was significantly more highly expressed 
in both BM271-MSCs and OM-MSCs (p<0.05 and p<0.01) compared to their 
unpurified counterparts, and expressed at very low levels, if at all, in flow 
through cells and fibroblasts. This further validates that BM271-MSCs and 
OM-MSCs are both pure populations of MSCs retained throughout the CD271 
selection process, and distinct from fibroblasts. 
 
3.3.3. Comparing Nestin mRNA Expression in OM-MSCs to that of 
Bone Marrow-Derived MSCs and Fibroblasts  
The expression of Nestin mRNA was detected in all MSC types, although 
expression was highest in OM-MSCs (Figure 3.3E). Nestin mRNA levels were 
significantly differentially expressed in OM-MSCs (p<0.01) compared to BM-
MSCs, BM271-MSCs, BM-Flowthrough cells, and fibroblasts. This greater 
expression was also observed in unpurified adherent OM cells and OM-flow 
through cells when compared to BM-MSCs, BM271-MSCs, BM-flow through 
cells, and fibroblasts, although this difference in  expression was 
insignificant by 1-way ANOVA. These data suggest that the observed 
difference in expression of Nestin may be related to the tissue niche. 
 
3.4. Validation of RT-qPCR Findings by Immunocytochemistry  
To determine whether the differences in transcriptional expression were 
translated to differences in expression of their respective proteins, 
immunocytochemistry was carried out on each cell type using the 
antibodies to CD90, CD54, CD105, CD73, Nestin, CD166, CD271 (p75NTR), 
and Stro-1 (Stro-1 gene has not been identified, so was unable to carry out 
RT-qPCR as primers could not be generated). A full list of antibodies used 
can be found in Materials and Methods Table 2.7. Protein expression 
profiles were determined by counting the number of immunoreactive cells 
for each of these MSC markers, and calculating a mean percentage of 
positive expressing cells per field of view (Figures 3.4 and 3.5). 
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Figure 3.4: Representative images of Immunocytochemistry analysis of n=3 
BM-MSCs, BM271-MSCs, BM271-flowthrough cells, OM-MSCs, OM-flowthrough 
cells, and fibroblasts. Staining was carried out for MSC markers CD90 
(green) and CD54 (red) (A-H), CD105 (green) and CD73 (red) (I-P), Nestin 
(green) and CD166 (red) (Q-W), and CD271 (p75NTR) (green) and Stro-1 (red) 
(X-δ). Isotype controls were stained with secondary antibody only. Images 
were taken at x40 magnification, scale bar represents 25 μm. 
 
3.4.1. Comparing Protein Expression Profiles of OM-MSCs and 
Fibroblasts  
CD90 immunoreactivity (IR) (Figure 3.5A), a well-known fibroblasts and 
MSC marker, was unsurprisingly highly expressed in fibroblasts, along with 
each of the other cell types. BM-MSCs however, displayed a significantly 
lower expression of CD90-IR compared to each of the other cell types 
(p<0.05) (Figure 3.5A). This may be due to the heterogenous nature of this 
population resulting in a “dilution” of CD90-IR positive cells. CD73-IR 
(Figure 3.5D) was also equivalently expressed in fibroblasts compared to 
each of the other cell types, it being a non-specific and relatively 
ubiquitous MSC marker. CD105-IR (Figure 3.5C) was expressed in a very 
small number of fibroblasts (<5%), compared to almost 40% of OM-MSCs, 
however, due to a very large sample variation in CD105-IR expression, this 
difference was not considered significant by 1-way ANOVA. Stro-1-IR 
(Figure 3.4H), regarded as a specific MSC marker (280-283), was expressed 
only in BM-MSCs and none of the other cell types (p<0.01). Stro-1-IR 
positive cells may not co-express CD271-IR, as all Stro-1-IR positive cells 
are lost during the CD271 positive selection process. It could be suggested 
that the loss of Stro-1-IR may be down to the fact that Stro-1 is an early 
MSC marker (514), and BM271-MSCs spend an extended time in culture 
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compared to BM-MSCs, however, CD271 is also an early MSC marker which 
is lost as MSCs differentiate (515), but CD271 positive BM-MSCs are still 
retained throughout this extended culture period. Stro-1-IR was also found 
to not be expressed in all OM-cell suspension samples or in fibroblasts. 
Each of the other markers (CD54-IR (Figure 3.5B), Nestin-IR (Figure 3.5E), 
CD166-IR (Figure 3.5F), and CD271-IR (Figure 3.5G)) were significantly 
differentially expressed in OM-MSCs compared to fibroblasts (p<0.05, 
p<0.001, and p<0.001 respectively). CD54-IR was expressed in ~50-60% of 
each cell type except fibroblasts, which lacked CD54 expression 
completely (P<0.001). Fibroblasts expressed Nestin-IR on ~45-55% of cells, 
in a similar manner to BM and BM271-MSCs. This was significantly different 
(p<0.05) to OM-MSCs which strongly express Nestin-IR in almost 100% of 
cells analysed. CD166-IR and CD271-IR were both weakly expressed in a 
very small number of fibroblasts (<5%) which was significantly lower 
(p<0.001) than OM-MSCs in both cases. These findings confirm that OM-
MSCs and fibroblasts are two completely distinct cell populations. It also 
confirms the RT-qPCR data which shows an expression of all MSC markers 
on each of the three cell types; BM-MSCs, BM271-MSCs, and OM-MSCs, and 
that Nestin-IR is expressed at a significantly higher level in OM-MSCs 
compared to BM- and BM271-MSCs. 
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Figure 3.5: Graphical representations of Immunocytochemistry 
quantification of BM-MSCs, BM271-MSCs, BM271-flowthrough cells, 
Unpurified adherent OM cells, OM-MSCs, OM-flowthrough cells, and 
fibroblasts for the expression of MSC markers CD90 (A), CD54 (B), CD105 
(C), CD73 (D), Nestin (E), CD166 (F), CD271 (G), and Stro-1 (H). Expression 
was calculated as the mean percentage of cells per field of view which 
expressed each marker, the mean being taken from 10 images per cell type 
per condition. Three separate sample donors were analysed throughout the 
experiment (n=3), and Statistical analysis was carried out by 1 way ANOVA 
using Tukey’s multiple comparison test, where *=p<0.05, **=p<0.01, 
***=p<0.005, and ****=p<0.001. n=3. 
 
3.4.2. Investigating CD271 Positive Selection as a Valid Method of 
Isolation by Immunocytochemistry 
These Immunocytochemistry data confirm findings from RT-qPCR that the 
CD271 positive selection protocol to generate MSCs used throughout this 
project is valid and reliable. Analysis of CD271 expression showed that ~40-
80% of BM-MSCs and ~35-45% of unpurified adherent OM cells expressed 
CD271-IR. However, almost 100% of both BM271-MSCs and OM-MSCs were 
immunolabelled with CD271 antibody (p<0.001), which suggests that most 
of the MSCs collected at the end of the positive selection method were 
indeed immunolabelled with the CD271 antibody. This is validated by 
analysing the “flowthrough” cells which were discarded from both BM271-
MSC and OM-MSC purifications, which showed that most of these cells 
analysed (>95%) did not label with the CD271 antibody.  
 
3.4.3. Comparing Nestin Immunoreactivity on OM-MSCs to that on 
Bone Marrow-Derived MSCs and Fibroblasts  
As shown using RT-qPCR, Nestin-IR was detected in almost 100% of OM-
MSCs, as well as unpurified adherent OM cells and OM-Flowthrough cells. 
This is significantly different to Nestin-IR on BM-MSCs (p<0.05), BM271-
MSCs (p<0.05), fibroblasts (p<0.05), and BM-Flowthrough cells (p<0.01). 
These significantly different levels of Nestin–IR appear niche dependant, 
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and possibly related to the high turnover of cells in the olfactory mucosa. 
Nestin is a marker for a number of cell types, but it is also an indicator of 
cell immaturity, as cells lose their expression of Nestin over time (284-
288). The olfactory mucosa is an area of constant insult due to breathing in 
pollutants and xenoparticles. This requires a quick turnover of cellular 
regeneration compared to a far more protected environment in which the 
bone marrow tissue resides, where cells are able to turn over much more 
slowly (35, 36, 289-294). 
 
3.5. Comparison of OM-MSCs and BM-MSCs by RT-qPCR and 
Immunocytochemistry, Using Markers of Fat, Bone, Neuron, Smooth 
Muscle, and Glia  
MSCs are capable of differentiating into fat, bone, and cartilage, (295-299) 
and possibly to trans-differentiate to other cell types such as smooth 
muscle, neurons, and glia, although this theory is still under debate (300-
304). Here we look at BM-MSCs, BM271-MSCs, and OM-MSCs, (Materials and 
Methods Table 2.5) and their inherent expression of mRNA associated with 
fat, bone, neuron, muscle, and glia differentiation. RT-qPCR was carried 
out using primers related to adipocytes (GLUT4 (Figure 3.6A) and Leptin 
(Figure 3.6B)), osteocytes (OPN (Figure 3.6C) and OCN (Figure 3.6D)), 
Neurons (Tuj-1 (Figure 3.6E) and MAP2 (Figure 3.6F)), myocytes (MyoD 
(Figure 3.6G), and SMA (Figure 3.6H)), and glia (GFAP (Figure 3.6I)) using 
the Livak (ΔΔCT) method. A full list of primers used can be found in 
Materials and Methods Table 2.4. With the exception of GFAP, SMA, and 
GLUT4, BM-MSCs had a trend towards higher mRNA expression of all other 
markers compared to BM271-MSCs and OM-MSCs, especially for OPN and 
OCN. None of these differences however, were statistically significant. 
Similar results were observed by immunocytochemistry when each cell 
type was immunolabelled with antibodies to each of the aforementioned 
markers. A full list of antibodies can be found in Materials and Methods 
Table 2.7. There was no significant difference in the expression of any of 
the protein markers across each cell type (Figure 3.8), with no expression 
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at all observed of OCN, MyoD, and MAP2 in any cell type. Representative 
images of these immunofluorescence can be found in Figure 3.7. 
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Figure 3.6: RT-qPCR analysis of transcripts associated to fat (GLUT4 (A) 
and Leptin (B)), bone (osteopontin (OPN) (C) and osteocalcin (D)), neuron 
(Tuj-1 (E) and MAP2 (F)), smooth muscle (SMA (G) and MyoD (H)), and glia 
(GFAP (I)) differentiation in n=3 BM-MSCs, BM271-MSCs, and OM-MSCs. 
Statistical analysis was carried out by 2 way ANOVA using Tukey’s multiple 
comparison test, where *=p<0.05, **=p<0.01, ***=p<0.005, and 
****=p<0.001. PCR was carried out using the Livak (ΔΔCT) method with 
GAPDH as the reference control gene. 
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Figure 3.7: Representative images of Immunocytochemistry analysis of BM-
MSCs, BM271-MSCs, and OM-MSCs. Staining was carried out for markers of 
fat (GLUT4 (green) (A-D) and Leptin (green) (E-H)), Bone (OPN (green) (I-L) 
and OCN (green) (M-P)), neuron (Tuj-1 (green) and MAP2 (red) (Q-T)), 
smooth muscle (MyoD (green) and SMA (red) (U-X)), and glia (GFAP (green)) 
(Y-β) differentiation. Nuceli (blue) were stained with DAPI. Images were 
taken at x40 magnification, scale bar represents 25 μm. n=3. 
 
 
 
Figure 3.8: Graphical representations of Immunocytochemistry analysis of 
BM-MSCs, BM271-MSCs, and OM-MSCs for the expression of fat (GLUT4 and 
Leptin), bone (OPN and OCN), smooth muscle (SMA and MyoD), neuron 
(Tuj-1 and MAP2), and glia (GFAP) differentiation markers. Expression was 
calculated as the mean percentage of cells per field of view which 
expressed each marker, the mean being taken from 10 images per cell type 
per condition. Three separate sample donors were analysed throughout the 
experiment (n=3), and Statistical analysis was carried out by 1 way ANOVA 
using Tukey’s multiple comparison test, where *=p<0.05, **=p<0.01, 
***=p<0.005, and ****=p<0.001. n=3. 
 
3.6. Comparison of the Ability of OM-MSCs and BM-MSCs to Differentiate 
Into Bone and Fat 
Differentiation into both bone and fat is indicative of classical MSC 
behaviour (304-307). This property was investigated in BM-MSCs, BM271-
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MSCs, and OM-MSCs (Materials and Methods Tables 2.8 and 2.9) by inducing 
bone and fat differentiation using osteogenic and adipogenic induction 
media (Materials and Methods Table 2.10). Visualisation of this 
differentiation can be detected by staining with Alizarin Red S and Oil Red 
O which bind to calcium deposits formed during osteogenesis, and to fat 
droplets formed during adipogenesis respectively. RT-qPCR analysis was 
also carried out on BM271-MSCs and OM-MSCs (Materials and Methods 
Tables 2.8 and 2.9) to assess any differences in the gene expression profile 
of these cells undergoing media induced differentiation. Samples were 
analysed using GLUT4 and Leptin primers as markers of fat differentiation, 
and using OPN and OCN primers for markers of bone differentiation. 
 
3.6.1. Comparison of the Adipogenic Differentiation Potential of 
BM271-MSCs and OM-MSCs by RT-qPCR 
RT-qPCR was carried out on BM271-MSCs and OM-MSCs to analyse levels of 
GLUT4 (Figure 3.9A) and Leptin (Figure 3.9B) transcripts after 21 days of 
media induced adipogenic differentiation. Treated samples were compared 
to untreated samples cultured for 1 day and 21 days in ordinary culture 
media. mRNA levels of GLUT4 and Leptin were significantly increased 
(p<0.05) in BM271-MSCs treated with adipogenic induction media compared 
to both untreated control conditions. Untreated day 21 samples show 
slightly elevated levels of mRNA for GLUT4 and Leptin compared to 
untreated day 1 samples, suggesting minor spontaneous differentiation, 
although these observations are not statistically significant. Levels of 
GLUT4 mRNA were significantly increased (p<0.05) in OM-MSCs treated 
with adipogenic induction media compared to both untreated control 
conditions. Levels of Leptin mRNA expression were also higher in treated 
OM-MSCs compared to untreated controls, although this differential 
expression was not statistically significant. As with BM271-MSCs, untreated 
day 21 samples show elevated but not statistically significant levels of 
GLUT4 mRNA and Leptin mRNA compared to untreated day 1 samples. 
Comparing expression levels of GLUT4 mRNA and Leptin mRNA in treated 
BM271-MSCs and OM-MSCs, it was seen that levels were much higher in 
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BM271-MSCs, although due to large sample variation, these differences are 
not statistically significant. We can conclude from this experiment that 
both BM271-MSCs and OM-MSCs are capable of significantly increasing 
levels of fat differentiation genes by adipogenic induction media, although 
this is observed with higher levels of efficacy in BM271-MSCs. 
 
 
 
 
Figure 3.9: RT-qPCR analysis of transcripts associated with fat 
differentiation, GLUT4 (A) and Leptin (B) in BM-MSCs, BM271-MSCs, and 
OM-MSCs after 21 of culture with adipogenic induction media. Treated 
samples were compared to untreated samples collected after 24 hr and 21 
B 
A 
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days which were in culture with DMEM:10% Hyclone. Statistical analysis was 
carried out by 2 way ANOVA using Tukey’s multiple comparison test, where 
*=p<0.05, **=p<0.01, ***=p<0.005, and ****=p<0.001. PCR was carried out 
using the Livak (ΔΔCT) method with GAPDH as the reference control gene. 
n=3. 
 
3.6.2. Comparison of the Adipogenic Differentiation of BM-MSCs, 
BM271-MSCs, and OM-MSCs Using Oil Red O 
BM-MSCs, BM271-MSCs, and OM-MSCs were stained with Oil Red O dye after 
21 days of media induced adipogenic differentiation, to identify any fat 
droplets formed (Figure 3.10). Treated samples were compared to Oil Red 
O stained untreated samples which were cultured for 21 days in ordinary 
culture media. Staining demonstrates the ability of each cell type to form 
fat, with BM-MSCs seeming to be more effective at this compared to 
BM271-MSCs and OM-MSCs. This was confirmed by measuring the stained oil 
droplets from each condition using ImageJ software. BM-MSCs and BM271-
MSCs produced significantly more oil droplets than untreated controls 
(p<0.001 and p<0.01 respectively) (Figure 3.11A). OM-MSCs produced 
noticeably more oil droplets than untreated controls, although due to a 
greater occurrence of spontaneous differentiation, the difference was not 
statistically significant (Figure 3.11A). This spontaneous differentiation 
likely occurred due to OM-MSCs becoming confluent quickly and the 
switching on of adipogenic mechanisms which occur under stressed 
conditions (516). Fold increases in fat droplet production in treated 
samples compared to untreated controls were calculated, confirming that 
BM-MSCs, produce fat droplets (~18-fold increase) with significantly more 
efficacy than both BM271-MSCs (p<0.01) (~8-fold increase) and OM-MSCs 
(~2-fold increase) (p<0.005) (Figure 3.11B). BM271-MSCs were also 
significantly more efficient at producing fat droplets compared to OM-MSCs 
(p<0.05) (Figure 3.11B). We can conclude from this experiment that BM-
MSCs, BM271-MSCs, and OM-MSCs are capable of adipogenic differentiation, 
with BM-MSCs doing so with much better efficacy than BM271-MSCs and 
OM-MSCs. The CD271 positive selection may affect the cell’s ability to 
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produce fat, but BM271-MSCs were still significantly more effective at this 
than OM-MSCs. These data correlate with the previous RT-qPCR data which 
showed significant increases in the expression of adipogenic markers 
GLUT4 and Leptin in cells treated with adipogenic induction media. 
Although the differences in expression of these mRNA was not significant in 
BM271-MSCs compared to OM-MSCs, there was a noticeable trend towards 
higher expression in BM271-MSCs.  
 
 
 
Figure 3.10: Representative images of adipogenic differentiation. BM-MSCs 
(B-D), BM271-MSCs (F-H), and OM-MSCs (J-L) after 21 days of culture with 
adipocyte induction media compared to those untreated after 21 days of 
culture in DMEM:10% Hyclone (A, E, and I). Adipocytes were stained red 
with Oil Red O dye, and images taken under phase microscope at x20 
magnification, with the scale bar representing 50 μm, n=3. 
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Figure 3.11: Graphical representations of adipogenic differentiation. BM-
MSCs, BM271-MSCs, and OM-MSCs after 21 days of culture in adipocyte 
induction media, compared to untreated control samples cultured for 21 
days in DMEM:10% Hyclone. Adipogenic differentiation was represented by 
analysing each of 10 images per condition using ImageJ software, and 
calculating the mean number of Oil Red O stained pixels per image (A). 
Fold increases in Oil Red O staining compared to untreated control samples 
are also represented (B). Statistical analysis was carried out by 2-way 
ANOVA using Tukey’s multiple comparison test, where *=p<0.05, **=p<0.01, 
***=p<0.005, and ****=p<0.001. n=3. 
A 
B 
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3.6.3. Comparison of the Osteogenic Differentiation Potential of 
BM271-MSCs and OM-MSCs by RT-qPCR  
The same RT-qPCR analysis was carried out as in 3.6.1, only using primers 
for bone differentiation, OPN (Figure 3.12A) and OCN (Figure 3.12B). 
Levels of OPN and OCN transcript were similar at day 1 and day 21 in both 
untreated BM271- and OM-MSCs. Treated BM271-MSCs showed significantly 
higher expression of OPN mRNA (p<0.01) (Figure 3.12A) and OCN mRNA 
(p<0.001) (Figure 3.12B) compared to their untreated controls, and also a 
significantly higher expression of OCN compared to the OM-MSC treated 
samples (p<0.05) (Figure 3.12B). Levels of OPN and OCN transcript were 
markedly different in treated OM-MSC samples compared to their 
untreated controls (Figure 3.12), although this difference was not 
statistically significant by 1-way ANOVA. It can be  concluded from this 
experiment that both BM271-MSCs and OM-MSCs are capable of increasing 
levels of bone differentiation genes by osteogenic induction media, 
although this observation is only statistically significant in BM271-MSCs.  
 
3.6.4. Comparison of the Osteogenic Differentiation of BM-MSCs, 
BM271-MSCs, and OM-MSCs Using Alizarin Red S 
Each cell type was stained with Alizarin Red S dye to identify calcified 
deposits formed after 21 days of culture in osteogenic induction media 
(Figure 3.13). Treated samples were compared to Alizarin Red S stained 
untreated samples which were cultured for 21 days in ordinary culture 
media. Staining demonstrates the ability of each cell type to form bone, 
with BM-MSCs seeming, like with fat differentiation, to be more effective 
at this compared to BM271-MSCs and OM-MSCs. This was again confirmed 
by measuring the stained calcified deposits from each condition using 
ImageJ software. BM-MSCs, BM271-MSCs, and OM-MSCs produced 
significantly more deposits than untreated controls (p<0.001) (Figure 
3.14A), and both BM- and BM271-MSCs produced significantly more 
calcified deposits (p<0.05) compared to OM-MSCs (Figure 3.14A). Fold 
increases in calcified deposit production in treated samples compared to 
untreated controls was calculated, confirming that BM-MSCs produce 
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calcified deposits (~3.75-fold increase) with significantly more efficacy 
than both BM271-MSCs (p<0.05) (~3-fold increase) and OM-MSCs (p<0.01) 
(~2-fold increase) (Figure 3.14B). The difference in calcified deposit 
production between BM271-MSCs and OM-MSCs was not statistically 
significant. We can conclude from this experiment that each of BM-MSCs, 
BM271-MSCs, and OM-MSCs are capable of osteogenic differentiation, with 
BM-MSCs doing so with much better efficacy than BM271-MSCs and OM-
MSCs. The CD271 positive selection clearly affects the cell’s ability to 
produce bone, but BM271-MSCs were still more effective at this than OM-
MSCs. 
 
 
A 
B 
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Figure 3.12: RT-qPCR analysis of transcripts associated with bone 
differentiation, OPN (A) and OCN (B) in BM-MSCs, BM271-MSCs, and OM-
MSCs after 21 days of culture with osteogenic induction media. Treated 
samples were compared to untreated samples collected after 24 hr and 21 
days in culture with DMEM:10% Hyclone. Statistical analysis was carried out 
by 2 way ANOVA using Tukey’s multiple comparison test, where *=p<0.05, 
**=p<0.01, ***=p<0.005, and ****=p<0.001. PCR was carried out using the 
Livak (ΔΔC
T
) method with GAPDH as the reference control gene. n=3. 
 
 
 
Figure 3.13: Representative images of osteogenic differentiation of BM-
MSCs (B-D), BM271-MSCs (F-H), and OM-MSCs (J-L) after 21 days of culture 
with osteocyte induction media compared to those after 21 days of culture 
in DMEM:10% Hyclone (A, E, and I). Osteocytes were stained red with 
Alizarin Red S dye, and images taken under phase microscope at 20x 
magnification, with the scale bar representing 50 μm. n=3. 
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Figure 3.14: Graphical representations of osteogenic differentiation of BM-
MSCs, BM271-MSCs, and OM-MSCs after 21 days of culture in osteocyte 
induction media, compared to untreated control samples cultured for 21 
days in DMEM:10% Hyclone. Osteogenic differentiation was represented by 
analysing each of 10 images per condition using ImageJ software, and 
calculating the mean number of Alizarin Red S stained pixels per image (A). 
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Fold increases in Alizarin Red S staining compared to untreated control 
samples are also represented (B). Statistical analysis was carried out by 2 
way ANOVA using Tukey’s multiple comparison test, where *=p<0.05, 
**=p<0.01, ***=p<0.005, and ****=p<0.001. n=3. 
 
3.7. Comparison of the Differentiation Potential of OM-MSCs and 
BM271-MSCs to Differentiate Towards Other Lineages  
RT-qPCR analysis was carried out to determine levels of transcripts 
associated with differentiation towards neuronal, smooth muscle, and glial 
lineages in BM271 and OM-MSCs which were cultured for 21 days with 
induction media. RT-qPCR was carried out using primers for Tuj-1 (Figure 
3.15A) and MAP2 (Figure 3.15B), MyoD (Figure 3.15C) and SMA (Figure 
3.15D), and GFAP (Figure 3.15E). mRNA collected from untreated BM271 
and OM-MSC samples at day 1 and day 21, and treated samples which were 
cultured for 21 days in the relevant induction media, was analysed to 
determine any increases in transcript expression within these treated 
samples, suggesting a potential to differentiate towards lineages other 
than bone and fat. Expression of mRNA for neuronal markers Tuj-1 and 
MAP2 was increased in treated BM271 and OM-MSCs, however these 
increases were only statistically significant with regards to Tuj-1 
expression in BM271-MSCs (p<0.01). Levels of MAP2 mRNA expression were 
noticeably higher in treated samples of both BM271-MSCs and OM-MSCs, 
however, large sample variation meant that these differences were not 
statistically significant. Similarly, expression of myogenic markers MyoD 
and SMA were increased in treated BM271-MSCs and OM-MSCs compared to 
untreated controls, although these increases were only statistically 
significant in BM271-MSCs (p<0.001 and p<0.01 respectively). These 
observations were not only significant compared to their untreated control 
samples, but treated BM271-MSCs also expressed significantly higher levels 
of MyoD expression compared to treated OM-MSCs (p<0.05). Both BM271-
MSCs and OM-MSCs showed significantly different expression of mRNA for 
GFAP compared to their untreated control (p<0.001 and p<0.05 
respectively), with levels of mRNA GFAP expression being significantly 
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higher in treated BM271-MSC samples compared to OM-MSCs (p<0.05). 
These findings mimic those from the previous bone and fat 
differentiations, in that both types of MSC display the potential to 
differentiate towards neuronal, myogenic, and glial lineages, with MSCs 
from the bone marrow niche being more efficient at this than MSCs from 
the olfactory system. 
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Figure 3.15: RT-qPCR analysis of transcripts associated with neuronal (Tuj-
1 (A) and MAP2 (B)), smooth muscle (MyoD (C) and SMA (D)), and glial 
(GFAP (E)) differentiation in n=3 BM271-MSCs, and OM-MSCs after 21 of 
culture with neurogenic, myogenic, and glial induction medias 
respectively. Treated samples were compared to untreated samples 
collected after 24 hr and 21 days in culture with DMEM:10% Hyclone. 
Statistical analysis was carried out by 2 way ANOVA using Tukey’s multiple 
comparison test, where *=p<0.05, **=p<0.01, ***=p<0.005, and 
****=p<0.001. PCR was carried out using the Livak (ΔΔCT) method with 
GAPDH as the reference control gene. 
 
3.8. Discussion 
MSCs are resident in a number of distinct cellular niches such as umbilical 
cord (308), adipose tissue (33, 309, 310), the developing tooth bud of the 
mandibular third molar (33), and amniotic fluid (34, 311), as well as the 
two niches identified throughout this study; bone marrow (312-314) and 
olfactory mucosa (1, 35, 36, 142). Although from completely distinct 
cellular niches, MSCs extracted from bone marrow were morphologically 
indistinguishable from those extracted from the lamina propria of the 
olfactory mucosa. This comparable morphology also extended to CD271 
positive MSCs selected from cultures of adherent bone marrow cells. These 
findings mirror previous comparisons of BM-MSCs and OM-MSCs which 
showed not only a morphological similarity between the two MSC types, 
but also similar membrane marker expression, gene expression, ability of 
both to produce bone and fat, and a much higher rate of proliferation in 
OM-MSCs compared to BM-MSCs (1, 36). To confirm and extend previous 
studies, numerous experiments were carried out throughout this chapter to 
characterise and compare both MSC types.  
 
Although the resident niche seems to have no effect on the cell’s 
morphology, it may affect its molecular and biological properties. The 
bone marrow is an encapsulated, protected niche, mainly responsible for a 
steady production of blood, bone, fat, and cartilage progenitors (312-314), 
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whilst the olfactory system is a far less protected niche which is constantly 
exposed to external insult from noxious chemicals and xenoparticles during 
respiration, necessitating a high cellular turnover (1, 35, 36, 142). These 
environmental factors may have a profound effect on cellular turnover, as 
it was observed that OM-MSCs proliferate at a significantly faster rate than 
both BM and BM271-MSCs, with almost 100-fold more OM-MSCs compared to 
BM-MSCs after 25 days in culture. 
 
As well as sharing morphology with each other, each MSC type shares a 
similar morphology to fibroblasts, hence being once known as colony 
forming unit fibroblasts (CFU-Fs) (11). It was important thus to distinguish 
these cells from fibroblasts as well as comparing each MSC to each other. 
Transcriptional analysis by RT-qRCR of each MSC type demonstrated that 
they share expression of a panel of typical MSC-associated genetic 
markers, which wasn’t seen in human fibroblasts. This was mirrored by 
analysis of the protein expression by immunocytochemistry which showed 
that each MSC type expressed the equivalent panel of MSC-associated 
protein markers (except Stro-1, which was only expressed by BM-MSCs). 
The absence of Stro-1 in BM271-MSCs could suggest that Stro-1 positive 
cells do not express CD271, as all Stro-1 positive cells seem to be lost 
during the CD271 positive selection process. This protein expression 
pattern observed in each MSC type was not observed in fibroblasts, which 
confirms that the cells used throughout this project were indeed MSCs, and 
not fibroblasts.  
 
This comparison also highlighted a significant difference in expression of 
Nestin at both a transcript and protein level. Nestin, although a relatively 
ubiquitous protein, is a generally transient one which is associated with 
naïve cells, as expression rarely persists into adulthood (284-287). This 
difference in Nestin expression could be related to the observed difference 
in proliferation between BM-derived and OM-derived MSCs, and the high 
cellular turnover of the olfactory niche. Williams et al. (291) identified a 
“rapid and reproducible” ability of the rat olfactory system to regenerate 
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and repair itself post-ablation by external insult, following on from 
previous studies outlining the unique regenerative capacity of sensory 
neurons within the olfactory epithelium (292-294).  Arranz et al. (288) 
demonstrates a distinct correlation between nestin expression and 
proliferation of haematopoietic stem cells (HSCs), and numerous studies 
have described a high turnover of a number of cells within the olfactory 
niche (35, 36, 142), and that OM-MSCs have a much higher proliferative 
capacity in vitro compared to BM-MSCs (1, 36). These findings along with 
those from this chapter could suggest that the observed increased rate of 
proliferation in OM-MSCs could be related to their elevated expression of 
Nestin, and that these inherent biological properties may be a necessary 
consequence derived from residing in their native niche which is a source 
of constant insult and regeneration. Perhaps the MSCs in the OM have an 
inherent necessity to proliferate in order to keep up with the constant 
maintenance of the olfactory system? 
 
Each MSC type was further compared using a panel of 9 differentiation-
associated genetic and protein markers, showing no significant difference 
in expression of either of these markers. This expression pattern was 
similar to those of adipogenic MSCs, dental pulp MSCs, umbilical cord MSCs, 
and amniotic fluid MSCs which, although from completely distinct niches, 
are shown to share expression of MSC markers CD54, CD90, CD105, CD166, 
and Nestin, as well as stromal markers such as SMA, Tuj-1, OPN, and GFAP 
(315-317). It is difficult to assess any differential expression of markers 
between MSCs from other niches however, as no direct comparison has 
been done using one consistent panel of the same markers. Huang et al. 
(316) did show a differential expression of antigenic markers when 
comparing stem cells from different areas of the mouth and dentistry 
whilst still maintaining the equivalent expression of certain classic MSC 
markers such as CD90, CD73, CD105 and CD106. This could suggest that 
niche may necessitate an MSC to perform a specific niche–dependant 
function whilst still maintaining its capacity as an MSC.  
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Bone and fat differentiation studies showed that both BM-derived and OM-
derived MSCs are capable of producing calcified bone deposits and fat 
droplets. BM-derived MSCs however, were much more efficient at this 
differentiation compared to OM-MSCs. This, again, could be niche 
dependant, as OM-MSCs are normally resident in a predominantly 
neurogenic environment where bone and fat production doesn’t occur, so 
their primary function within the olfactory niche may not be to form bone 
and fat, but perhaps to form cartilage or connective tissue, or to play a 
supportive role in the neurogenesis of within the olfactory niche. However, 
these findings are slightly at odds with the findings of DeLorme et al. (36) 
who did find that both BM-MSCs and OM-MSCs could produce bone and fat, 
but that OM-MSCs produced more bone deposits identified by Von Kossa, 
Alizarin Red S, and Alkaline Phosphatase staining, and by expression of 
Runx2-IR. With regards to adipogenesis, DeLorme et al. (36) identified 
similar findings in that BM-MSCs were able to produce more adipocytes 
compared to OM-MSCs, although in his experiments both OM-MSCs and BM-
MSCs were isolated using different methods, and neither were purified by 
CD271 (or any other antigenic) selection.  
 
The lower efficacy to bone and fat differentiation in OM-MSCs observed 
throughout my experiments could also be related to the observed 
difference in Nestin expression between MSCs from the two niches. As 
Nestin is an indicator of naïve cells (284-287), they may not be mature 
enough to produce bone and fat at levels comparable to MSC from bone 
marrow where Nestin expression is significantly lower, although this is at 
odds with Delorme et al. who saw a 7 fold increase in Nestin expression in 
OM-MSCs but also an enhanced ability to form bone compared to BM-MSCs 
(36). As stated before though, the OM-MSCs and BM-MSCs were isolated 
using completely separate methods to the ones used throughout this study. 
OM-MSC cultures in Delorme’s study did not go through CD271 positive 
selection and therefore could contain a more heterogenous population of 
cells. We also observed that BM271-MSCs were less efficient at producing 
bone and fat compared to non-purified BM-MSCs. CD271 is downregulated 
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throughout the culture of MSCs (318, 319), therefore whilst bulking up 
enough BM-MSCs to carry out the CD271 positive selection, a large number 
of BM-MSCs will lose their expression of CD271, and as a consequence the 
majority of these will be lost during the process. This downregulation of 
CD271 also meant that among these discarded cells are not only CD271 
negative MSCs, but also populations of bone and fat progenitors, which by 
their part-differentiated nature would not express CD271. This might 
explain why we observed this increase in efficiency of bone and fat 
differentiation in BM-MSCs compared to BM271-MSCs. This also gives some 
credence to the hypothesis that Delorme’s less purified OM-MSCs are 
capable of enhanced bone production compared to those in this study due 
to their differing isolation methods. It is entirely possible that the CD271 
selection process results in the discarding of potentially osteogenic cells or 
osteogenic precursors. 
 
These observations aren’t limited to bone and fat differentiation. Using 
media induced differentiation we observed significant increases in 
transcript expression for genes related to neuronal, myogenic, and glial 
differentiation in each MSC type compared to their untreated controls. 
However as seen previously, BM-derived MSCs expressed the tested mRNA 
at a much higher level compared to those from the olfactory niche. This 
suggests that, although OM-MSCs possess an inherent ability to 
differentiate, this may not be their primary function within the olfactory 
system. It is perhaps more likely that they play a more supportive role in 
the neurogenesis of other cell types within the niche, whereas the primary 
function of BM-MSCs is to generate cells from the mesenchymal lineage. 
 
3.9. Summary 
 BM-MSCs, BM271-MSCs, and OM-MSCs are morphologically 
indistinguishable 
 OM-MSCs proliferate at a significantly higher rate than BM and BM271-
MSCs in vitro 
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 OM-MSCs are genetically and antigenically similar to BM and BM271-
MSCs, and are completely distinct from fibroblasts 
 OM-MSCs express significantly higher levels of Nestin at a transcript 
and protein level compared to BM-MSCs and BM271-MSCs 
 BM-MSCs, BM271-MSCs, and OM-MSCs are each capable of 
differentiating to bone and fat, with BM- and BM271-MSCs being more 
efficient at this compared to OM-MSCs 
 CD271 selection of BM-MSCs reduces the efficacy of these cells to 
differentiate towards bone and fat 
 Media induced differentiation towards neuronal, myogenic, and glial 
lineages results in significant increases in transcripts related to these 
lineages in each of BM271-MSCs, and OM-MSCs, with bone marrow-derived 
MSCs expressing more of these mRNA compared to OM-MSCs 
 CD271 selection of BM-MSCs results in a reduction of mRNA related to 
differentiation towards neuronal, myogenic, and glial lineages when 
compared to non-selected BM-MSCs 
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4. Cell/Substrate Interactions of MSCs 
Cells throughout the body are exposed not only to external chemical cues 
(320-323), but also to physical ones (255, 324, 325). Receptors and 
matrices external to the cell surface can respond to stiffness (45, 326-330), 
and to symmetrical and non-symmetrical nanotpographies (46, 256, 325, 
331-334) within the cellular niche in a manner which defines their fate. 
Previous studies have investigated niche effect on MSCs (335-337), and 
recreated environmental cues in vitro using artificial substrates such as 
hydrogels (338-343), matrigels (344, 345), and different plastic polymers 
(256, 257, 346-350). The previous chapter investigated the biological 
properties of each MSC type but in this chapter we look at cell/substrate 
interactions, and the ability of BM-derived and OM-derived MSCs to 
differentiate under normal culture conditions, using only 
nanotopographical cues via polycaprolactone surfaces which have been 
embossed with a controlled disordered pattern at heights of 20 – 25 nm. 
 
4.1. Identification of the Nanotopographically embossed PCL Substrates 
by Atomic Force Microscopy (AFM) 
Having demonstrated the ability of MSCs from both niches to differentiate 
under induction media conditions, here I investigated their ability to 
differentiate via their interactions with certain nanotopographies, without 
the use of exogenous chemical triggers. Also investigated were any 
differences between BM-MSCs and BM271-MSCs, and whether the CD271 
selection process has any effect on their interactions with 
nanotopographically embossed substrates. Prior to this however, I had to 
determine the different nanotopographies onto which these MSCs were 
cultured. AFM analysis of each of the three surfaces; smooth, surface A, 
and surface B, confirmed the controlled disordered pattern on surfaces A 
and B (Figure 4.1), and also determined a relative roughness value (RQ) of 
each surface, a peak to valley roughness which measures the difference 
between the highest peak and the deepest valley, and a mean pit height 
value measuring the average height of each of the peaks over a 1 µm2 
area. All values can be found in Table 4.1, and confirm that the “smooth” 
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surface, although not actually smooth, is smooth in the sense that it has no 
nanotopography patterned onto its surface. The values also confirm that 
surfaces A and B are distinct, although having the same controlled 
disordered pattern, the relative roughness of surface A is much higher than 
surface B, and the mean pit height is also higher on surface A compared to 
surface B. Images taken from the AFM analysis also show that the width 
between each pit is greater in surface A compared to surface B (Figure 
4.1). 
 
 
 
Figure 4.1: Atomic force microscopy (AFM) images of polycaprolactone 
(PCL) nanotopographically embossed with metal shims of controlled 
disordered patterns to give surface A (B) and surface B (C) substrates onto 
which cells can be cultured and differentiated. The control sample (A) is a 
non-embossed (smooth) PCL substrate formed between glass instead of a 
patterned metal shim. 
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Table 4.1: Values of relative surface roughness (RQ), maximum peak to 
valley roughness, and mean pit height of each of the three PCL substrates 
(smooth, surface A, and surface B) used throughout this chapter. Values 
were calculated from 1 μm2 images taken using atomic force microscopy 
and analysed using JPKSPM Data Processing software. 
 
4.2. Comparison of the Expression of mRNA Markers of Differentiation 
in BM-MSCs and OM-MSCs when cultured on Nanotopographically 
Embossed PCL 
The effects of these substrates on the biological properties of MSCs were 
looked at in two ways; how the nanotopgraphy of the substrate effects cell 
behaviour, and how this behaviour differs from cell to cell. Three different 
substrates were used throughout the comparison of cells; PCL 
nanotopographically embossed with surface A and surface B patterns, and 
a non-embossed “smooth” surface control. It is important to first identify 
how these different surfaces influence MSC differentiation. The cell-cell 
comparison was divided into BM-MSC vs. BM271-MSC to investigate whether 
or not the CD271 selection process influences the behaviour of BM-MSCs on 
these substrates, and into BM271-MSC vs OM-MSC to investigate any 
potential influence of niche on MSC behaviour on these substrates. RT-
qPCR was carried out on each sample using the Livak (ΔΔCT) method at day 
1, day 7, day 14, and day 21 time points, using BM-MSC day 1 samples as a 
point of reference for BM-MSC vs. BM271-MSC comparisons, and BM271-MSC 
day 1 samples as a point of reference for BM271-MSC vs. OM-MSC 
comparisons. A full list of samples used throughout this experiment can be 
found in Materials and Methods Table 2.11. All primers used are the same 
as in Materials and Methods Table 2.7. 
 
166 
 
4.2.1. Substrate vs. Substrate Comparison  
Due to the complexity of the analysis of the RT-qPCR data, it was divided 
into two separate comparisons; substrate vs substrate and cell vs cell. Here 
each phenotype is separated to identify the differences in expression of 
each transcript by comparing the statistical analysis of each substrate to 
the other. Tables 4.2, 4.3, and 4.4 detail the statistical significance of the 
differences in gene expression laid out in figure 4.2 by comparing smooth 
surface vs surface A, smooth surface vs surface B, and surface A vs surface 
B effects on BM-MSCs (Table 4.2), BM271-MSCs (Table 4.3), and OM-MSCs 
(Table 4.4).  
 
4.2.1.1. BM-MSCs 
Expression of each transcript, except GFAP mRNA, was significantly 
increased via interactions with both surfaces A and B compared to controls 
by at least day 21 (Table 4.2). With the exception of Leptin mRNA, MyoD 
mRNA, and GFAP mRNA, these observations occurred with all other 
transcripts by day 14 on at least one of either surface A or surface B (Table 
4.2). GLUT4 mRNA was significantly differentially expressed in BM-MSCs 
interacting with surfaces A and B compared to controls at day 7, however 
expression dropped to non-significant levels at day 14 (Table 4.2). No 
significant difference in expression of any of the transcripts was observed 
when comparing surfaces A and B, except that of OCN mRNA in BM-MSCs 
cultured on surface B at day 21 (Table 4.2). 
 
4.2.1.2. BM271-MSCs 
Expression of each transcript was significantly increased via interactions 
with both surfaces A and B compared to controls by day 21, and via 
interactions with at least one of either surface A or surface B by day 14 
(Table 4.3). Expression of GLUT4 mRNA was significantly differentially 
expressed by BM271-MSCs on surfaces A and B compared to controls at day 
7 (Table 4.3). No significant difference in expression of any of the 
transcripts was observed when comparing surfaces A and B, except that of 
OCN mRNA in BM271-MSCs cultured on surface B at day 21 (Table 4.3). 
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Table 4.2: Statistical analysis of data from Figure 4.2 comparing levels of 
expression of transcripts related to adipogenic (GLUT4 (Figure 4.2A and B) 
and Leptin (Figure 4.2C and D)), osteogenic (OPN (Figure 4.2E and F) and 
OCN (Figure 4.2G and H)), neurogenic (Tuj-1 (Figure 4.2I and J) and MAP2 
(Figure 4.2K and L)), myogenic (MyoD (Figure 4.2M and N) and SMA (Figure 
4.2O and P)), and glial (GFAP (Figure 4.2Q and R)) differentiation. 
Statistical analysis was carried out by comparing substrate vs. substrate 
levels of transcript expression in BM-MSCs cultured on  Smooth, Surface A, 
and Surface B topographies for 7, 14, and 21 days. Statistical analysis was 
carried out by 2 way ANOVA using Tukey’s multiple comparison test, where 
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ns = not significant, *=p<0.05, **=p<0.01, ***=p<0.005, and ****=p<0.001. 
n=3. 
 
 
 
Table 4.3: Statistical analysis of data from Figure 4.2 comparing levels of 
expression of transcripts related to adipogenic (GLUT4 (Figure 4.2A and B) 
and Leptin (Figure 4.2C and D)), osteogenic (OPN (Figure 4.2E and F) and 
OCN (Figure 4.2G and H)), neurogenic (Tuj-1 (Figure 4.2I and J) and MAP2 
(Figure 4.2K and L)), myogenic (MyoD (Figure 4.2M and N) and SMA (Figure 
4.2O and P)), and glial (GFAP (Figure 4.2Q and R)) differentiation. 
Statistical analysis was carried out by comparing substrate vs. substrate 
levels of transcript expression in BM271-MSCs cultured on  Smooth, Surface 
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A, and Surface B topographies for 7, 14, and 21 days. Statistical analysis 
was carried out by 2 way ANOVA using Tukey’s multiple comparison test, 
where ns = not significant, *=p<0.05, **=p<0.01, ***=p<0.005, and 
****=p<0.001. n=3. 
 
4.2.1.3. OM-MSCs 
Expression of each transcript was significantly increased via interactions 
with both surfaces A and B compared to controls by day 21, with the 
exceptions of GFAP, MAP2, and Tuj-1 (surface A only) (Table 4.4). No 
significant difference in GFAP mRNA expression was observed under any 
condition, and differential expression of GLUT4 mRNA was observed at day 
in OM-MSCs on surface B (Table 4.4). There was no significant difference in 
expression of any gene at any time point in OM-MSCs on surface A 
compared to surface B (Table 4.4). 
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Table 4.4: Statistical analysis of data from Figure 4.2 comparing levels of 
expression of transcripts related to adipogenic (GLUT4 (Figure 4.2A and B) 
and Leptin (Figure 4.2C and D)), osteogenic (OPN (Figure 4.2E and F) and 
OCN (Figure 4.2G and H)), neurogenic (Tuj-1 (Figure 4.2I and J) and MAP2 
(Figure 4.2K and L)), myogenic (MyoD (Figure 4.2M and N) and SMA (Figure 
4.2O and P)), and glial (GFAP (Figure 4.2Q and R)) differentiation. 
Statistical analysis was carried out by comparing substrate vs. substrate 
levels of transcript expression in OM-MSCs cultured on  Smooth, Surface A, 
and Surface B topographies for 7, 14, and 21 days. Statistical analysis was 
carried out by 2 way ANOVA using Tukey’s multiple comparison test, where 
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ns = not significant, *=p<0.05, **=p<0.01, ***=p<0.005, and ****=p<0.001. 
n=3. 
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Figure 4.2: Key is for BM- and BM271-MSC only. No key for BM271- vs OM-
MSC. Graphical representation of the transcript expression profiles of BM-
MSCs vs BM271-MSCs, and BM271-MSCs vs OM-MSCs when cultured over 21 
days on nanotopographically embossed PCL substrates of smooth, surface 
A, and surface B topographies. Gene expression was measured at days 7, 
14, and 21, and values were all measured relative to the expression of 
each particular gene in BM-MSCs at day 1. Each condition was analysed for 
genetic markers of differentiation for fat (GLUT4 and Leptin) (A-D), bone 
(OPN and OCN) (E-H), neuron (Tuj-1 and MAP2) (I-L), smooth muscle (MyoD 
and SMA) (M-P), and Glia (GFAP) (Q-R). Statistical analysis was carried out 
by 2 way ANOVA using Tukey’s multiple comparison test, where *=p<0.05, 
**=p<0.01, ***=p<0.005, and ****=p<0.001. PCR was carried out using the 
Livak (ΔΔCT) method with GAPDH as the reference control gene. Statistical 
analysis shows that both surfaces A and B have a significant influence on 
the expression of each gene compared to controls, so statistics bars on the 
graphs represent the cell vs cell comparison data found in section 4.2.2. 
Tables 4.2 – 4.7 contain all of the statistical analysis carried out in this 
experiment. n=3. 
 
4.2.2. Cell vs. Cell Comparison  
Here each surface was separated to identify the differences in expression 
of each transcript by comparing the statistical analysis of each phenotype 
to the other. Table 4.5, 4.6, and 4.7 detail the statistical significance of 
the differences in gene expression laid out in Figure 4.2 by comparing BM-
MSCs vs BM271-MSC, and BM271-MSC vs OM-MSC on smooth surface controls 
(Table 4.5), surface A (Table 4.6), and surface B (Table 4.7).  
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4.2.2.1. Smooth surface 
There was no significant difference in the expression of either transcript 
between BM-MSCs and BM271-MSCs, and between BM271-MSCs and OM-MSCs 
(Table 4.5). 
 
4.2.2.2. Surface A 
The only significant differences observed between BM-MSCs and BM271-
MSCs on surface A were in the expression of Leptin at day 21 (p<0.01) and 
SMA at day 21 (p<0.01) (Table 4.6). More differential expression was 
observed when comparing BM271-MSCs and OM-MSCs, with OPN showing a 
significantly differential expression at day 14 (p<0.05), Tuj-1 at days 14 
(p<0.005) and 21 (p<0.005), MAP2 at days 14 (p<0.01) and 21 (p<0.001), 
and MyoD at day 21 (p<0.05) (Table 4.6). 
 
4.2.2.3. Surface B 
The only significant differences observed between BM-MSCs and BM271-
MSCs on surface B were in the expression of Leptin at day 21 (p<0.01), OPN 
at day 21 (p<0.05), and GFAP at day 21 (p<0.05) (Table 4.7). As with 
surface A, more significant differences were observed when comparing 
BM271-MSCs with OM-MSCs, with Leptin showing a significantly differential 
expression at day 21 (p<0.05), OPN at days 14 (p<0.05) and 21 (p<0.01), 
Tuj-1 at day 21 (p<0.005), MAP2 at day 21 (p<0.005), MyoD at day 21 
(p<0.01), and SMA at day 21 (p<0.05) (Table 4.7). 
 
From these observations it could be suggested that both surfaces A and B 
are capable of significant stimulation of a number of genetic markers 
within BM-MSCs, BM271-MSCs, and OM-MSCs, with surface A causing a 
higher level of bioreactivity compared to surface B. It was also observed 
that, with only a few exceptions, gene expression profiles of BM-MSCs and 
BM271-MSCs were very similar under these experimental conditions. OM-
MSCs however, seemed less bioreactive compared to BM271-MSCs under 
these conditions, and their peak gene expression levels were generally at 
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an earlier time point compared to BM-derived MSCs, whose gene expression 
patterns showed a continuous rise to day 21. 
 
 
 
Table 4.5: Statistical analysis of data from Figure 4.2 comparing levels of 
expression of transcripts related to adipogenic (GLUT4 (Figure 4.2A and B) 
and Leptin (Figure 4.2C and D)), osteogenic (OPN (Figure 4.2E and F) and 
OCN (Figure 4.2G and H)), neurogenic (Tuj-1 (Figure 4.2I and J) and MAP2 
(Figure 4.2K and L)), myogenic (MyoD (Figure 4.2M and N) and SMA (Figure 
4.2O and P)), and glial (GFAP (Figure 4.2Q and R)) differentiation. 
Statistical analysis was carried out by comparing levels of transcript 
expression in BM-MSCs vs BM271-MSCs, and in BM271-MSCs vs OM-MSCs 
cultured on  smooth, non-patterned topographies for 7, 14, and 21 days. 
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Statistical analysis was carried out by 2 way ANOVA using Tukey’s multiple 
comparison test, where ns = not significant, *=p<0.05, **=p<0.01, 
***=p<0.005, and ****=p<0.001. 
 
 
 
Table 4.6: Statistical analysis of data from Figure 4.2 comparing levels of 
expression of transcripts related to adipogenic (GLUT4 (Figure 4.2A and B) 
and Leptin (Figure 4.2C and D)), osteogenic (OPN (Figure 4.2E and F) and 
OCN (Figure 4.2G and H)), neurogenic (Tuj-1 (Figure 4.2I and J) and MAP2 
(Figure 4.2K and L)), myogenic (MyoD (Figure 4.2M and N) and SMA (Figure 
4.2O and P)), and glial (GFAP (Figure 4.2Q and R)) differentiation. 
Statistical analysis was carried out by comparing levels of transcript 
expression in BM-MSCs vs BM271-MSCs, and in BM271-MSCs vs OM-MSCs 
cultured on  surface A topographies for 7, 14, and 21 days. Statistical 
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analysis was carried out by 2 way ANOVA using Tukey’s multiple comparison 
test, where ns = not significant, *=p<0.05, **=p<0.01, ***=p<0.005, and 
****=p<0.001.  
 
 
 
Table 4.7: Statistical analysis of data from Figure 4.2 comparing levels of 
expression of transcripts related to adipogenic (GLUT4 (Figure 4.2A and B) 
and Leptin (Figure 4.2C and D)), osteogenic (OPN (Figure 4.2E and F) and 
OCN (Figure 4.2G and H)), neurogenic (Tuj-1 (Figure 4.2I and J) and MAP2 
(Figure 4.2K and L)), myogenic (MyoD (Figure 4.2M and N) and SMA (Figure 
4.2O and P)), and glial (GFAP (Figure 4.2Q and R)) differentiation. 
Statistical analysis was carried out by comparing levels of transcript 
expression in BM-MSCs vs BM271-MSCs, and in BM271-MSCs vs OM-MSCs 
cultured on  surface B topographies for 7, 14, and 21 days. Statistical 
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analysis was carried out by 2 way ANOVA using Tukey’s multiple 
comparison test, where ns = not significant, *=p<0.05, **=p<0.01, 
***=p<0.005, and ****=p<0.001. 
 
4.3. Confirmation of RT-qPCR Analysis of Cell/Substrate Reactions by 
Immunocytochemistry  
To further investigate if these nanotopographically embossed PCL 
substrates were able to induce differentiation as seen for BM-MSC 
previously [16,36], the three MSC types described in this thesis, were 
cultured on the three substrates  A, B, and smooth control. 
Immunocytochemistry was carried out on each cell type cultured on the 
three substrates (A, B, and Smooth), to see if the observed increases in 
transcript expression translated into protein expression. The same 
experimental conditions were carried out as in section 4.2, only cells were 
fixed in PFA at day 21 for immunocytochemistry. The day 21 time point 
was used for this study as it was the point when protein expression 
appeared comparatively optimal based on the PCR studies. A full list of 
samples used throughout this experiment can be found in Materials and 
Methods Table 2.12. 
 
Figure 4.3 contains representative images of the immunocytochemistry. 
There was no observed immunoreactivity for either MAP2 or MyoD 
antibodies, so their representative images were omitted. For all other 
markers, more intense fluorescence immunoreactivity was observed on 
each MSC type when cultured on surfaces A and B compared to smooth 
surface controls. This suggests that more protein is being expressed within 
each cell or on each cell surface. To quantify this, ImageJ software was 
used to measure the intensity of fluorescence as the number of fluorescent 
pixels per cell per field of view. Figures 4.4 and 4.6 contain graphical 
representations of this data, displayed in 2 ways as described previously in 
section 2.2; comparing substrate vs. substrate (Figure 4.4), and comparing 
cell type vs. cell type (Figure 4.6). Immunoreactivity was also quantified 
by identifying the number of immunoreactive cells (Figures 4.5 and 4.7). 
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Cells showing any amount of immunoreactivity to any of the antibody 
markers were considered positive, and immunoreactivity quantified as a 
percentage of positive cells per field of view. The data was again displayed 
in 2 ways; comparing substrate vs. substrate (Figure 4.5), and comparing 
cell vs. cell (Figure 4.7). Due to numerous previous experiments 
determining no compelling difference between BM-MSC and BM271-MSC 
immunoreactivity, immunocytochemical analysis of Tuj-1, SMA, and GFAP 
immunoreactivity was restricted to BM271-MSCs vs OM-MSCs only. 
Immunocytochemistry for OPN and OCN was carried out before this 
conclusion, so BM-MSCs were analysed for these markers.  
 
4.3.1. Substrate vs. Substrate Comparison  
ImageJ analysis of immunocytochemistry images identified distinct 
immunoreactivity patterns. As with the RT-qPCR data in section 4.2, this is 
best described by separating each phenotype. A summary of all the 
statistical analysis carried out can be found in tables 4.8 – 4.10. 
 
4.3.1.1. BM-MSCs 
OPN and OCN immunoreactivity (IR) was significantly increased in BM-MSCs 
cultured on surfaces A and B compared to smooth surface controls (OPN = 
p<0.001 for A and B, OCN = p<0.005 for A and p<0.001 for B) (Figure 4.4A 
and B). Due to BM-MSCs expressing OPN-IR under normal conditions, there 
was no increase in the percentage of cells which were positive for OPN-IR 
(Figure 4.5A). However, there was a significant increase in the percentage 
of BM-MSCs expressing OCN-IR on surfaces A and B compared to smooth 
controls (p<0.001) (Figure 4.5B). Analysis for other IR markers was not 
carried out on BM-MSCs. 
 
4.3.1.2. BM271-MSCs 
OPN-IR and OCN-IR was significantly increased in BM271-MSCs cultured on 
surfaces A and B compared to smooth surface controls (OPN = p<0.005 for 
A and B, OCN = p<0.01 for A and B) (Figure 4.4A and B). This significant 
increase in IR was also seen when analysed for SMA (p<0.001 for A and B), 
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Tuj-1 (p<0.005 for A and p<0.001 for B), and GFAP (p<0.01). No 
immunoreactivity was observed for MyoD or MAP2. Due to BM271-MSCs 
expressing OPN-IR under normal conditions, there was no increase in the 
percentage of cells which were positive for OPN-IR (Figure 4.5A). However, 
there was a significant increase in the percentage of BM271-MSCs 
expressing OCN-IR on surfaces A and B compared to smooth controls 
(p<0.001) (Figure 4.5B). This significant increase was also observed for Tuj-
1-IR (p<0.01), SMA (p<0.05), and GFAP (p<0.05) (Figure 4.5C, D, and E). 
 
4.3.1.3. OM-MSCs 
OPN-IR and OCN-IR was significantly increased in OM-MSCs cultured on 
surfaces A and B compared to smooth surface controls (p<0.05 for OPN and 
OCN on both A and B). This significant increase in IR was also seen when 
analysed for SMA and Tuj-1 (p<0.05 for both on both surfaces A and B). 
There was a slight increase in GFAP-IR in OM-MSCs cultured on surfaces A 
and B compared to smooth surface controls, but this difference was not 
significant. No immunoreactivity was observed for MyoD or MAP2. Due to 
OM-MSCs expressing OPN-IR under normal conditions, there was no increase 
in the percentage of cells which were positive for OPN-IR (Figure 4.5A). 
However, there was a significant increase in the percentage of OM-MSCs 
expressing OCN-IR on surfaces A and B compared to smooth controls 
(p<0.001) (Figure 4.5B). This significant increase was also observed for Tuj-
1-IR (surface A = p<0.01, surface B = p<0.005), and SMA (surface A = 
p<0.005, surface B = p<0.01) (Figure 4.5C and D). There was no significant 
difference in the percentage of OM-MSCs showing positive GFAP-IR 
expression (Figure 4.5E). 
 
These observations show that IR for OPN, OCN, SMA, Tuj-1, and GFAP was 
significantly increased in each phenotype when cultured on the controlled 
disordered surfaces A and B (except GFAP-IR in OM-MSCs) compared to non-
patterned surfaces when looking at both intensity of IR and the percentage 
of positively expressing cells. The absence of MyoD and MAP2 IR suggests 
that no trans-differentiation has occurred via this mechanism. 
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Figure 4.3: Representative images of immunocytochemistry for BM-MSCs 
(OPN and OCN only), BM271-MSCs, and OM-MSCs seeded onto 
nanotopographically embossed PCL substrates A and B, and smooth surface 
controls. Fluorescent markers of osteogenic differentiation, OPN (A-I) and 
OCN (J-R) myogenic differentiation, SMA (S-X) and MyoD (no MyoD-IR 
obeserved), neurogenic differentiation, Tuj-1 (Y-iv) and MAP2 (no MAP2-IR 
observed), and glial differentiation, GFAP (v-x) were used to identify 
immunoreactivity. Nuclei (blue) were visualised with DAPI. Images were 
taken at x40 magnification, scale bar represents 25 μm. n=3.   
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Table 4.8: Statistical analysis of data from Figures 4.4 and 4.5 comparing 
intensity of IR expression and percentage of IR positive cells expressing 
markers related to osteogenic (OPN (Figure 4.4 and 4.5A)) and OCN 
(Figures 4.4 and 4.5B)) differentiation. Statistical analysis was carried out 
by comparing intensity of IR expression, and percentage of IR positive BM-
MSCs cultured on smooth vs surface A, smooth vs surface B, and surface A 
vs surface B topographies for 21 days. Statistical analysis was carried out 
by 2 way ANOVA using Tukey’s multiple comparison test, where ns = not 
significant, *=p<0.05, **=p<0.01, ***=p<0.005, and ****=p<0.001. 
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Table 4.9: Statistical analysis of data from Figures 4.4 and 4.5 comparing 
intensity of IR expression and percentage of IR positive cells expressing 
markers related to osteogenic (OPN (Figure 4.4 and 4.5A)) and OCN 
(Figures 4.4 and 4.5B)), neurogenic (Tuj-1 (Figures 4.4 and 4.5C)), 
myogenic (SMA (Figures 4.4 and 4.5D)), and glial (GFAP (Figures 4.4 and 
4.5E)) differentiation. Statistical analysis was carried out by comparing 
intensity of IR expression, and percentage of IR positive BM271-MSCs 
cultured on smooth vs surface A, smooth vs surface B, and surface A vs 
surface B topographies for 21 days. Statistical analysis was carried out by 2 
way ANOVA using Tukey’s multiple comparison test, where ns = not 
significant, *=p<0.05, **=p<0.01, ***=p<0.005, and ****=p<0.001. 
 
 
 
Table 4.10: Statistical analysis of data from Figures 4.4 and 4.5 comparing 
intensity of IR expression and percentage of IR positive cells expressing 
markers related to osteogenic (OPN (Figure 4.4 and 4.5A)) and OCN 
(Figures 4.4 and 4.5B)), neurogenic (Tuj-1 (Figures 4.4 and 4.5C)), 
myogenic (SMA (Figures 4.4 and 4.5D)), and glial (GFAP (Figures 4.4 and 
4.5E)) differentiation. Statistical analysis was carried out by comparing 
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intensity of IR expression, and percentage of IR positive OM-MSCs cultured 
on smooth vs surface A, smooth vs surface B, and surface A vs surface B 
topographies for 21 days. Statistical analysis was carried out by 2 way 
ANOVA using Tukey’s multiple comparison test, where ns = not significant, 
*=p<0.05, **=p<0.01, ***=p<0.005, and ****=p<0.001. 
 
 
 
Figure 4.4: Graphical representations of immunocytochemistry for BM-
MSCs (OPN and OCN only), BM271-MSCs, and OM-MSCs seeded onto 
nanotopographically embossed PCL substrates A and B, and smooth surface 
controls. Markers of osteogenic differentiation, OPN (A) and OCN (B), 
myogenic differentiation, SMA (C) and MyoD (no MyoD-IR obeserved), 
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neurogenic differentiation, Tuj-1 (D) and MAP2 (no MAP2-IR observed), and 
glial differentiation, GFAP (E) were used to identify protein expression. 
Analysis was carried out using ImageJ software by measuring intensity of 
fluorescence by counting the mean number of fluorescent pixels per cell 
per image. Statistical analysis was carried out by 2 way ANOVA using 
Tukey’s multiple comparison test, where *=p<0.05, **=p<0.01, ***=p<0.005, 
and ****=p<0.001, n=3. 
 
 
 
 
 
        
 
Figure 4.5: Graphical representations of immunocytochemistry for BM-
MSCs (OPN and OCN only), BM271-MSCs, and OM-MSCs seeded onto 
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nanotopographically embossed PCL substrates A and B, and smooth surface 
controls. Markers of osteogenic differentiation, OPN (A) and OCN (B), 
myogenic differentiation, SMA (C) and MyoD (no MyoD-IR obeserved), 
neurogenic differentiation, Tuj-1 (D) and MAP2 (no MAP2-IR observed), and 
glial differentiation, GFAP (E) were used to identify protein expression. 
Analysis was carried out by calculating the mean number of positively 
expressing cells per image. Statistical analysis was carried out by 2 way 
ANOVA using Tukey’s multiple comparison test, where *=p<0.05, **=p<0.01, 
***=p<0.005, and ****=p<0.001, n=3. 
 
4.3.2. Cell vs. Cell Comparison  
When analysing the immunocytochemistry data from this perspective, 
similar patterns were observed as were seen when comparing substrate vs 
substrate. All statistical analysis is summarised in tables 4.11-4.13, and 
showed that when analysing intensity of IR expression, BM-derived MSCs 
showed significantly higher immunoreactivity of each marker where IR was 
observed (no MyoD or MAP2-IR was observed) compared to OM-MSCs (Figure 
4.6). With regards to bone markers OPN and OCN, BM-MSCs demonstrated a 
significantly higher IR expression compared to both BM271-MSCs and OM-
MSCs (Figure 4.6A and B), suggesting that the ability of BM-MSCs to express 
OPN-IR and OCN-IR may be affected by the CD271 positive selection 
process. Due to the expression under normal conditions of OPN-IR, SMA-IR, 
and Tuj-1-IR, no significant difference was observed between the 
percentage of IR positive BM-MSCs, BM271-MSCs, and OM-MSCs, although 
expression was noticeably higher in BM271-MSCs for SMA-IR and Tuj-1-IR 
(Figure 4.7A, C, and D). The only significant difference in OCN-IR 
expression between the phenotypes was observed in BM271-MSCs compared 
to BM-MSCs (figure 4.7B), which goes against what was earlier 
hypothesised. Finally, GFAP-IR was observed in a significantly higher 
percentage of BM2721-MSCs compared to OM-MSCs.  
 
These findings back up the substrate vs substrate observations, and the RT-
qPCR analysis, which suggests that BM-MSCs have more bioactive potential 
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compared to both BM271-MSCs and OM-MSCs when cultured on controlled 
disordered nanotopographies compared to smooth surfaces, although all 
three show significantly increased bioreactivity using both RT-qPCR and 
immunocytochemistry.  
 
 
 
Table 4.11: Statistical analysis of data from Figures 4.6 and 4.7 comparing 
intensity of IR expression and percentage of IR positive cells expressing 
markers related to osteogenic (OPN (Figure 4.6A and 4.7A)) and OCN 
(Figures 4.6B and 4.7B)), neurogenic (Tuj-1 (Figures 4.6C and 4.7C)), 
myogenic (SMA (Figures 4.6D and 4.7D)), and glial (GFAP (Figures 4.6E and 
4.7E)) differentiation. Statistical analysis was carried out by comparing 
intensity of IR expression, and percentage of IR positive cells cultured on 
smooth surface topographies for 21 days, comparing BM-MSCs vs BM271-
MSCs, BM-MSCs vs OM-MSCs, and BM271-MSCs vs OM-MSCs. Statistical 
analysis was carried out by 2 way ANOVA using Tukey’s multiple 
comparison test, where ns = not significant, *=p<0.05, **=p<0.01, 
***=p<0.005, and ****=p<0.001. 
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Table 4.12: Statistical analysis of data from Figures 4.6 and 4.7 comparing 
intensity of IR expression and percentage of IR positive cells expressing 
markers related to osteogenic (OPN (Figure 4.6A and 4.7A)) and OCN 
(Figures 4.6B and 4.7B)), neurogenic (Tuj-1 (Figures 4.6C and 4.7C)), 
myogenic (SMA (Figures 4.6D and 4.7D)), and glial (GFAP (Figures 4.6E and 
4.7E)) differentiation. Statistical analysis was carried out by comparing 
intensity of IR expression, and percentage of IR positive cells cultured on 
surface A topographies for 21 days, comparing BM-MSCs vs BM271-MSCs, 
BM-MSCs vs OM-MSCs, and BM271-MSCs vs OM-MSCs. Statistical analysis was 
carried out by 2 way ANOVA using Tukey’s multiple comparison test, where 
ns = not significant, *=p<0.05, **=p<0.01, ***=p<0.005, and ****=p<0.001. 
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Table 4.13: Statistical analysis of data from Figures 4.6 and 4.7 comparing 
intensity of IR expression and percentage of IR positive cells expressing 
markers related to osteogenic (OPN (Figure 4.6A and 4.7A)) and OCN 
(Figures 4.6B and 4.7B)), neurogenic (Tuj-1 (Figures 4.6C and 4.7C)), 
myogenic (SMA (Figures 4.6D and 4.7D)), and glial (GFAP (Figures 4.6E and 
4.7E)) differentiation. Statistical analysis was carried out by comparing 
intensity of IR expression, and percentage of IR positive cells cultured on 
surface B topographies for 21 days, comparing BM-MSCs vs BM271-MSCs, 
BM-MSCs vs OM-MSCs, and BM271-MSCs vs OM-MSCs. Statistical analysis was 
carried out by 2 way ANOVA using Tukey’s multiple comparison test, where 
ns = not significant, *=p<0.05, **=p<0.01, ***=p<0.005, and ****=p<0.001. 
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Figure 4.6: Figure 4.4 data with a statistical focus of a cell-cell 
comparison as opposed to a substrate-substrate comparison. Analysis was 
carried out using ImageJ software by measuring intensity of fluorescence 
by counting the mean number of fluorescent pixels per cell per image. 
Statistical analysis was carried out by 2 way ANOVA using Tukey’s multiple 
comparison test, where *=p<0.05, **=p<0.01, ***=p<0.005, and 
****=p<0.001. n=3. 
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Figure 4.7: Figure 4.5 data with a statistical focus of a cell-cell 
comparison as opposed to a substrate-substrate comparison. Analysis was 
carried out using ImageJ software by measuring intensity of fluorescence 
by counting the mean number of fluorescent pixels per cell per image. 
Statistical analysis was carried out by 2 way ANOVA using Tukey’s multiple 
comparison test, where *=p<0.05, **=p<0.01, ***=p<0.005, and 
****=p<0.001. n=3. 
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4.4. Transcriptional Analysis of the Expression of Classic MSC Markers in 
BM-MSCs and OM-MSCs when Cultured on Nanotopographically Embossed 
PCL 
To determine whether the observed increases in protein expression were in 
fact due to differentiation of the MSCs, we cultured BM-MSCs, BM271-MSCs, 
and OM-MSCs on the same nanotopographically embossed PCL substrates 
under the same conditions as in experiments 4.2 and 4.3. mRNA was 
collected and analysed as in experiment 4.2, excepting that transcripts 
analysed were typical MSC markers instead of differentiation markers. 
Levels of CD90, CD166, and Nestin were used as additional indicators of 
differentiation, as they are typical MSC markers whose expression is lost 
during differentiation (284-286, 351-353).  
 
As observed in chapter three, expression of CD90, CD166, and Nestin at day 
1 was expressed at higher levels in MSCs derived from the OM compared to 
those derived from BM, with little difference in expression of either marker 
in BM and BM271-MSCs (Figure 4.8). By day 7, expression of each marker 
had decreased significantly compared to day 1 levels across each of the 
three substrates, and expression continued to decrease with time until 
levels were negligible by day 21 (p<0.01 – p<0.001) (Figure 4.8). Expression 
levels of each marker were also much lower on patterned surfaces 
compared to smooth surface controls across each time point, although due 
to sample variation, these differences weren’t always statistically 
significant (Figure 4.8). Levels of mRNA for CD90 expressed in BM-MSCs, 
BM271-MSCs, and OM-MSCs were significantly lower (p<0.01) in cells 
cultured on patterned surfaces compared to controls at each time point, 
except for in OM-MSCs at day 21, by which point levels of CD90 mRNA were 
very low (Figures 4.8A and B). Levels of nestin mRNA expression were 
significantly decreased in BM-MSCs cultured on patterned surfaces 
compared to controls at days 7 and 14 (p<0.01), and in BM271-MSCs 
cultured on patterned surfaces compared to controls at day 14 (p<0.01). 
All other differences in the expression of Nestin mRNA between patterned 
and smooth surfaces were not statistically significant (Figures 4.8E and F). 
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There were also marked decreases in the expression of CD166 mRNA in 
each MSC type cultured on patterned surfaces compared to smooth surface 
controls at each time point, although due to sample variation, these 
differences weren’t statistically significant (Figures 4.8G and H). 
 
 
 
 
 
 
 
 
 
 
Figure 4.8: Graphical representations of RT-qPCR carried out on BM-MSCs, 
BM271-MSCs, and OM-MSCs cultured on smooth surface PCL, and PCL 
embossed with surface A and surface B nanotopographies for 21 days. Each 
C D 
A B 
E F 
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condition was analysed for MSC-related mRNA markers; CD90 (A-B), CD166 
(C-D), and Nestin (E-F), and comparison was of BM-MSCs vs BM271-MSCs (A, 
C, and E) using the BM-MSC Day 1 condition as the point of comparison, and 
BM271-MSCs vs OM-MSCs (B, D, and F) using the BM271-MSC condition as the 
point of comparison. Statistical analysis was carried out by 2 way ANOVA 
using Tukey’s multiple comparison test, where *=p<0.05, **=p<0.01, 
***=p<0.005, and ****=p<0.001. PCR was carried out using the Livak (ΔΔCT) 
method with GAPDH as the reference control gene, n=3. 
 
4.6. Discussion 
Previous studies have shown that nanotopographies of a controlled 
disordered pattern can stimulate osteoprogenitors to differentiate towards 
mature calcified bone cells (256, 354, 355), and have also suggested that 
this may be possible with bone marrow-derived MSCs (257, 346). The 
experiments in this chapter were designed to confirm whether this 
substrate induced osteogenic differentiation is possible in my BM-MSCs, 
BM271-MSCs, and OM-MSCs. From the data compiled throughout this 
chapter we can also see whether CD271 selected BM-MSCs behave in a 
similar manner to non-selected BM-MSCs, and whether or not there are any 
other differentiation mechanism taking place via these cell/substrate 
interactions. 
 
Intially, the nanotopographies of the PCL substrates to be used throughout 
these experiments were confirmed. Using shims from previous studies 
which produced controlled disordered nanotopographies with pit heights of 
16 nm (surface A) and 18 nm (surface B) (257), PCL was embossed and 
analysed using atomic force microscopy (AFM). This AFM analysis 
determined that surfaces A and B were both DNSQ and distinct in pit 
height, but pit heights were measured at 25 nm and 20 nm respectively. 
Non-embossed smooth surface controls were confirmed as being without 
any pattern. 
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BM-MSCs, BM271-MSCs, and OM-MSCs were cultured on these substrates and 
levels of mRNA analysed for changes in levels of differentiation markers for 
fat, bone, neuron, muscle, and glia. Levels of all transcripts were 
stimulated to some degree in cells cultured on the patterned surfaces 
compared to non-patterned controls, and in most cases to significant levels 
at later time points. This stimulation was much greater and in most cases 
significantly different in BM-derived MSCs compared to OM-derived MSCs, 
with there being little difference in expression of any transcript between 
BM-MSCs and BM271-MSCs. These findings were unexpected however. 
Upregulation of mRNA can suggest a measure of protein changes, and thus 
changes in function, but this clearly wasn’t the case here. mRNA markers 
of adipogenesis, myogenesis, and neurogenesis were upregulated by the 
cell’s interactions with the nanotopographies, but were not translated to 
their respective proteins. The MSCs seemed to be undergoing a certain 
differentiation but this was more likely to be towards a single lineage 
rather than multiple. The ability of controlled disordered nanotopographies 
to induce osteogenic differentiation is well documented (256, 257, 346, 
354, 355). These studies, and others looking at genetic changes in MSCs 
during osteogenic differentiation (356-359) show a downregulation of 
indicators of other lineages of differentiation. This could suggest that the 
markers of differentiation used were perhaps not the most appropriate, 
i.e. GLUT4 and Leptin transcripts were stimulated by surfaces A and B but 
no fat droplets were observed to suggest any adipogenic differentiation 
had occurred. 
 
Immunocytochemistry showed that as well as their respective transcripts, 
levels of OPN-IR, OCN-IR, Tuj-1-IR, SMA-IR, and GFAP-IR were also 
stimulated, suggesting that these transcripts were translated to increased 
protein expression. Expression of OPN-IR and OCN-IR, both bone 
differentiation markers, was significantly increased in each MSC type 
cultured on patterned PCL surfaces, with BM-derived MSCs showing much 
greater immunoreactive intensity and percentage of immunoreactive 
positive cells compared to OM-MSCs. Tuj-1 and SMA, although often 
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considered to be neuronal and myogenic differentiation markers 
respectively (360-364), are also quite ubiquitous structural proteins which 
are naturally present in undifferentiated MSCs (365-371). Their increase in 
expression doesn’t necessarily suggest differentiation towards neuronal or 
myogenic lineages, but may be due to a cytoplasmic structural 
reorganisation that is occurring during osteogenic differentiation. This was 
seen by Chetakun et al. (372) who demonstrated an upregulation in ECM 
and skeletal proteins Tenascin and Fibronectin during osteogenesis, 
alongside bone-related proteins OPN, Bone Sialoprotein (BSP), and Bone 
Morphogenic Protein (BMP). Although GFAP is widely considered a classic 
glial marker (373, 374), previous studies have also identified that GFAP 
expression is stimulated during osteogenic differentiation (374), which 
would account for the observed increase in GFAP expression. Like with OPN 
and OCN, the observed increases in Tuj-1, SMA, and GFAP were 
significantly more pronounced in BM-derived MSCs compared to OM-MSCs. 
The observed increases in MAP2 and MyoD transcripts were not seen to be 
translated to their respective proteins. These proteins are specific markers 
of neuronal and myogenic differentiation, and their absence suggests that 
trans-differentiation may not have occurred in these MSCs via this 
particular mechanism, and that the up-regulation of Tuj-1 and GFAP may 
be related to the osteogenic differentiation that has more likely occured. 
This lack of translation seems inefficient but may be due to an absence of 
the required transcription factors. 
 
To further confirm that differentiation has occurred, transcripts were 
analysed using classic MSC markers CD90, CD166, and Nestin which are lost 
during differentiation (284-286, 351-353). This analysis confirmed that 
expression of these transcripts was significantly decreased in each MSC 
type cultured on patterned surfaces compared to undifferentiated MSCs. 
This decrease in expression of these transcripts was very pronounced and 
continued over time until only negligible levels were observed by day 21. 
 
198 
 
These experiments collectively confirm that PCL substrates 
nanotopographically embossed in a controlled disorder of 20 nm and 25 nm 
pit heights are capable of inducing osteogenic differentiation in BM-MSCs, 
BM271-MSCs, and OM-MSCs, that BM-derived MSCs are more efficient at 
such differentiation compared to OM-derived MSCs, and that trans-
differentiation did not occur via these specific cell/substrate mechanisms.    
 
Although there have been numerous studies into the biological effects of 
nanotopography on stem cell adhesion, survival, and differentiation, these 
have mainly been focussed on bone marrow-derived MSCs and embryonic 
stem cells (ESCs) (334, 375-377). Here with OM-MSCs we have introduced 
another potential source of autologous MSCs which display the same 
osteogenic capabilities as bone marrow-derived MSCs when cultured on 
controlled disordered nanoscale topographies. This opens the door to many 
more studies to determine whether indeed OM-MSCs are a viable 
alternative to BM-MSCs in fields such as orthopaedics where the 
relationship between BM-MSCs and nanotopography has proved very 
successful. (248, 378). 
 
4.8. Summary 
 Three separate PCL substrates were confirmed as controlled 
disordered surface A; relative roughness = 8.473 nm, peak to valley 
roughness = 81.87 nm, and mean peak height = 24.64 nm, controlled 
disordered surface B; relative roughness = 4.383 nm, peak to valley 
roughness = 33.37 nm, and mean peak height = 20.40 nm, and smooth 
surface control; relative roughness = 3.807. 
 BM-MSCs, BM271-MSCs, and OM-MSCs cultured on both surface A and 
surface B nanotopographies stimulated transcript expression of a number 
of differentiation markers compared to those MSCs cultured on non-
patterned PCL substrates. This stimulation is more pronounced, often 
significantly, in bone marrow-derived MSCs compared to olfactory mucosa-
derived MSCs, with very little difference at all between transcript profiles 
of BM-MSCs and BM271-MSCs. 
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 Observed increases in transcript expression were not always 
translated into increases in protein expression. Expression of OPN-IR, OCN-
IR, Tuj-1-IR, SMA-IR, and GFAP-IR was stimulated significantly in BM and 
OM-derived MSCs, again with BM-derived MSCs expressing these proteins 
with more efficacy compared to OM-derived MSCs. Each of these proteins 
have been associated with bone differentiation, confirming previous 
studies which have demonstrated an ability of DNSQ nanotopographies to 
stimulate bone differentiation in MSCs and osteoprogenitors. 
 Observed increases in expression of non-mesenchymal transcripts 
MyoD and MAP2 were not translated into increases in protein expression. 
These findings suggest that DNSQ surfaces A and B do not stimulate trans-
differentiation in either bone marrow or olfactory mucosa-derived MSCs.  
Expression of typical MSC markers using CD90, CD166, and Nestin mRNA 
decreased significantly in each MSC type when cultured on 
nanotopographically embossed PCL substrates over time, confirming that 
the MSCs are undergoing a differentiation process via these cell/substrate 
interactions. 
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5. Dissection of the Mechanisms of the Pro-Myelinating Effect of OM-
MSCs 
Previous studies have identified a pro-myelinating effect elicited by OM-
MSCs but not by BM-MSCs (1). To investigate the possible mechanisms 
which drive this effect, a number of arrays were carried out comparing not 
only BM271-MSCs and OM-MSCs, but also other cells from within the bone 
marrow and olfactory niches, as well as fibroblasts. The first part of our 
investigation was a comparative analysis of BM271-MSC and OM-MSC 
miRNA. This analysis was performed by the biomedical company Sistemic 
using miRNA fingerprinting techniques. The data supplied by Sistemic is 
covered in detail in sections 5.1.1 and 5.1.2.  
 
Experiments in the previous two chapters detected no significant or 
discernible difference in profile or behaviour patterns between CD271 
selected BM271-MSCs and non-selected BM-MSCs. Therefore, subsequent 
experiments, detailed in this chapter, compare BM271-MSCs and OM-MSCs 
only, with the exception of the human cytokine arrays in which the 
secretory profiles of a number of different cell types were compared. 
 
5.1. Comparison of Micro RNA (miRNA) Profiles of BM271-MSCs and OM-
MSCs by SistemQC™ miRNA-Based Fingerprinting 
Sistemic are a registered company who specialise in a range of 
technologies including miRNA fingerprinting. A collaboration was instigated 
aimed at comparing the miRNA profiles of MSCs from bone marrow and the 
olfactory system to determine how related they were, and to establish if 
they had characteristics of MSCs. We provided lysates of BM271-MSC (n=4) 
and OM-MSC samples (n=4) to Sistemic, and initial studies were made on 
the RNA of each sample with the view of establishing the viability of the 
RNA, and thus the comparative similarity of the samples submitted within 
each phenotype (Figure 5.1). Analysis was then carried out at miRNA level 
to create a full profile of all miRNA present in each cell type (Appendix 3), 
encompassing those which were equivalently expressed (EE) between each 
cell type (Appendix 4), and of those which were differentially expressed 
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(DE) between each cell type (Figure 5.3). Once these DE miRNAs were 
identified, Sistemic then identified key markers of cell phenotype (KmiRs™) 
which may be responsible for already identified differences in behaviour 
between BM-derived MSCs and OM-derived MSCs, namely cell survival, 
proliferation, and the ability to influence axonal myelination.  
 
The SistemQC™ miRNA-based fingerprinting assay screened each sample for 
a total of 1205 human adult miRNAs, and identified from these 195 which 
were present in both BM271 and OM-MSCs. Details of all samples used 
throughout this experiment can be found in Material and Methods Tables 
2.13 and 2.14. 
 
5.1.1. Validation of Sample Groups by Principle Component 
Analysis (data provided by Sistemic) 
A 3D PCA plot was configured to determine the relationship between each 
sample group, and between each sample within each group (Figure 5.1). 
This plot is derived from variations between each sample based on the 195 
miRNAs identified (microRNA-ome), and is effectively an indicator of how 
similar each sample is compared to each other (points within elipse), and 
how different each sample set is compared to the other (distance between 
elipses). This PCA plot shows that the samples within each sample set are 
similar enough, and within Sistemic’s QC parameters, to be considered part 
of the same data set. It also shows that each sample set is different 
enough to be considered as two distinct sample sets. 
 
5.1.2. Identification of EE and DE miRNAs (data provided by 
Sistemic) 
It was important to establish not only which miRNAs are expressed in MSCs, 
but also those which are expressed in both BM271-MSCs and OM-MSCs, as an 
observed homology between the two MSC types would further support OM-
MSCs as a novel and distinct MSC. Most importantly however, is to establish 
any miRNAs which are highly expressed in one MSC type and not the other. 
These DE miRNAs could contribute to some of the observed behavioural 
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differences between the two MSC types which have been previously 
outlined in this study. 
 
Of the 195 miRNAs identified during this array, 125 were considered to be 
equivalently expressed in both BM271-MSCs and OM-MSCs, giving a 64% 
homology between the 2 cell types at a miRNA level. Within these 
homologous miRNAs, 27 of the 195 have been previously identified as being 
associated with bone marrow-derived MSCs (Figure 5.2). Of the remaining 
70 miRNAs, 26 were found to be differentially expressed between BM271 
and OM-MSCs (Figure 5.3), leaving 44 which were in a statistical “grey 
area” in which the difference between expression of these miRNAs was too 
great to be considered equivalent, and too small to be considered 
differential. Of the 26 DE miRNAs, 16 were down-regulated in OM-MSCs 
compared to BM271-MSCs, and three were particularly identified in the 
Sistemic report as being associated with myelination (miR-140-5p), cell 
survival (miR-146a-5p), and proliferation (miR-335-5p) from previous 
studies (379-383). A full list of differentially expressed miRNAs and their 
relative fold changes can be found in Table 5.1. 
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Figure 5.1: Principal Component Analysis (PCA) comparison of n=4 samples 
from both BM271-MSC and OM-MSC groups based on all 195 detected 
miRNAs in the Sistemic miRNA array. The ellipse around each sample set 
captures how much variation there is in each of the Principal Component 
Scores for each group. The centre of the ellipse is the mean PCA score for 
the first and second components for that cell group while the 
circumference represents points in the plane which are 2 standard 
deviations away from the centre. This Figure 3.1 was taken directly from 
Sistemic’s final report. 
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Figure 5.2: Box plot representation taken from Sistemic’s final report, 
showing the 27 of the 125 miRNAs which were equivalently expressed (EE) 
between n=4 BM-MSCs and OM-MSCs (shown here as LP-MSCs) which have 
been shown in previous studies (Guo et al., 2011; Gao et al., 2011) to be 
consistently expressed in BM-MSCs. The full list of the 125 EE miRNAs can 
be found in Appendix 4. Significance was called at p
FDR
< 0.05 and an 
absolute fold-change (FC) = 1.5 (i.e. the allowed ‘equivalence range’). 
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Figure 5.3: Box plot representation taken from Sistemic’s final report, 
showing the 26 miRNAs which were differentially expressed (DE) between 
n=4 BM-MSCs and OM-MSCs (shown here as LP-MSCs). Significance was 
called at p
FDR
 < 0.05 and an absolute fold-change (FC) = 1.5 (i.e. the 
allowed ‘equivalence range’). 
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* False Discovery Rate (p value), calculated by Benjamini and Hochberg 
method 
** Fold change in expression from BM-MSCs vs OM-MSCs 
 
Table 5.1: List of each of the 26 miRNAs which were differentially 
expressed (DE) between n=4 BM-MSCs and OM-MSCs. Highlighted miRNAs 
miR-140-5p, miR-335-5p, and miR-146a-5p have been previously associated 
with the regulation of myelination, cell proliferation, and cell survival 
respectively, three mechanisms that have previously been noted as being 
different in BM-MSCs compared to OM-MSCs, and will therefore be the 
focus of the study forthwith. 
 
5.1.3. Confirmation of DE miRNAs; miR-140-5p, miR-146a-5p, and 
miR-335-5p by RT-qPCR  
From the list of 26 DE miRNAs, subsequent analysis will be focusing on the 
three DE miRNAs; miR-140-5p, miR-146a-5p, and miR-335-5p, which are 
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most pertinent to previously observed behavioural differences between 
BM271 and OM-MSCs; myelination, cell survival, and proliferation 
respectively. To confirm Sistemic’s findings, RT-qPCR was carried out on 
each of the samples analysed by Sistemic using the standard curve method 
to determine the levels of miR-140-5p, miR-146a-5p, and miR-335-5p in 
each sample, and also the fold increases/decreases of expression in BM271-
MSCs compared to OM-MSCs (Figure 5.4). Each RT-qPCR assay passed the 
minimum standard curve requirement of an r2 value of >0.95 (each 
standard curve can be found in Figures 5.4 B, D, and F). A summary of the 
differential expression and fold increases can be found in Table 5.2, the 
results of the RT-qPCR were as follows: 
The expression of miR-140-5p in OM-MSCs varied from ~1 to ~7 ng/sample, 
giving a mean value of 5.4 ng/sample (2.7 ng/µL). This was compared to 
expression in BM271-MSCs which varied from ~7 to ~28 ng/sample, with a 
mean value of 16.3 ng/sample (8.15 ng/µL). This difference was 
statistically significant (p<0.05) (Figure 5.4A), and gave a mean fold 
increase in expression of 3.66 in BM271-MSCs compared to OM-MSCs (Figure 
5.4G). 
 
The expression of miR-146a-5p in OM-MSCs varied from ~10 to ~50 
ng/sample, giving a mean value of 26.5 ng/sample (13.25 ng/µL). This was 
compared to expression in BM271-MSCs which varied from ~1 to ~8 
ng/sample, with a mean value of 3.3 ng/sample (1.65 ng/µL). This 
difference was statistically significant (p<0.05) (Figure 5.4C), and gave a 
mean fold decrease in expression of 15.45 in BM271-MSCs compared to OM-
MSCs (Figure 5.4G). 
 
The expression of miR-335-5p in OM-MSCs varied from ~2 to ~4 ng/sample, 
giving a mean value of 3.1 ng/sample (1.55 ng/µL). This was compared to 
expression in BM271-MSCs which varied from ~11 to ~34 ng/sample, with a 
mean value of 17.3 ng/sample (8.65 ng/µL). This difference was 
statistically significant (p<0.05) (Figure 5.4E), and gave a mean fold 
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increase in expression of 7.60 in BM271-MSCs compared to OM-MSCs (Figure 
5.4G). 
 
These data, although giving slightly different values to Sistemic’s data, 
showed similar expression patterns to those found by Sistemic, and is 
therefore confirmation of their findings of differential expression of these 
miRNAs in BM271-MSCs compared to OM-MSCs.  
 
 
 
Table 5.2: Summary of RT-qPCR analysis on BM271-MSCs and OM-MSCs 
outlined in section 3.1.3. showing minimum, maximum, mean, and fold 
change values regarding the expression of miR-140-5p, miR-146a-5p, and 
miR-335-5p in each phenotype. 
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Figure 5.4: RT-qPCR analysis confirming Sistemics’ findings of differential 
expression of miRNAs miR-140-5p (A), miR-335-5p (C), and miR-146a-5p (E) 
between BM271-MSCs and OM-MSCs. RT-qPCR was carried out using the 
standard curve method, and the standard curves from which the miRNA 
values were extrapolated are shown (B, D, and F), showing y-intercept, 
gradient, and R
2
 values. Fold increases/decreases in expression of each of 
the miRNAs in BM271-MSCs relative to OM-MSCs are shown in graph G. 
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Statistical analysis was carried out using a two-tailed ratio paired t-test, 
where *=p<0.05. n=4 different biological samples. 
 
5.2. Comparative analysis of chemokine/cytokine expression in media 
collected from BM-MSC and OM-MSCs  
MSCs, as well as their function as precursors to cells from the mesenchymal 
lineage, can also play an immunoregulatory role throughout the body (214, 
384-386). They are known to secrete a vast number of signalling molecules 
such as growth factors and chemokines which attract and modulate a range 
of different cells via chemotaxis to help repair and regenerate their niche 
(387-389). A number of studies have suggested that MSCs from different 
niches may secrete different signalling molecules according to the 
surrounding tissues and the unique regulation that each specific 
environment requires (390-394). In order to try and identify any cytokines 
which might be differentially secreted between BM-derived and OM-
derived MSCs as well as other cells from their resident niches, conditioned 
media was collected and analysed from each cell type, with an aim to 
identify any potential factors which could instigate the different 
myelination capacity observed with the BM-MSCs and OM-MSCs.  
 
Previously it has been shown that chemokines can affect myelination. Nash 
et al. demonstrated an inhibitory effect of CXCL10 on myelination (66), 
likely due to its IFN-γ induced pro-inflammatory effects via CXCR3 (395-
403), whilst CXCL12, via its interactions with CXCR4 and CXCR7, has been 
shown to stimulate myelination, and promote neural cell function by 
increasing neuronal migration and proliferation of cells within the CNS 
(404-406). These conditioned media, in which each cell type had been 
cultured for 48 hours, is rich in all of the secreted factors unique to each 
cell type. Human Luminex cytokine arrays covering a wide range of 
cytokines were used to analyse each conditioned media sample for the 
presence of these molecules. Analysis of each sample was compared 
against the others to identify any which may be considered as being 
differentially secreted, and thus potentially important regarding 
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identifying possible mechanisms involved in the observed differences in 
behaviour between each MSC phenotype. Analysis was carried out using 
three commercially bought human Luminex® cytokine bead arrays 
comparing conditioned media collected from confluent  flasks of BM-MSCs, 
BM271-MSCs, BM-flow through cells, OM-MSCs, OM-flow through cells, and 
fibroblasts, using non-conditioned DM- media as negative controls. Analysis 
of conditioned media from embryonic stem cell-derived MSCs was also 
carried out, however the data wasn’t considered when comparing BM-MSCs 
and OM-MSCs as its secretory profile was so uniquely different to both. 
 
Since data from the lab has shown that rat olfactory ensheathing cells 
(OECs) promote myelination in myelinating cultures while conditioned 
media from rat Schwann cells inhibits myelination (163), we had a good 
reason to compare this conditioned media with that of OM-MSCs and BM-
MSCs which share similar pro-myelinating and non-myelinating properties. 
Thus, analysis of n=4 different biological samples of each rat CM was also 
carried out using a rat Luminex® cytokine array comparing conditioned 
media from rat BM-MSCs, rat OM-MSCs, rat olfactory ensheathing cells 
(OECs), and rat Schwann cells, using non-conditioned DM- media as a 
negative control.  
 
5.2.1. Human Luminex® Cytokine Arrays 
Lindsay et al. recently demonstrated that axonal myelination is stimulated 
by the use of OM-MSC conditioned media (OM-MSC-CM) in vitro (1), 
suggesting a secreted factor is playing a role. Numerous studies have 
demonstrated a link between the stimulation of axonal myelination and 
CXCL12 (396-399, 407) but here for the first time we show a common link 
between OM-MSCs, CXCL12, and the stimulation of myelination. 
 
In total, conditioned media was analysed for 62 separate cytokines over 
three separate arrays (some cytokines overlapping in more than one array). 
Full details of all of the cytokines used throughout these arrays can be 
found in Materials and Methods section 2.15.2. Of these 62 cytokines, 18 
214 
 
were statistically differentially secreted between BM-derived MSCs and 
OM-derived MSCs. However, to determine whether or not this difference 
was completely specific to OM-MSCs, the secretory profiles of the other 
cells from their niche tissue has to also be considered. If a significant 
increase in the secretion of a particular cytokine is observed in OM-MSCs 
compared to BM-MSCs, but is also observed in the OM-flow through cells, 
then this differential secretion must be considered not specific to that cell 
type. For any significant difference in secretion of a particular cytokine to 
be considered unique to the MSC itself, it must be significantly different to 
OM-Flow through cells as well as those from the bone marrow niche, so 
factors were identified that were secreted by only one cell type. This was 
observed in just 4 of the 18 aforementioned cytokines; CCL11, IL-9, G-CSF, 
and CXCL12 (SDF-1). Table 5.3 summarises the cytokines which were 
differentially secreted by the various cell types identified using these 
arrays. In this table, secretion is assessed relative to OM-MSCs. Instead of a 
specific concentration value, cytokines are scored with either a + or – 
symbol depending on whether their secretion is higher or lower compared 
to the factors detected in OM-MSCs. Graphs of actual concentrations and 
statistics of the 4 cell-specific differentially secreted cytokines are 
represented in Figure 5.5.   
 
CCL11 was found to be secreted at a significantly higher concentration in 
OM-MSCs compared to OM-flowthrough cells (p<0.05) and all other cells 
(except ESC-derived MSCs) (p<0.001) from the Invitrogen 41-plex array 
(Figure 5.5A), and significantly higher compared to all cell types (p<0.001) 
in the Millipore 30-plex array (Figure 5.5B).  
 
BM-MSCs and BM271-MSCs were shown to secrete a significantly higher 
amount of IL-9 compared to each other cell type (p<0.001) (Figure 5.5C). 
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Table 5.3: Three luminex bead arrays using the kits outlined in materials 
and methods section 2.16 were carried out with conditioned medium 
collected from Fibroblasts, BM271-MSCs, BM-MSCs, OM-MSCs, OM-Flow 
through cells, BM-Flow through cells, and MSCs derived from ESCs. This 
table lists all differentially expressed chemokines taken from the combined 
results of the three separate human Luminex chemokine arrays. 
Highlighted cytokines are ones which are expressed at significantly 
different levels in BM-MSCs compared to both OM-MSCs and OM-
flowthrough cells, i.e. the difference is specific to the OM-MSC and not just 
the other cell types that could be found isolated from this tissue. +/- 
refers to a <5-fold increase/decrease. ++/-- refers to a >5-fold 
increase/decrease. 
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Figure 5.5: Graphical representations of the concentration of factor in 
conditioned media taken from human BM-MSCs (n=3), BM271-MSCs (n=8), 
BM-flowthrough cells (n=3), OM-MSCs (n=8), OM-flowthrough cells (n=3), 
ESC-derived MSCs (n=3), and Fibroblasts (n=3). Figures show the 
chemokines taken from the three separate human Luminex arrays which 
were differentially expressed between OM-MSCs and all other cell types 
analysed for. CCL11 was shown in the 41-Plex array to be significantly 
differentially expressed in OM-MSCs compared to all other cell types 
except ESC-derived MSCs (A), and in the 30-Plex array to be significantly 
differentially expressed in OM-MSCs compared to all other cell types (B). 
IL-9, analysed only in the 41-Plex array, was significantly differentially 
expressed in OM-MSCs compared to all other cell types (C), G-CSF was 
shown to be significantly differentially expressed in OM-MSCs compared to 
all other cell types in both the 41-Plex and 30-Plex arrays (D-E), and 
CXCL12 was shown to be significantly differentially expressed in OM-MSCs 
compare to all other cell types in the 23-Plex array (F). Statistical analysis 
was carried out by 1 way ANOVA using Tukey’s multiple comparison test, 
where *=p<0.05, **=p<0.01, ***=p<0.005, and ****=p<0.001. 
 
The 41-plex array (Figure 5.5D) showed a high concentration of G-CSF was 
secreted by BM-MSCs, and to a significantly lower extent in BM271-MSCs 
(p<0.01) and BM-Flow through cells (p<0.05), suggesting that G-CSF 
producing cells may be lost during CD271 positive selection. This was not 
observed however in the 30-plex array, where G-CSF was secreted at very 
low concentrations from all bone marrow-derived cells (Figure 5.5E). In 
both arrays though, we see a very high concentration of G-CSF secreted 
from OM-MSCs which is significantly higher than that secreted by all other 
cells (p<0.01 – p<0.001). 
 
Figure 5.5F shows that CXCL12 is secreted by BM-MSCs, OM-MSCs, and OM-
Flow through cells. However, secretion of CXCL12 is at a significantly 
higher concentration in media collected from OM-MSCs compared to each 
of the other cell types. This would suggest that this difference in CXCL12 
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secretion is specific to OM-MSCs. This finding is of particular importance, 
as CXCL12 has been shown to be one of the signalling molecules regulated 
by miR-140-5p (Figure 5.7), which, as was shown in section 5.1, was 
upregulated 3.66 fold in BM-MSCs compared to OM-MSCs (Figure 5.4). 
 
5.2.2. Rat Luminex Cytokine Array 
Lamond et al. also showed a link between a pro-myelination effect and 
cells from the olfactory system. It was demonstrated that conditioned 
media from rat olfactory ensheathing cells (OEC-CM) stimulated 
myelination, as opposed to that from rat Schwann cells (SC-CM) which 
showed an inhibitory effect on myelination (163). As these opposing 
biological effects mirror those of OM-MSCs and BM-MSCs, analysis of each 
conditioned media was carried out by Luminex array to determine any 
cytokines which showed commonality in secretion patterns between OM-
MSCs and OECs, and between BM-MSCs and Schwann cells. As it was 
technically demanding to isolate and culture human OECs, rat cells were 
used as an alternative. Conditioned media collected from rOM-MSCs, rBM-
MSCs, rOECs, and rSCs was analysed for a panel of 27 different cytokines 
(n=4 different biological samples). Table 5.4 lists each cytokine which was 
significantly differentially secreted in at least one of the conditioned 
media. The highlighted cells show cytokines that showed a significant 
increase/decrease in concentration from OM-MSCs compared to BM-MSCs 
and OECs compared to SCs. These were MIP-1α (Figure 5.6A), MIP-2 (Figure 
5.6B), IP-10 (Figure 5.6C), RANTES (Figure 5.6D), Fracktalkine (Figure 
5.6E), and LIX (Figure 5.6F). Although these cytokines show a commonality 
between OM-MSCs and OECs, and between BM-MSCs and SCs, more work 
will have to be carried out to determine whether or not either of them 
have any effect of axonal myelination.  
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Table 5.4: List of all differentially expressed chemokines taken from the 
rat Luminex chemokine array comparing the conditioned media taken from 
rat-derived BM-MSCs and OM-MSCs, and rat OECs and Schwann cells. 
Highlighted cytokines are those which are secreted at significant different 
concentrations from both OM-MSCs compared to BM-MSCs and OECs 
compared to Schwann cells. +/- refers to a <5-fold increase/decrease, and 
++/-- refers to a >5-fold increase/decrease. 
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Figure 5.6: Graphical representations of the concentration of factors from 
conditioned media taken from rat BM-MSCs, OM-MSCs, OECs, and Schwann 
cells. Figures show the chemokines identified in the rat Luminex array 
which were differentially expressed between OM-MSCs and BM-MSCs, and 
between OECs and Schwann cells. Statistical analysis was carried out by 1 
way ANOVA using Tukey’s multiple comparison test, where *=p<0.05, 
**=p<0.01, ***=p<0.005, and ****=p<0.001. n=4.   
 
5.3. Determining the Relationship Between miR-140-5p, OM-MSCs, 
CXCL12, and Myelination 
Previous data has shown a significant increase in the expression of miR-
140-5p in BM271-MSCs compared to OM-MSCs, and a significant decrease in 
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the secretion of CXCL12 in BM271-MSCs compared to OM-MSCs. Lindsay et 
al. (1) demonstrated that OM-MSC-CM promoted myelination significantly 
in mixed spinal cord cultures (myelinating cultures) when compared to BM-
MSCs-CM, and as discussed previously, numerous studies have associated 
CXCL12 with enhanced myelination (396-399, 407). We also showed that 
miR-140-5p has an inverse correlation with CXCL12 expression (Figure 5.8) 
(379). All of these findings put together suggest that axonal myelination 
may be enhanced by CXCL12 secreted by OM-MSCs, and regulated by miR-
140-5p. In this section we set out to confirm this link via a series of 
experiments including i) applying inhibitors and mimicks of miR-140-5p, ii) 
biological analysis of the subsequent conditioned media collected from 
these transfected cells on myelinating cultures, and iii) the use of CXCL12 
receptor blocker, CXCL12 protein, and CXCL12 neutralising antibody on 
myelinating cultures. 
 
5.3.1. RT-qPCR Demonstrates the Inverse Relationship of CXCL12 
by miR-140-5p  
Nicolas et al. (379) had previously identified miR-140-5p as a target for 
CXCL12 regulation (Figure 5.7), and separately, using SistemQC™ miRNA 
fingerprinting, we and Sistemic identified an upregulation of miR-140-5p in 
BM271-MSCs compared to OM-MSCs (section 5.1). As miR-140-5p is a 
negative regulator of CXCL12, it could be assumed that there would be an 
inverse relationship between miR-140-5p and CXCL12. Here we transfect 
BM271-MSCs and OM-MSCs with an inhibitor and mimic of miR-140-5p to 
simulate the regulation of miR-140-5p.  RT-qPCR was used to identify any 
changes in the expression of CXCL12 mRNA with the view of confirming the 
relationship between miR-140-5p and CXCL12 (Figure 5.8). Figure 5.7 
illustrates a miRNA map generated by Sistemic for their final report using 
high-confidence interactions from GeneGO MetaCoreTM analyses. This 
miRNA map outlines signalling molecules which are known to be regulated 
by miR-140-5p. Figure 5.8 confirms the relationship between miR-140-5p 
and CXCL12, and demonstrates the role miR-140-5p plays in negatively 
regulating CXCL12. Confirmation that the transfections were successful is 
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shown in Figures 5.8A and 5.8C which demonstrate a downregulation of 
miR-140-5p in both BM271-MSCs and OM-MSCs when transfected with miR-
140-5p inhibitor, and an upregulation of miR-140-5p in BM271-MSCs and 
OM-MSCs when transfected with mir-140-5p mimic. The negative control 
conditions are BM271-MSCs and OM-MSCs transfected with a “scrambled” 
piece of miRNA which has no affinity to miR-140-5p, and the “no miRNA” 
control is BM271-MSCs and OM-MSCs transfected with ddH2O only. These 
controls both follow the expected mRNA expression pattern of miR-140-5p 
being normally expressed at a higher level in BM271-MSCs. 
 
 
 
 
Figure 5.7: miRNA network plot built using high-confidence interactions 
form GeneGO MetaCoreTM analyses (taken from Sistemic’s final report) 
showing a number of chemokines known to be regulated by miR-140, and 
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its constituent miRNAs miR-140-3p and miR-140-5p. The highlighted 
chemokine CXCL12 was shown in our previous Luminex analysis to be 
differentially expressed in OM-MSCs compared to BM-MSCs. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5.8: RT-qPCR analysis on BM271-MSCs (A-B) and OM-MSCs (C-D) 
which have been transfected with miR-140-5p inhibitor, miR-140-5p mimic, 
“scrambled” miRNA (-ve control), and ddH2O control in which no miRNA is 
transfected. Samples were analysed for miR-140-5p and its downstream 
effector CXCL12 to demonstrate a relationship between the miRNA and the 
chemokine. RT-qPCR was carried out using the standard curve method. All 
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standard curves can be found in supplementary data S3. Statistical analysis 
was carried out by 1 way ANOVA using Tukey’s multiple comparison test, 
where *=p<0.05, **=p<0.01, ***=p<0.005, and ****=p<0.001, n=3. 
Figures 5.8B and D confirm the negative regulatory effect of miR-140-5p on 
CXCL12, by demonstrating that an increase in the expression of miR-140-5p 
translates to a decrease in the expression of CXCL12 mRNA, and vice versa. 
 
5.3.2. CXCL12 is Confirmed to Stimulate Axonal Myelination in 
vitro 
As discussed previously in section 5.2, CXCL12 acts upon the receptors 
CXCR4 and CXCR7 (408-414). CXCL12 signalling can be abrogated by the 
blocking of CXCR4 using the chemical AMD-3100 (415-417) which also acts 
as an allosteric agonist to CXCR7 (418). CXCL12 in conditioned medium can 
also be neutralised using an antibody to CXCL12 which binds to the 
chemokine, thus rendering it unable to bind to its receptor. Here a number 
of conditions were set up whereby myelinating cultures were treated with 
CXCL12 to assess any stimulatory effects on myelination. Cultures were 
also treated with OM-MSC-CM to confirm the findings of Lindsay et al. that 
it stimulates myelination. Cultures were also pre-treated with AMD-3100 to 
block CXCL12 in the OM-MSC-CM from binding to CXCR4/CXCR7, and with a 
CXCL12 neutralising antibody to bind free CXCL12 in the OM-MSC-CM, 
preventing its interaction with CXCR4/CXCR7 (Figures 5.9 and 5.10).  
Controls were carried out using DM- only, DM- plus AMD-3100, and DM- plus 
anti-CXCL12.  
 
 
 
 
 
 
 
 
 
Control (DM- Only)           A 
AA3/SMI31 
DM- plus anti-CXCL12      B 
AA3/SMI31 
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Figure 5.9: Representative immunocytochemistry images of the effects of 
CXCL12 on myelinating cultures (D), in the presence of the CXCR4 receptor 
blocker AMD3100 (E), the effects of OM-MSC conditioned media (CM) (taken 
from n=3 OM-MSC donors) on myelinating cultures (F); in the presence of 
neutralising antibody to CXCL12 (G), and in the presence of AMD3100 (H). 
These data suggest that the pro-myelinating effect may be CXCL12 
dependant. Images (B) and (C) illustrate the effect of anti-CXCL12 antibody 
and AMD-3100 alone on myelination in culture. All conditions were 
compared to an untreated control (A). Immunocytochemistry was carried 
out using AA3, a myelin marker for Proteolipid protein 1 (PLP) (green), and 
DM- plus CXCR4 Blocker   C 
AA3/SMI31 
CXCL12 (100ng)                D 
AA3/SMI31 
CXCL12 (100ng)               E 
+CXCR4 Blocker 
AA3/SMI31 
OM-MSC-CM                      F 
AA3/SMI31 
OM-MSC-CM                     G 
+ anti-CXCL12 
AA3/SMI31 
OM-MSC-CM                      H 
+ CXCR4 Blocker 
AA3/SMI31 
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axons were visualised using SMI31 (red). All images were taken at x10 
magnification, scale bar =100 μm. n=3. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5.10: Graphical representation of the effects of CXCL12 and OM-
MSC-CM (n=3 different OM-MSC donors) on myelination in vitro, in the 
presence of a neutralising antibody to CXCL12, and a blocker of the CXCL12 
receptor (CXCR4), AMD3100.  Myelination was quantified using CellProfiler 
Cell Image Analysis Software to calculate a percentage of myelinated axons 
per image. Mean values per condition were calculated, and a fold increase 
in myelination relative to the untreated control was represented in the 
graph. Statistical analysis was carried out by 1 way ANOVA using Tukey’s 
multiple comparison test, where *=p<0.05, **=p<0.01, ***=p<0.005, and 
****=p<0.001. n=3. 
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These data confirm the stimulatory effect of OM-MSC-CM on in vitro 
myelination, and correlate this with CXCL12 expression. Percentages of 
myelinated axons treated with CXCL12 and with OM-MSC-CM were >2-fold 
that observed in the untreated control samples. Untreated controls, AMD-
3100 only, and anti-CXCL12 only controls showed very similar percentages 
of myelinated axons. Moreover, the percentage of myelinated axons 
decreased dramatically in cultures treated with CXCL12 that were pre-
treated with AMD-3100, which confirms that AMD-3100 does indeed act in 
abrogating the signalling between CXCL12 and its receptors CXCR4 and 
CXCR7. The 2 fold increase in percentage of myelinated axons observed in 
cultures treated with OM-MSC-CM was diminished to around the levels of 
untreated controls by pre-treatment with AMD-3100 and with anti-CXCL12. 
This suggests that the pro-myelinating effect of the OM-MSC-CM may 
indeed be mediated by CXCL12 in OM-MSCs via CXCL12/CXCR4/CXCR7 
interactions. 
 
5.3.3. Inhibitors and Mimics of miR-140-5p Affect in vitro CNS 
Myelination. 
It was demonstrated in section 5.5.1 that inhibition of miR-140-5p 
increases the ability of BM271-MSCs and OM-MSCs to produce CXCL12 
mRNA, and contrastingly that mimicking of miR-140-5p decreases this 
ability. Conditioned media was collected from both BM271-MSCs and OM-
MSCs which have been transfected with an inhibitor and mimic of miR-140-
5p, to assess any effect on the myelinating cultures previously used in 
section 5.3.2 (Figures 5.11 and 5.12). This would validate biological 
activity of CXCL12 after transfection with modifiers of miR-140-5p. 
Controls included untreated control (DM- only), CM collected from cells 
transfected with negative “scrambled” miRNA, and CM collected from cells 
transfected with ddH2O only. 
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Figure 5.11: Representative images of the effect of conditioned media 
taken from BM271-MSCs and OM-MSCs transfected with inhibitor (D and H) 
and mimic (E and I) of miR-140-5p on in vitro myelination. Conditioned 
media was also used from BM-MSCs and OM-MSCs transfected with 
“scrambled” miRNA (-ve control) (B and F), and with H2O (No miRNA 
control) (C and G). All conditions were compared to an untreated control 
(A). Staining was carried out using AA31 as a myelin marker for 
polylipoprotein (green), and axons were visualised using SMI31 (red). All 
images were taken at x10 magnification, with the scale bar representing 
100 μm. n=3. 
 
 
 
Figure 5.12: Graphical representation of the effect of conditioned media 
taken from BM271-MSCs and OM-MSCs transfected with inhibitor and mimic 
of miR-140-5p on in vitro myelination. Myelination under these conditions 
was compared to control conditions using BM-MSC-CM and OM-MSC-CM from 
cells transfected with “scrambled” miRNA (-ve control), and with H2O (No 
miRNA control). All conditions were compared to an untreated (non-
transfected) control which was cultured as normal with DM-. Myelination 
was determined using CellProfiler Cell Image Analysis Software to calculate 
a percentage of myelinated axons per image. Mean values per condition 
were calculated, and a fold increase in myelination relative to the 
untreated control was represented in the graph. Statistical analysis was 
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carried out by 2 way ANOVA using Tukey’s multiple comparison test, where 
*=p<0.05, **=p<0.01, ***=p<0.005, and ****=p<0.001. n=3. 
 
These data confirm that manipulation of miR-140-5p in both BM271-MSCs 
and OM-MSCs can affect myelin production on in vitro myelination, and it is 
likely that this is due to subsequent changes in the secretion of CXCL12 
from these cells. Figure 5.12 shows an almost 2 fold increase in the 
percent of myelinated axons when treated with CM from BM271-MSCs and 
OM-MSCs transfected with miR-140-5p inhibitor, suggesting inhibition 
resulted in an increase in secretion of CXCL12 into the CM. This percent of 
myelinated axons was significantly higher (p<0.01) than in cultures treated 
with CM from BM271-MSCs and OM-MSCs transfected with miR-140-5p 
mimic.  
 
Cultures treated with OM-MSC-CM controls (“scrambled” miRNA and ddH2O) 
showed increased percentages of myelinated axons compared to untreated 
controls and to cultures treated with OM-MSC-CM from cells transfected 
with miR-140-5p mimic. These increases were significant (scrambled  
untreated and mimic = p<0.01), ddH2O  untreated = p<0.05, ddH2O  
mimic = p<0.01) but were not different when compared to conditions 
treated with OM-MSC-CM transfected with miR-140-5p inhibitor. The 
observations in the control treatments were expected, but the lack of 
difference between the controls  and the “inhibitor” treatment suggests a 
possible saturation point, where the pro-myelinating effect of the secreted 
CXCL12 cannot be further enhanced by more CXCL12 being secreted. The 
significant difference in axonal myelination between scrambled, ddH2O, 
and inhibitor treatments compared to mimic treatments shows that miR-
140-5p is inhibiting at least one pro-myelinating factor secreted by OM-
MSCs, most likely CXCL12 based on previous observations. 
 
Cultures treated with BM271-MSC-CM controls (“scrambled” and ddH2O) 
showed percentages of axonal myelination similar to those of untreated 
controls. This would be expected, as previous observations have shown no 
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pro-myelinating effect of BM271-MSC-CM on in vitro myelination. Cultures 
treated with the mimic transfected BM271-MSC-CM had less myelinated 
axons compared to untreated controls and transfected controls, but these 
differences were not significant. Cultures treated with BM271-MSC-CM from 
cells transfected with miR-140-5p inhibitor showed a significantly higher 
percentage of axonal myelination compared to untreated controls, 
transfected controls; scrambled and ddH2O (p<0.05), and compared to 
cultures treated with BM271-MSC-CM from cells transfected with miR-140-
5p mimic (p<0.01). This data illustrates that miR-140-5p inhibition results 
in increased secretion of at least one pro-myelinating factor, most likely 
CXCL12 based on previous experiments. 
 
5.3.4. miR-140-5p Regulates the Secretion of Cytokines Other Than 
CXCL12 
Data presented in Sections 5.3.2 and 5.3.3 showed a potential for miR-140-
5p to regulate CXCL12 secretion by BM271-MSCs and OM-MSCs, and Figure 
5.7 showed that miR-140-5p is responsible for the regulation of a number 
of different cytokines other than CXCL12, such as BMP2, SP1, HDAC4, and 
SMAD3. Here we try to identify other cytokines which may be regulated by 
miR-140 5p by analysing CM taken from BM271-MSCs which have been 
transfected with an inhibitor and mimic of miR-140-5p. Analysis was 
carried out by the same 30-plex and 41-plex Luminex arrays used in section 
5.2.1 (Figure 5.13).   
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Figure 5.13: Graphical representation of human Luminex array analysis of 
CM taken from BM271-MSCs transfected with inhibitor and mimic of miR-
140-5p. Also analysed was CM taken from BM-MSCs transfected with 
“scrambled” miRNA (-ve control), and H2O (no miRNA control), and a non-
CM control of DM- alone. N=3 sets of CM were analysed on 30-Plex (A-C, E, 
G, J) and 41-Plex (D, F, H-I) arrays, and graphs presented represent 
chemokines which were differentially expressed in either mimic or 
inhibitor samples compared to each other, suggesting a possible regulatory 
effect on these chemokines by miR-140-5p. Statistical analysis was carried 
out by 1 way ANOVA using Tukey’s multiple comparison test, where 
*=p<0.05, **=p<0.01, ***=p<0.005, and ****=p<0.001. n=3. 
 
CCL11 (Eotaxin-1) was shown to be secreted at a significantly higher 
concentration from OM-MSCs compared to BM271-MSCs (Figure 5.5A). 
Figure 5.13A shows that when the amount of miR-140-5p produced by 
BM271-MSCs is increased (mimic), the cells secrete a significantly lower 
concentration of CCL11 compared to controls, and to those where miR-140-
5p is inhibited. This mirrors previous data when looking at CXCL12, 
suggesting that CCL11 may also be negatively regulated by miR-140-5p. 
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Figure 5.13B shows a significant increase in the secretion of MCP-1 
(p<0.005) from cells transfected with miR-140-5p mimic compared to 
controls, and to those transfected with inhibitor.  
 
In both the 30-plex and 41-plex arrays we show a significant increase in the 
secretion of IL-6 from BM271-MSCs which have been transfected with miR-
140-5p compared to controls and those transfected with inhibitor 
(p<0.001). This suggests that miR-140-5p may be inhibiting an upstream 
effector which regulates the secretion of IL-6. 
 
In both the 30-plex and 41-plex arrays it was shown that BM271-MSCs 
transfected with miR-140-5p secreted a significantly higher concentration 
of IL-8 compared to controls and to those transfected with inhibitor 
(p<0.05 – p<0.01). This also could suggest that miR-140-5p may be 
inhibiting an upstream effector which regulates the secretion of IL-8. 
 
G-CSF, described in section 5.2.1, was seen to be secreted at high 
concentrations in BM-MSCs but not so in BM271-MSCs (Figure 5.5D), 
suggesting a possible loss of G-CSF secreting cells during the CD271 positive 
selection process. However OM-MSCs, which also undergo this CD271 
positive selection, were seen to secrete a significantly higher amount of G-
CSF compared to all other cell types (Figures 5.5D and 5.5E), suggesting 
that this increased secretion is specific to OM-MSCs. This experiment shows 
us that BM271-MSCs which have been transfected with miR-140-5p mimic 
secrete a significantly higher amount of G-CSF compared to controls and to 
those transfected with miR-140-5p inhibitor (p<0.001) (Figures 5.13G and 
5.13H).  
 
FGF-2 (basic fibroblast growth factor) and HGF (hepatocyte growth factor) 
show a similar relationship between their secretion and miR-140-5p 
expression in BM271-MSCs in that mimicking of miR-140-5p increases the 
secretion of both of these factors compared to controls and to cells 
transfected by miR-140-5p inhibitor (Figures 5.13I and 5.13J). This 
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suggests, as before, that the secretion of these factors is regulated by an 
upstream effector that is directly regulated by miR-140-5p. 
 
5.4. miR-146a-5p Regulates Fas Receptor (CD95) Expression. A Possible 
Mechanism for Increased Cell Survival? 
Although neither BM-MSCs, BM271-MSCs, nor OM-MSCs were used 
throughout this study beyond passage 5, it was observed during numerous 
cell cultures that OM-MSCs had a much better survival rate compared to 
both BM-MSCs and BM271-MSCs (anecdotal evidence only). BM-derived MSCs 
would start to look very unhealthy by passage 7, and would die soon after, 
whereas OM-MSCs would look very healthy for numerous passages beyond 
that. No studies were carried out to assess the viability of OM-MSCs at such 
late passages, but these observations became quite pertinent with regards 
to miR-146a-5p expression. Suzuki et al. and Guo et al. (47-48) 
demonstrated a direct relationship between miR-146a-5p and CD95 (FasR) 
which is the receptor for the Fas ligand (CD95L) (Figure 5.14).CD95 is part 
of what’s known as “the death receptor family” of ligands, as its 
interaction with CD95 induces apoptosis (49-53). In section 3.1 we 
demonstrated a 15.5 fold increase in miR-146a-5p expression in OM-MSCs 
compared to BM271-MSCs. This would suggest that downstream molecules 
which are suppressed by miR-146a-5p would be downregulated in OM-MSCs 
compared to BM271-MSCs. As CD95 (FasR) is one of these downstream 
molecules (Figure 5.14), its suppression could account for the increased 
survival of OM-MSCs compared to BM-MSCs that has been anecdotally 
observed during cell culture. The major flaw in this theory is that once you 
remove these cells from their respective niches and place them into 
culture, you are removing any exposure to the Fas ligand which would 
propagate the cell death effect. Unless of course the cells themselves 
secrete Fas ligand as a self-regulatory mechanism, but this is unlikely and 
was not investigated. The relationship between miR-146a-5p and CD95 will 
be further investigated in the preceding sub-chapters however, as any 
effects that this relationship might have in situ could cause epigenetic 
changes within the cells which are carried with them to in vitro cell 
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culture conditions. Any such relationship would have to be investigated 
with far more scrutiny however, before any connection could be made 
between miR-146a-5p, CD95, and cell survival.  
 
5.4.1. Western Blot Analysis Shows Higher Expression of CD95 in 
BM271-MSCs Compared to OM-MSCs 
Importantly we had to first identify and compare normal levels of CD95 
expressed in both BM271-MSCs and OM-MSCs. Here we analysed 4 separate 
donor samples of each cell type by western blot, and demonstrated that 
there was a significantly higher expression of CD95 on BM271-MSCs 
compared to OM-MSCs (p<0.01) (Figure 5.15). A full list of sample donors 
can be found in Materials and Methods Table 2.18. 
 
5.4.2. RT-qPCR Demonstrates the Viability of the miR-146a-5p 
Transfection 
To further investigate the effect that miR-146a-5p has on CD95 expression, 
transfection experiments were carried out exactly as in section 3.3.1, only 
using miR-146a-5p transcripts as the transfected agent. Figures 5.16A and 
5.16B demonstrate the ability of the transfection to mimic and inhibit 
expression of miR146a-5p, showing a significant increase in miR-146a-5p 
expression in cells transfected with miR-146a-5p mimic compared to 
controls and to those transfected with miR-146a-5p inhibitor (p<0.01 – 
p<0.001), and also showing a significant decrease in expression of miR-
146a-5p in cells transfected with miR-146a-5p inhibitor compared to 
negative controls (BM271-MSCs = p<0.01, OM-MSCs = p<0.05). 
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Figure 5.14: miRNA network plot built using high-confidence interactions 
form GeneGO MetaCoreTM analyses (taken from Sistemic’s final report) 
showing a number of chemokines known to be regulated by miR-146a, the * 
denoting the minor products of miR-146a regulation. The highlighted 
molecule FasR (CD95) is one that is known to be related to cell survival. 
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Figure 5.15: Scan of western blot of Fas Receptor (CD95) on BM271-MSCs 
and OM-MSCs, using GAPDH as a loading control (A), and a graphical 
representation of this western blot analysis (B). Densitometry of each 
protein band was analysed using ImageJ software, and amounts of CD95 
were calculated relative to the loading control protein GAPDH. Statistical 
analysis was carried out using a two-tailed unpaired t-test, where 
*=p<0.05, **=p<0.01, ***=p<0.005, and ****=p<0.001. n=4. 
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Figure 5.16: RT-qPCR analysis on BM271-MSCs (A) and OM-MSCs (B) which 
have been transfected with miR-146a-5p inhibitor, miR-146a-5p mimic, 
“scrambled” miRNA (-ve control), and ddH
2
O as a control in which no 
miRNA is transfected. Samples were analysed for miR-146a-5p to 
demonstrate that the miRNA had been inhibited/stimulated. RT-qPCR was 
carried out using the standard curve method. Statistical analysis was 
carried out by 1 way ANOVA using Tukey’s multiple comparison test, where 
*=p<0.05, **=p<0.01, ***=p<0.005, and ****=p<0.001. n=3. 
 
5.4.3. Western Blot Analysis Confirms a Direct Relationship 
Between miR-146a-5p and CD95 
CD95 as a molecule regulated by miR-146a-5p has been previously 
discussed. Here, the direct relationship between CD90 and miR-146a-5p is 
identified by manipulating levels of miR-146a-5p in each cell type, and 
analysing expression of CD95 by western blot (Figure 5.17).  
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Figure 5.17: Representative scan of western blot analysis of protein from 
BM271-MSCs and OM-MSCs transfected with miR-146a-5p inhibitor and 
mimic (A). Cells were also transfected with a “scrambled” miRNA (-ve 
control) and H
2
O (no miRNA control). Figure B is a Graphical representation 
of this western blot analysis. Densitometry of each protein band was 
analysed using ImageJ software, and values for CD95 were calculated 
relative to the loading control protein GAPDH. Statistical analysis was 
carried out by 1 way ANOVA using Tukey’s multiple comparison test, where 
*=p<0.05, **=p<0.01, ***=p<0.005, and ****=p<0.001. n=3.  
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BM271-MSCs and OM-MSCs transfected with miR-146a-5p showed 
significantly higher levels of CD95 expression compared to their respected 
cells transfected with miR-146a-5p mimic (p<0.05). BM271-MSCs 
transfected with miR-146a-5p inhibitor also showed a significantly higher 
expression of CD95 compared to OM-MSCs transfected with mimic (p<0.05), 
and to OM-MSC negative controls (p<0.05). Although expression of CD95 
was higher in BM271-MSC controls compared to OM-MSC controls, this 
difference was not statistically significant. 
 
5.5. Determining the Relationship Between miR-335-5p and 
Proliferation 
In section 3.2 it was demonstrated that OM-MSCs showed a significantly 
higher rate of proliferation compared to both BM-MSCs and BM271-MSCs 
(p<0.001). This observation may be quite pertinent with regards to miR-
335-5p, which Figure 3.4 showed was upregulated 7.6 fold in BM271-MSCs 
compared to OM-MSCs. Tomé et al. (381) demonstrated a relationship 
between miR-335-5p and cell proliferation via the Wnt signalling pathway 
which regulates miR-335 expression. To try and confirm this relationship 
with proliferation, a transfection of BM271-MSCs and OM-MSCs with mimic 
and inhibitor of miR-335-5p was carried out using the same transfection 
methods as in sections 5.3 and 5.4. 
 
5.5.1. RT-qPCR Confirms the Viability of the miR-335-5p 
Transfection 
Before determining any effect of miR-335-5p manipulation on MSC 
proliferation, the transfection itself had to be validated. Transfection of 
each cell type was carried out in a similar manner as described in sections 
5.3.1 and 5.4.2, only using miR-335-5p as the target transcript. Figure 5.18 
shows the validation of the mimicking and inhibition of miR-335-5p in 
BM271-MSCs and OM-MSCs. Cells transfected with a “scrambled” miRNA 
transcript was used as a negative control. Due to the vast difference in 
expression of miR-335-5p between the inhibited and mimicked samples, log 
values of the actual quantities were plotted onto the graphs. In both 
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BM271-MSCs and OM-MSCs, cells transfected with miR-335-5p mimic 
expressed a significantly higher level of miR-335-5p compared to those 
transfected with miR-335-5p inhibitor (p<0.001) (Figure 5.18A and 5.18B). 
Mimic transfected cells also showed a significant increase in miR335-5p 
expression compared to negative controls (BM271-MSCs = p<0.005 (Figure 
5.18A), OM-MSCs = p<0.01 (Figure 5.18B)), and BM271-MSCs transfected 
with miR335-5p inhibitor showed a significant decrease in miR-335-5p 
expression compared to negative controls (p<0.01) (Figure 5.18A). 
 
5.5.2. Manipulation of miR-335-5p Led to Changes in Proliferation 
of BM271-MSCs and OM-MSCs 
To assess any effect of mimicking and inhibition of miR-335-5p on MSC 
proliferation, transfected BM271-MSCs and OM-MSCs were fixed in 4% PFA 
and mounted onto glass cover slips using a mounting media containing the 
fluorescent nuclear dye DAPI. Samples of each MSC type under each 
condition were imaged under UV at 24, 48, and 72 hours post-transfection 
(Figure 5.20) and cell counts plotted against each other (Figure 5.19).  
 
 
 
 
Figure 5.18: RT-qPCR analysis on BM271-MSCs and OM-MSCs transfected 
with miR-335-5p inhibitor and mimic, and with a “scrambled” miRNA (-ve 
control). Analysis was for the presence of miR-335-5p, 24, 48, and 72 hours 
post-transfection to demonstrate the effectiveness and transience of the 
transfection. Due to the substantial difference between cells transfected 
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with inhibitor and mimic, log values were calculated, and their means 
plotted. Statistical analysis was carried out by 2 way ANOVA using Tukey’s 
multiple comparison test, where *=p<0.05, **=p<0.01, ***=p<0.005, and 
****=p<0.001, n=3.  
 
 
 
 
 
Figure 5.19: Representative images from n=3 BM271-MSCs and OM-MSCs 
transfected with miR-335-5p inhibitor and mimic, and with a “scrambled” 
miRNA (-ve control). Cell nuclei was stained with DAPI, and counted using 
CellProfiler Cell Image Analysis Software. Images were taken at x10 
magnification, with the scale bar representing 100 μm.  n=3. 
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Figure 5.20: Graphical representation of the proliferation of BM271-MSCs 
and OM-MSCs transfected with miR-335-5p inhibitor and mimic, and 
“scrambled” miRNA (-ve control). DAPI stained nuclei was counted using 
CellProfiler Cell Image Analysis Software, and statistical analysis was 
carried out by 2 way ANOVA using Tukey’s multiple comparison test, where 
*=p<0.05, **=p<0.01, ***=p<0.005, and ****=p<0.001. n=3. 
 
Due to the relatively slow proliferation rates of BM271-MSCs under normal 
conditions, there was no significant difference in proliferation rates 
between either of the transfected conditions. There was a significant 
difference in proliferation between OM-MSCs transfected with miR-335-5p 
inhibitor and those transfected with mimic, however neither of these were 
significantly different to the control condition. These observations suggest 
that, while miR-335-5p may be involved in regulating certain molecules 
which are involved in cell proliferation, this may only be one of many 
mechanisms involved, and simply inhibiting or mimicking the production of 
miR-335-5p would not be sufficient to control the vast difference in the 
rates of proliferation between BM271-MSCs and OM-MSCs. 
 
5.6. Discussion 
Previously it was demonstrated that secreted factors from OM-MSCs but not 
BM-MSCs promoted myelinaton in vitro (Lindsay et al. (1)). Thus far, except 
for a significantly higher Nestin expression and proliferation rate, OM-MSCs 
have proved to be almost indistinguishable to their bone marrow-derived 
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counterparts. Throughout this chapter we analyse both MSC types at a 
molecular and miRNA level to better understand the underlying 
mechanisms which are responsible for OM-MSCs ability to stimulate myelin 
production in our myelinating culture system. 
 
In collaboration with Sistemic we carried out a SistemQC™ miRNA 
fingerprint analysis on BM271-MSC and OM-MSC samples, and discovered a 
64% homology in miRNA expression between BM271-MSCs and OM-MSCs, i.e. 
125 of the 195 identified miRNAs were equivalently expressed (EE) 
between the two MSC types. Guo et al. (382) and Gao et al. (383) had 
previously identified 27 of these 125 miRNAs as being associated with BM-
MSCs, but no such studies have been carried out using OM-MSCs. 13% (26 of 
195 identified miRNAs) were considered to be differentially expressed 
(DE), leaving 23% of identified miRNAs as neither equivalently nor 
differentially expressed under Sistemic’s experimental conditions. A 
focused contextual approach was adopted whereby miRNAs associated with 
MSC biology were identified. We chose miR-335-5p, miR-146a-5p and miR-
140-5p from the DE kmiRTM list. Networks were built around these three 
miRNAs consisting of high-confidence mRNA targets for each miRNA. miR-
140-5p, miR-146a-5p, and miR-335-5p have previously been associated with 
myelination (379, 419), cell survival (380), and proliferation (381) 
respectively; three behaviours which have been identified as significantly 
different between the two MSC types throughout. Focus therefore would 
be on these three miRNA for the remainder of the study. Each of these 
miRNAs were confirmed by RT-qPCR as significantly differentially 
expressed in BM271-MSCs compared to OM-MSCs. 
 
Since previous studies have identified that chemokines could inhibit 
myelination (66), and that MSCs are known to secrete high levels of 
cytokines/chemokines (207, 214, 384-394) we were interested to see if 
there was a differential secretion of these by the two types of MSC. 
Luminex cytokine arrays, analysing molecules secreted by BM-MSCs, BM271-
MSCs, OM-MSCs, Fibroblasts, and the flow through cells from BM- and OM-
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MSC CD271 positive selection identified 4 cytokines which were secreted at 
significantly higher levels from OM-MSCs compared to all other cell types, 
or from BM-MSCs compared to all other cell types. Interleukin-9 (IL-9) and 
Granulocye colony stimulating factor (G-CSF) were secreted at significantly 
higher levels in BM-MSCs compared to all others. This could be expected 
considering the bone marrow niche, as IL-9 is a cytokine produced by T 
cells and Mast cells (420), and is important in the regulation of 
haematopoietic stem cells (421), and G-CSF, otherwise known as Colony 
Stimulating Factor 3, is a glycoprotein that is secreted by a number of 
immune cells which acts on precursor cells in the bone marrow, stimulating 
them to produce granulocytes and haematopoietic stem cells (422, 423). 
CCL11 (CCL11) and CXCL12 were both secreted at significantly higher 
levels from OM-MSCs compared to all other cell types, and have both been 
associated with myelination. CCL11, is a chemokine which is pertinent in 
the body’s allergic response as it recruits eosinophils by chemotaxis (424-
426). It has also been shown to decrease neurogenesis and hippocampal 
cognitive function in mice (427). It has been implicated in having a pro-
myelinating effect by acting on its receptor CCR3 which is expressed on 
oligodendrocytes (428, 429), thus stimulating myelin production. CXCL12, 
is a ubiquitous chemokine which is secreted by a number of cells 
throughout the body (430-432), acting on its receptors CXCR4 (408-410, 
414) and CXCR7 (411-414) to direct migration of cells such as 
haematopietic stem cells (432), astrocytes (407), neuronal cells (433), and 
immune cells (395). Like CCL11, it has been associated as having a pro-
myelinating effect by acting on its receptors CXCR4 and CXCR7 which are 
also expressed on oligodendrocytes (395-399, 407, 410-414, 433).  
 
Previous studies had shown a relationship between miR-140-5p and 
myelination, and also that miR-140-5p has an inverse relationship with 
CXCL12 (379, 419). This coupled with the decreased expression of miR-140-
5p and increased secretion of CXCL12 in OM-MSCs observed in Figures 5.4 
and 5.5, could suggest that the myelinating potential of OM-MSCs observed 
by Lindsay et al. (1) may be due, at least in part, to CXCL12.  
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The pro-myelinating effect of rat OECs observed by Lamond et al. (163) 
was also investigated in comparison to rat OM-MSCs to try and identify any 
commonly secreted cytokines between the two cell types, and also any 
commonly secreted cytokines between rat BM-MSCs and rat Schwann cells 
which have a de-myelinating effect on myelinating cultures (163). A 
number of cytokines common to both OECs and OM-MSCs were identified; 
MIP-2, IP-10, RANTES, Fraktalkine, and LIX were all secreted at 
significantly higher levels in OECs and OM-MSCs compared to BM-MSCs and 
Schwann cells, suggesting that there may be a possible stimulatory effect 
elicited by them on the in vitro myelination model. Interestingly though, 
despite the significant increase in secretion in OM-MSCs, ablation of MIP-2 
(otherwise known as CXCL2) has been shown to have a neuroprotective role 
in the CNS by suppressing macrophage accumulation (434), so may not play 
any role in myelination. IP-10 (CXCL10), as previously discussed, has been 
shown to inhibit myelination (66) but it is possible that this could play a 
role in regulating myelin production so as to maintain equilibrium. RANTES 
(CCL5) however, could play a more direct role in myelination, as CCL5 
defects have been identified in experimental autoimmune 
encephalomyelitis (EAE) mice, an in vivo model for de-myelinating 
disorders (435). Fractalkine (CX3CL1) has been shown to be highly up-
regulated in EAE mice (436) which could suggest a potential role for this 
chemokine in neuroregeneration. The final chemokine which was up-
regulated in OM-MSCs and OECs compared to BM-MSCs and Schwann cells 
was LIX (CXCL5). Stongly implicated in inflammatory conditions (437), 
CXCL5 has been identified as having a demyelinating effect, along with 
MIP-1α (438). This is contrary to what you might speculate from the 
significantly high secretion in OM-MSCs and OECs, but does support the 
significantly high secretion of MIP-1α seen in BM-MSCs and Schwann cells. 
These data indicate that more extensive work needs to be carried out on 
these chemokines to make any connection between them and an actual 
effect on myelination, or on any other biological functions which could 
potentially be modulated in this manner. 
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The connection between CXCL12 and OM-MSCs was confirmed earlier in this 
chapter. By blocking CXCR4 and CXCR7, and applying a CXCL12 neutralising 
antibody to OM-MSC-CM, we could firmly establish that CXCL12 was indeed 
secreted by OM-MSCs and was capable of increasing myelination in vitro. 
The relationship between CXCL12 and miR-140-5p was also confirmed by 
showing that CXCL12 secretion, and thus myelination, could be 
manipulated by inhibition and mimicking of miR-140-5p. Also identified 
was a potential relationship between CCL11 and miR-140-5p, when it was 
demonstrated that, as with CXCL12, mimicking of miR-140-5p significantly 
decreased the secretion of CCL11 from BM271-MSCs. This was discussed 
earlier as having a potential association with myelination, although further 
study will have to be carried out to determine any effect of CCL11 on our 
myelinating cultures.  
 
Other chemokines outlined in this same array as being potentially 
regulated by miR-140-5p were MCP-1, IL-6, IL-8, and G-CSF. MCP-1, also 
known as CCL2 and small inducible cytokine A2, is a chemokine which 
recruits monocytes, memory T cells, and dendritic cells (439, 440) and has 
been associated with neuroinflammation (441), where its expression by 
glial cells is upregulated in a number of degenerative conditions in the CNS 
(442-447). As miRNAs generally have an inverse relationship with signalling 
molecules, it is unlikely that the significant increase in MCP-1 secretion in 
BM271-MSCs transfected with miR-140-5p mimic is due to a direct effect on 
MCP-1 by miR-140-5p, but it may be that enhanced inhibition of a separate 
downstream effector is resulting in an enhanced secretion of MCP-1. 
Interleukin 6 (IL-6) acts as a pro-inflammatory cytokine and anti-
inflammatory myokine, and is important is a number of inflammatory 
conditions (448-451). It is also secreted by osteoblasts to induce bone 
resorption (452), which may explain why it is present in relatively high 
concentrations in BM271-MSC under control conditions. Its significantly 
higher secretion in cells transfected with miR-140-5p mimic might also 
suggest that this is perhaps not due to a direct relationship, but rather the 
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upstream effect of another molecule being inhibited directly by miR-140-
5p. Interleukin 8 (IL-8), also known as neutrophil chemotactic factor, is 
another pro-inflammatory cytokine that induces chemotaxis in neutrophils 
and granulocytes so they migrate to the site of injury (453). As before, the 
observed effect is likely upstream of the direct inhibitory effect by miR-
140-5p of a related chemokine. G-CSF was described previously as it was 
highlighted as being differentially secreted by OM-MSCs compared to 
BM271-MSCs (Figure 3.5). As miR-140-5p is upregulated in BM271-MSCs 
compared to OM-MSCs, mimicking miR-140-5p should result in a decrease in 
secretion of any molecule directly regulated by miR-140-5p, therefore the 
observed increased secretion of G-CSF in BM271-MSCs transfected with 
miR-140-5p mimic must mean that G-CSF is regulated by a separate 
downstream effector which is directly regulated by miR-140-5p. 
 
A possible mechanism for the increased survival rates of OM-MSCs 
compared to BM-MSCs was explored via the miR-146a-5p relationship with 
the death receptor CD95. Figure 5.15 showed a significantly higher 
expression of CD95 in BM271-MSCs under normal conditions, which could be 
manipulated by inhibition and mimicking of miR-146a-5p (Figure 5.17). 
 
A connection between miR-335-5p and proliferation was also explored 
using the same transfection techniques (Figures 5.19 and 5.20), although 
BM271-MSCs were not able to be manipulated in such a way as to increase 
their proliferation to that of OM-MSCs, suggesting that many more 
mechanisms are responsible for this difference than simply the effect of 
miR-335-5p. 
 
As previously stated, there have been numerous studies associating CXCL12 
and CCL11 with myelination via various mechanism and cell types such as 
astrocytes, neuronal cells, optic nerve cells, and oligodendrocytes, but 
none have made the connection with the pro-myelinating effect of CXCL12 
via OM-MSCs or of CCL11 via OM-MSCs. Here the pro-myelinating effect of 
OM-MSCs can be attributed, at least in a contributory way, to the secretion 
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of CXCL12 which is regulated by miR-140-5p. The effect of CCL11 on our in 
vitro myelination model was not investigated here, but there is a case for 
the potential of CCL11 to influence myelination also, and that it too is 
regulated by miR-140-5p. 
 
The secretome of the MSC is of vast important for vital biological 
functions, from immunomodulation (454-458) to regulation of 
haematopoiesis (459-462). Secretomes of MSCs from other niches such as 
umbilical cord have been shown to differ slightly from that of bone 
marrow-derived MSCs (388), but no studies have focused on the secretome 
of the OM-MSC. Not shown in this study were the full results of each 
cytokine array that was carried out, showing all of the cytokines that were 
expressed by both BM-MSCs and OM-MSCs. As a comparative study, my 
focus was on the differentially secreted cytokines, so equivalently secreted 
cytokines were not mentioned. Park et al. however, carried out an 
extensive study into the secretome of BM-MSCs (388), listing 120 cytokines 
found to be secreted by BM-MSCs. Interestingly, all of the cytokines found 
to be secreted by BM-MSCs and OM-MSCs during my analysis were found to 
be secreted by BM-MSCs in this study, which further validates both my 
data, and the identity of OM-MSCs as a unique MSC phenotype. This shows 
that although BM-MSCs and OM-MSCs share a similar secretome which is 
typical of the known MSC secretome, certain cytokines are secreted at 
significantly different levels from either BM-MSCs or OM-MSCs, suggesting 
that their niche may be regulating the secretion of certain cytokines, and 
thus the biology of the MSC, depending on its behavioural requirement in 
that particular environment. 
 
As previously discussed with regard to the differentially secreted 
cytokines, they each have uniquely separate chemotactic or 
immunomodulatory functions. Although they may not be related to 
myelination, cell survival, or cell proliferation as focused on in this study, 
their differential expression suggests that they play a distinct role in 
regulating their niche via other mechanisms, which are very specific to 
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that particular niche. For example, a number of distinct signalling 
pathways such as wnt (463, 464), BMP (465), and notch (459, 466) regulate 
haematopoiesis via cytokines secreted by BM-MSCs. It would be very 
interesting to see if these same pathways are activated in a similar way by 
OM-MSCs whose primary role in the olfactory system may not be associated 
with haematopoiesis. 
 
Throughout this chapter we demonstrated that the secretion of cytokines 
such as CXCL12 and CD95 could be manipulated by targeting their 
upstream regulatory miRNA. This has been demonstrated in other studies 
that have identified miRNA as targets for pathway regulation. For example, 
Selvamani et al. (467) demonstrated that the NF-κB pathway can be 
regulated by targeting miR-146a-5p.  NF-κB was identified in Figure 3.14 by 
Sistemic’s miRNA network map to be regulated by miR-146a-5p, and is a 
ubiquitous cytokine with numerous modulatory effects throughout the body 
such as Nitric Oxide production (468), cancer cell migration (469), 
apoptosis (470), and neuroinflammation (513). This ability to control 
cytokine secretion, and the promiscuity of these cytokine/miRNA 
relationships (numerous cytokines regulated by the same miRNA), mean 
that these targeting strategies have great therapeutic potential for the 
future. 
 
5.7. Summary  
 miR-140-5p and miR-335-5p are upregulated 3.7 and 7.6 fold 
respectively in BM271-MSCs compared to OM-MSCs, and miR-146a-5p is 
downregulated 15.5 fold in BM271-MSCs compared to OM-MSCs 
 Cytokine arrays demonstrate a relationship between CXCL12 and 
CCL11 with the myelination associated miR-140-5p 
 Pro-myelinating effect of CXCL12 is confirmed, and this effect is 
shown to be related to the secretion of CXCL12 by OM-MSCs 
 Pro-myelinating effect of CXCL12 can be manipulated by controlling 
expression of miR-140-5p, as can levels of CCL11 
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 Rat cytokine arrays demonstrate comparable secretion patterns of 
cytokines MIP-2, IP-10, RANTES, Fraktalkine, and LIX in pro-myelinating 
cells OECs and OM-MSCs which isn’t seen in de-myelinating cells BM-MSCs 
and Schwann cells 
 Relationship between miR-146a-5p and “death receptor” CD95 was 
confirmed, suggesting a possible mechanism for the increased survival 
rates of OM-MSCs 
 Manipulation of miR-335-5p showed significant differences in 
proliferation between OM-MSCs transfected with inhibitor and mimic of 
miR-335-5p but not compared to controls 
 No significant difference in proliferation of BM271-MSCs was observed 
after transfection with inhibitor and mimic of miR-335-5p, suggesting 
additional mechanisms responsible for the observed difference in 
proliferation between the two MSC types  
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Discussion: 
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6. General Discussion 
6.1. Overview 
MSCs generated from any cellular niche within the body have a number of 
defining properties. As stem cells, they have the ability to self-replicate 
and to differentiate to a fully mature functioning cell, which is true for all 
stem cells. What makes MSCs unique is their combined ability to form any 
cell of mesenchymal lineage (bone, fat cartilage, connective tissue, and 
muscle), their ability to migrate to a specific site of injury, their plastic 
adhesion capabilities, their immunomodulatory effects, their “bystander 
effects” due to their substantial secretome, and their potential (disputed) 
to trans-differentiate towards cells of other lineages such as neurons (39, 
40). It is the combination of these traits which separate MSCs from all 
other adult stem cells, and which give them such exciting potential in the 
field of regenerative medicine. These traits are true of all MSCs throughout 
the body, but are MSCs from different niches really the same? Do they 
express the same genes and possess the same cell surface markers? Do they 
differentiate in the same way or react to the same substrates in the same 
way? Do they have the same secretomes and pre-translation mechanisms? 
And most importantly of all, do they produce the same effect on various 
other biological systems that they will contact within the body, and thus 
have the same therapeutic potential? These are all questions which were 
addressed throughout this thesis when comparing MSCs from two 
completely distinct cellular niches; the bone marrow and the more 
neurogenic olfactory system.  
 
It had been previously shown that MSCs from the olfactory system possess a 
pro-myelinating effect which is not observed with MSCs from the bone 
marrow. This thesis explored the differences and similarities of both MSC 
phenotypes to try and understand any underlying mechanisms pertaining to 
this effect, and more importantly, if these mechanisms can be potentially 
manipulated for therapeutic benefit with regards to certain 
neurodegenerative conditions such as Multiple Sclerosis and Spinal Cord 
Injury. 
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6.2. Summary of Results 
Due to the different isolation methods of BM-MSCs and OM-MSCs, BM-MSCs 
were separated into two types; BM-MSCs which were isolated from bone 
marrow using normal plastic adhesion methods, and BM271-MSCs which 
were first isolated in this manner, and then underwent the same CD271 
isolation as the OM-MSCs. This was to eliminate any question of effect of 
the different isolation methods on the cell’s behaviour. Imaging under 
phase microscopy showed that each of the three MSC phenotypes were 
morphologically indistinguishable under normal culture conditions. 
 
Behavioural analysis showed that OM-MSCs proliferated at a significantly 
higher rate than both BM phenotypes, which were very similar in their 
proliferation rates. This difference in proliferation was substantial, with 
OM-MSCs generating almost 100x more cells than both BM phenotypes after 
25 days. This related to anecdotal observations of a fully confluent flask of 
OM-MSCs a week after isolation, compared to one month after isolation of 
BM-MSCs. 
 
Profiling of each cell type comparing mRNA expression, and 
immunoreactivity of a number of MSCs markers, showed that each MSC 
type expressed all MSC classical markers at both a pre- and post-
transcriptional level, except for the early MSC marker Stro-1, which was 
only expressed in around 40% of BM-MSCs. The lack of Stro-1 observed in 
OM-MSCs could be due to the fact that they simply don’t express it, or that 
CD271 cells do not co-express Stro-1, and therefore all Stro-1 cells were 
lost during the isolation process. This reason could also be put forward for 
the lack of Stro-1 expression observed in BM271-MSCs, but this could also 
be down to the extended periods in which BM271-MSCs remain in culture 
due to the CD271 antibody mediated isolation process. Although each MSC 
type expressed all the same markers (except Stro-1), levels of expression 
of some of these markers were not the same. For example, levels of classic 
MSC markers CD90, CD166, and CD271 were significantly higher in OM-MSCs 
and BM271-MSCs at either mRNA or protein level, suggesting a “purer”, 
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possibly more homogenous population of MSCs. Most interestingly however, 
was the significantly higher expression of Nestin mRNA and protein in OM-
MSCs compared to both BM-MSC phenotypes confirming previous data of 
Delorme et al. (36). Nestin is not just an MSC marker but also a marker of a 
number of neuroectoderm-derived cells such as neurons and glia. Nestin 
expression was also significantly higher in non-purified OM tissue and OM-
flowthrough cells compared to both BM-MSC types and fibroblasts, 
suggesting that this is likely associated with the olfactory niche. Nestin is 
also down regulated upon differentiation, and is associated with immature 
cells and cells which are generated post-pathological scenarios (471, 472). 
The vulnerable nature of the OM could be a possible explanation for this 
elevated nestin expression, and perhaps even the observed increase in 
proliferation. It is important to add that when compared against 
fibroblasts, it was demonstrated that neither MSC type exhibited a similar 
mRNA or profile of markers, and thus the OM-MSCs can be considered as 
legitimate MSC phenotypes. Figure 6.1 outlines the numerous different MSC 
phenotypes and their resident niches. I have added the olfactory mucosa to 
the figure as a new niche, as OM-MSCs have been shown to be a new 
addition to the MSC family, and a viable, easily accessible alternative to 
BM-MSCs for MSC transplant-based therapies. 
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Figure 6.1: Schematic diagram representing the different MSC niches 
throughout the body. Adapted from Kuhn and Tuan (473). 
 
Comparison of the differentiation capabilities of each MSC type 
demonstrated that each had the ability to form bone and fat, but that non-
purified BM-MSCs produced significantly more bone and fat than OM-MSCs, 
and more fat compared to BM271-MSCs. These comparisons also show 
BM271-MSCs produced significantly more bone and fat than OM-MSCs. Non-
purified BM-MSCs contain not just MSCs but also a range of mesenchymal 
progenitors (474). These data suggest that these progenitors are 
contributing to the increased bone and fat production, and that they may 
be lost during the CD271 selection process. The data also suggests that 
there may be an inherent niche-dependant effect on OM-MSCs which may 
be preventing them from differentiating into bone and fat as efficiently as 
those derived from BM, such as an increased expression of Nestin perhaps? 
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Due to the neuroregenerative nature of the OM, and the lack of 
mesenchymal tissue, the production of bone and fat may not be the 
primary role of MSCs within the OM. 
 
Analysis of differentiation potential was not limited to bone and fat 
however, nor was it limited to media induced differentiation. BM271-MSCs 
and OM-MSCs were induced under different media conditions to 
differentiate towards neuronal, myogenic, and glial lineages. RT-qPCR 
showed a significant increase in expression of mRNA associated with each 
of these lineages in treated BM271-MSCs compared to untreated controls, 
except MAP2, a neuronal marker, which showed a trend of increased 
expression which was not significant. Any increased expression of these 
mRNA observed in OM-MSCs was either lower than that observed in BM271-
MSCs or not significant. These data add credence to the hypothesis that 
the immature (Nestin positive) state of OM-MSCs, and the 
neuroregenerative, non-mesenchymal OM niche are not conducive to the 
production of mesenchymal tissue being the primary function of the OM-
MSCs. i.e. OM-MSCs may help to generate new bone, fat and cartilage 
tissue in the nose and skull, but the soft tissue, neurogenic environment 
where they reside could require OM-MSCs to provide a more “bystander 
effect” role such as regulating neurogenesis via their secretome.  
 
The ability to induce MSC differentiation along specific lineages was not 
limited to culture condition but could also be instigated by substrate 
topography (46, 256, 325, 331-334). Each cell type was cultured on 
nanotopography embossed PCL, a substrate that had been shown from 
previous studies to induce osteogenic differentiation (257). I observed an 
enhanced ability for BM-MSCs and BM271-MSCs to express not only mRNA 
associated with osteogenesis, but mRNA associated with other lineages 
too, compared to OM-MSCs. Immunocytochemistry showed that not all of 
these mRNA were translated into their respective proteins, but did 
demonstrate an increase in IR for OPN, OCN, SMA, Tuj-1, and GFAP, each 
of which can be associated with osteogenic differentiation. As before, each 
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of these proteins were expressed at significantly higher levels in BM- or 
BM271-MSCs compared to OM-MSCs, suggesting an enhanced ability for 
nanotopography induced osteogenic differentiation in MSCs derived from 
the bone marrow compared to those derived from the olfactory mucosa. 
No work has been done using these particular surfaces and MSCs from other 
niches, and indeed very little work has been carried out using MSCs 
isolated from other niches on any nanotopographies, however, Nemeth et 
al. (475) has shown an enhanced chondrocytic differentiation of dental 
pulp MSCs when cultured on nanopatterned hydrogels, and adipose-derived 
MSCs have been differentiated towards an endothelial lineage using 
nanograted quartz substrates (476). Little is known about the mechanisms 
of differentiation by cell/nanotopography interactions, but a number of 
studies have put forward hypotheses. Teo et al. and McNamara et al. (46, 
477) both discuss how specific nanotopographies guide signals through the 
extracellular matrix via proteins such as Focal Adhesion Kinase (FAK). This 
triggers their phosphorylation, and in turn stimulates numerous signalling 
cascades which terminate in the nucleus and lead to specific translational 
events, such as increased production of bone proteins such as Runx2 and 
osteopontin. These hypotheses relate only to BM-MSCs however, as no such 
studies have been carried out using MSCs from any other niches. 
Importantly, with regards to my findings, although increases in expression 
of MAP2 mRNA and MyoD mRNA were observed, there was no evidence that 
any trans-differentiation occurred under these conditions. Additionally, by 
this stage in the thesis, there was nothing to suggest that any observed 
differences between BM- and OM-MSCs would be affected by the CD271 
positive selection process, therefore only BM271-MSCs would be used as a 
comparison against OM-MSCs henceforth. 
 
Analysis of pre-translational differences between BM271- and OM-MSCs 
enabled the investigation into possible mechanisms behind the pro-
myelinating effects of OM-MSCs observed by Lindsay et al. SistemQC™ 
miRNA fingerprinting carried out by Sistemic uncovered a 64% homology in 
the miRNA expression of BM- and OM-MSCs, but more importantly, showed 
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26 miRNA which were significantly differentially expressed between the 
two MSC phenotypes. Through previous studies, three of these miRNA; miR-
140-5p, miR-146a-5p, and miR-335-5p were linked to three important 
biological differences which have been observed between BM- and OM-
MSCs; myelination, cell survival, and proliferation respectively. These 
differential expression were confirmed by RT-qPCR, and cytokines 
networks were provided by Sistemic, outlining a number of different 
cytokines known to regulated by each miRNA. 
 
The secretomes of both cell types were compared to investigate any 
cytokines which were secreted at a significantly different concentration, 
and if so, to identify any links between them and the differentially 
expressed miRNA. A number of different cytokines were identified such as 
CCL11, and CXCL12, which have also been previously associated with 
myelination (424, 429). CXCL12 now became a very important molecule, as 
it had not only been shown to be secreted at a significantly higher 
concentration in OM-MSCs compared to BM271-MSCs and to OM-flowthrough 
cells, but had also been previously identified as being regulated by miR-
140-5p, which was shown to be upregulated significantly in BM271-MSCs 
compared to OM-MSCs. This particular miRNA is important, as miR-140-5p 
has previously been associated with influencing CNS axonal myelination 
(379, 419). These data suggested that the decrease in miR-140-5p 
expression in OM-MSCs could lead to an increase in CXCL12 secretion, and 
thus a potential pro-myelinating effect. The pro-myelinating effect of 
CXCL12 was confirmed by its addition to the myelinating culture system at 
100 ng/µL, and it’s connection to OM-MSCs was confirmed using AMD3100, 
a blocker of CXCR4 and CXCR7 on which CXCL12 acts, and a neutralising 
antibody to CXCL12. When these were added to the myelinating culture 
system prior to the addition of pro-myelinating OM conditioned media, the 
result was a significant decrease in myelination. This confirmed that the 
promyelinating effects of OM-MSCs were at least in part due to the 
secretion of CXCL12. Further to this, it was demonstrated that the 
secretion of CXCL12 could be manipulated by targeting miR-140-5p. 
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Transfection of both MSC types with an inhibitor of miR-140-5p led to a 
significant increase in the secretion of CXCL12, which in turn led to an 
increase in myelination when the conditioned media from these 
transfections was added to the myelinating cultures.  
 
This targeting was also carried out for miR-146a-5p, which has been 
associated with cell survival due to its regulation of FasR (CD95), a “death 
receptor” which triggers apoptosis. The ~15 fold increase in expression of 
miR-146a-5p in OM-MSCs compared to BM271-MSCs was proposed as a 
potential hypothesis as to why OM-MSCs are able to survive many more 
passages than BM271-MSCs. Western blotting confirmed that expression of 
CD95 was expressed at a significantly lower level in OM-MSCs compared to 
BM-MSCs, and also that CD95 expression could be manipulated by 
transfecting the cells with either an inhibitor or mimic of miR-146a-5p. 
Further experiments would have to be carried out however, to determine 
whether or not this manipulation of CD95 would actually have a significant 
effect of the cell survival rates of these MSCs. 
 
Finally, under the same transfection procedure, miR-335-5p was targeted 
to determine any potential manipulation of cell proliferation rates. A 
considerable benefit of OM-MSCs over BM-MSCs is there advanced 
proliferative capacity, and miR-335-5p has been previously implicated in 
the regulation of cell proliferation. If BM-MSCs could be manipulated to 
achieve the same rates of cell production by way of a simple transfection, 
this would be of enormous benefit in MSC research. This experiment 
however, yielded little significant data. Although trends were observed 
which suggested an effect between OM-MSCs transfected with miR-335-5p 
inhibitor and miR335-5p mimic, these observations were not significant 
when compared to controls. BM271-MSCs which were transfected with miR-
335-5p inhibitor certainly showed no suggestion of an ability to increase 
their proliferation via this mechanism. miR-335-5p may play a role in cell 
proliferation, but there are likely many other mechanisms involved, and 
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this one-step approach to manipulating MSC proliferation is unfortunately 
not a viable one. 
 
6.3. Observed Differences 
These data offer up a number of differences between MSCs derived from 
bone marrow and from the olfactory system. Their MSC phenotype has 
been firmly established, so why are OM-MSCs so different when they 
originate from the same mesenchymal lineage as BM-MSCs? I would first 
approach this question by asking, are OM-MSCs definitely from the 
mesenchymal lineage? As mentioned in the introduction, there are a 
population of ectodermally-derived mesenchymal cells which originate at 
the neural crest. These cells go on to form the bone and cartilage in the 
head, so it may be possible that OM-MSCs have their origins in the neural 
crest as opposed to the mesodermally derived BM-MSCs. Studies have 
looked at the potential of using neural crest mesenchymal cells in the 
treatment of SCI repair (478, 479), and Achilleos et al. has looked at 
neural crest stem cells in great detail regarding their properties and 
therapeutic potential (480), but there has been no direct comparison 
between mesodermally-derived BM-MSCs and ectodermally-derived 
mesenchymal cells (EDMCs), or indeed between OM-MSCs and EDMCs, so it 
may be that OM-MSCs and BM-MSCs do not share the same origins after all. 
Assuming that they do though, the observed differences must surely be a 
niche effect? The BM-MSC niche is an encapsulated, protected, and 
predominantly stromal environment. Matrices are stiff and topographies 
are rough, conducive of osteogenesis and chondrogenesis, but also with 
cues to encourage adipogenesis (248, 481). BM-MSCs are also the minority 
stem cell in the bone marrow which is essentially a haematopoietic niche 
with a slow and steady cell turnover (312-314). The olfactory mucosa is in 
complete contrast to bone marrow. Consisting predominantly of soft 
tissue, it is exposed with only the protection of a mucous membrane, and 
is therefore an area of high cellular turnover (1, 35, 36, 142). OM-MSCs are 
also the minority stem cell within the OM, which is essentially a neurogenic 
niche, so even if OM-MSCs and BM-MSCs are both mesodermally-derived 
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MSCs, they may perform very distinct functions driven by niche-dependant 
external cues. The chemokine arrays carried out in section 3.2.1 of the 
results showed an increased secretion from BM-MSCs of chemokines such as 
IL-9, a very important cytokine in the regulation of haematopoiesis (421), 
and IL-6 which is secreted by osteoblasts and is important in bone 
resorption (452). Whereas significant increases in the secretion of 
chemokines such as CCL11 and CXCL12 were observed in OM-MSCs, both of 
which are important in neurogenesis, glial proliferation, and myelination 
(395-399, 407, 410-414, 428, 429, 433). These observations add credence 
to the hypothesis that these two distinct MSC phenotypes have distinct 
inherent behaviours which are guided by the necessity of their particular 
niche for them to carry out particular functions which are unique to that 
niche. It would be very interesting to carry out in vivo experiments where 
each MSC is ectopically transplanted into the other’s niche to investigate 
the niche effect further. Perhaps neurogenesis in the OM might be 
impaired by a replacement of OM-MSCs by BM-MSCs, or perhaps the BM-
MSCs may inherit the features and behaviours of the OM-MSCs over time in 
the OM niche.   
 
OM-MSC, although from a very different, neurogenic niche have very 
similar properties to BM-MSCs, and due to their promyelinating capacity 
could indeed be considered as viable alternatives to BM-MSCs. Moreover, 
their more accessible location within the olfactory mucosa adds extra 
credence to this proposal. 
 
6.4. Therapeutic Potential of Phenotypic Differences 
The observed differences between OM-MSCs and BM-MSCs have great 
research potential. The extensive proliferative capacity of OM-MSCs is a 
great asset in terms of tissue culture. One of the limitations of BM-MSCs in 
research is their slow proliferation. From a 20 mL bone marrow aspirate (a 
normal size from a patient donation), it is common to isolate a very small 
number of MSCs, often <20 cells. Under optimal conditions you may be able 
to bulk these 20 cells up to ~106 cells after one month in culture, by which 
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time you may already have passaged them twice. With only a maximum of 
six passages per sample, you really require a constant supply of bone 
marrow aspirates to allow for the amount of cells required for 
experimental purposes. Without a constant supply, often some techniques 
which require large volumes of cells, like FACS analysis for example, have 
to be discounted. With OM-MSCs however, their rate of proliferation is so 
high, and the cells are so much more robust, that 20 MSCs isolated from a 
tissue biopsy could be bulked up to ~5x106 within one week, with only one 
passage. This number can be doubled every 2-3 days forthwith, allowing 
for the collection of a vast number of low passage cells very quickly. OM-
MSCs were able to survive passaging far beyond the recommended 6-8 
passages which BM-MSCs cannot exceed, although throughout this study, 
cells were never used beyond passage 5. Anecdotally, OM-MSCs were still 
incredibly robust and viable beyond 10 passages, although their stemness 
was never investigated. BM-MSCs are known to lose their defining markers 
such as Nestin, CD271, and Stro-1 over time, and are also thought to 
spontaneously differentiate towards chondrocytes or osteocytes after 
multiple divisions on plastic surfaces, therefore losing their stemness (482, 
483). It would be very interesting to find out if OM-MSCs are able to 
maintain their stem cell traits over multiple passages. Their enhanced 
expression of Nestin suggests that they may be more embryonic in terms of 
development, so may be able to survive much longer in culture. 
  
MSCs currently have a number of potential therapeutic applications from 
stroke, Alzheimer’s, autoimmune diseases, amyotrophic lateral sclerosis 
(ALS), and SCI, as well as orthopaedic conditions such as osteo imperfecta 
(176-181). These therapies are predominantly focused on the use of BM-
MSCs, but OM-MSCs which display a number of similar behavioural and 
biomolecular properties compared to BM-MSCs can now be considered to be 
a viable alternative source for autologous MSC transplant-based therapies. 
They may also be considered a preferred alternative based on their 
location and relative ease of accessibility compared to BM-MSCs, retrieval 
of which requires very painful and invasive surgery. More research would 
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have to be carried out to determine exactly how viable an alternative they 
are, but the data presented in this thesis certainly highlights their 
potential as such. Connick et al. (197) studied 10 patients of secondary MS 
treated with ex-vivo expanded BM-MSCs, and observed a significant overall 
increase in many of the visual impairments which are symptomatic of the 
disease. It is not possible to determine the exact mechanisms involved in 
this improvement, but it is likely due to a regeneration of the optic nerve 
which gets progressively demyelinated throughout the course of the 
disease. It would be very interesting to see if OM-MSCs, which elicit an 
enhanced myelination response in vitro compared to BM-MSCs, could 
stimulated a more improved response and an increased regeneration of 
symptomatic MS damage.  
 
The differences between BM-MSCs and OM-MSCs outlined in this thesis, and 
by Lindsay et al. also suggest potential therapeutic applications for OM-
MSCs for which BM-MSCs may not be a viable candidate. The significantly 
increased secretion of CXCL12 observed in OM-MSCs is very important in 
terms of regenerative capabilities, especially neuroregeneration. CXCL12 is 
quite a ubiquitously expressed chemokine, acting on receptors CXCR4 and 
CXCR7, which are expressed on a number of different cells throughout the 
body (414). This receptor/ligand interaction results in the proliferation, 
and thus increased activity of the cells which express either (or both) 
receptor(s) (398, 414, 433). This is the proposed mechanism of action of 
the increased axonal myelination observed by Lindsay et al. (1) and 
throughout this thesis. It is hypothesised that CXCL12 stimulates the 
proliferation of CXCR4 expressing oligodendrocytes, and therefore 
increases the amount of myelin produced within that particular locus. It 
may also be possible that the CXCL12/CXCR4 interaction stimulates the 
oligodendrocytes themselves to produce more myelin. More work will have 
to be carried out to determine exactly how oligodendrocytes elicit this 
response, but recent data in our lab (not shown) has demonstrated this 
increase in in vitro myelination is by CXCL12/oligodendrocyte interactions. 
This has major therapeutic implications with regards to conditions such as 
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MS and SCI where stimulation of local oligodendrocyte populations to 
enhance myelination could have a profound effect on the pathologies and 
progression of these conditions. Studies have already shown a regeneration 
of optic nerve damage after treatment with CXCL12 (397), and CXCL12 has 
also been shown to decrease neuroinflammation and stimulate neuronal 
cell migration (395, 433), thus, the application of CXCL12 alongside other 
complimentary applications could provide the neuroregenerative capacity 
that is needed to reverse the effects of all demyelinating and 
neurodegenerative conditions. 
 
6.5. Therapeutic Targets 
CXCL12 is clearly a chemokine of therapeutic interest, but in what manner 
could its regulation be targeted? As mentioned in the introduction, the CNS 
is a very sensitive structure, vulnerable to secondary damage, so in situ 
administration would be difficult. As MSCs have been shown to migrate to a 
site of injury after intravenous, intracranial, or intraperitoneal 
administration (186-189), OM-MSCs could be administered in either of 
these ways to allow secretion of CXCL12 into the site of injury via 
exogenous and autologous OM-MSC populations. This could be coupled with 
an increase in the expression of CXCL12’s receptors CXCR4 and CXCR7, to 
increase the amount of receptor/ligand interaction, and potentially 
stimulate an increase in myelin production. CXCR4 has been shown to be 
regulated by a number of transcription factors and signalling molecules. 
Nuclear Respiratory Factor-1 (NRF-1), YingYang-1 (YY-1), cyclic AMP 
(cAMP), Interleukin-2 (IL-2), IL-4, IL-7, IL-10, IL-15, TGF-1β, VEGF, and EGF 
have all been shown to stimulate the production of CXCR4, and Tumour 
Necrosis Factor-1 (TNF-1), Interferon-γ (IFN-γ), and IL-1β have all been 
shown to attenuate CXCR4 expression (473, 484-493). Therefore the effects 
of CXCL12/CXCR4 interactions in situ could be stimulated by gene 
knockouts directly effecting the production of these attenuating factors, or 
by knocking out genes of downstream effectors which would lead to the 
increased expression of the stimulatory factors. One other approach that 
was discussed in section 3 of the results chapter could be to target miR-
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140-5p. It was shown in this chapter that inhibition of miR-140-5p lead to 
an increased expression of CXCL12 in both OM- and BM-MSCs, which led to 
an increase in axonal myelination. This approach could therefore be 
targeted to encourage endogenous populations of cells such as 
oligodendrocytes, whose myelinating effect is regulated by the action of 
CXCL12 on their cell surface receptors, CXCR4 and CXCR7 (398, 419), to 
increase their secretion of CXCL12, and thus potentially stimulate axonal 
remyelination at lesion sites. This however could pose the issue of an 
unwanted regulation of miR-140-5p in other local cell populations, which 
could result in a shift in equilibrium, and further potential issues. It would 
have to be established first, which potentially affected cells express miR-
140-5p, and what knock on effects a regulation of this would have on other 
endogenous populations. Furthermore, with CNS injuries and disorders 
having so many different pathologies, any CXCL12-based therapies would 
have to be just one part of a multifaceted approach to be fully efficacious, 
encompassing many fields of biomedical science such as cell engineering, 
immunology, glial biology, stem cell biology, and neuroscience.  
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7. Conclusion 
Throughout this thesis, MSCs from bone marrow and from the olfactory 
system have proved to be very similar in many respects, but also 
profoundly different in a number of their behaviours. They certainly are a 
viable alternative autologous source for MSC-based therapies, which may 
even be better alternatives for some conditions, especially those 
dependant on remyelination and neuroregeneration strategies. Data 
compiled throughout suggests that the observed promyelinating effects of 
OM-MSCs is likely due to the secretion of CXCL12, which acts on CXCR4 and 
CXCR7, and which is regulated by the microRNA miR-140-5p. Each of these 
are credible target scenarios for CNS repair, and future research into 
complimentary therapies to accompany these scenarios could yield a very 
promising outlook in the field of cell-based regenerative medicine. 
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8. Appendices 
 
GU020.001 sample ID 
Yield 
(ng/µl) 
rRNA 
ratio 
RIN 
OM-MSC 1 151.5 2 10 
OM-MSC 2 90.56 2.1 10 
OM-MSC 3 252.18 2 10 
OM-MSC 4 103.47 2.2 10 
BM-MSC1 150.91 2 10 
BM-MSC2 121.81 2.1 10 
BM-MSC3 145.91 2.1 10 
BM-MSC4 105.94 1.9 10 
 
Appendix 1: Summary of RNA QC checks, taken from Sistemic’s draft 
report 
 
Appendix 2: Summary of miRNA array QC checks, taken from Sistemic’s 
draft report 
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Appendix 3: Table of the 195 miRNA detected in at least one sample 
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Appendix 4: Table of the 125 miRNA which were equivalently expressed in 
OM-MSCs and BM-MSCs 
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